Repeated low-level red light (650 nm) slows childhood myopia progression — among the strongest human PBM signals, with real safety questions
Strong evidence· Points toward a benefit
Repeated low-level red-light (RLRL) therapy is one of the best-evidenced PBM applications anywhere: across 73 human studies including multiple RCTs, 650 nm RLRL slows axial elongation and myopic shift in children — the landmark Jiang (2021) double-blind RCT (n=264) and a large 600-child trial (Wang 2025) found RLRL comparable to 1% atropine and better than orthokeratology for controlling axial length and spherical equivalent. Efficacy for slowing progression is well supported; the genuinely open issues are durability (rebound after stopping) and long-term retinal safety, where isolated injury reports demand respect.
Studied in Children/adolescents with or at risk of myopia (typically ages 6-16)clinical studies
How strong the finding is
139 studies (73 human, 44 reviews) incl. multiple RCTs: Jiang 2021 (double-blind RCT, n=264, 650 nm, slowed AL/SER), Wang 2025 (starred, n=600, RLRL approx equal to 1% atropine, > OK lens), Xiang 2024 (RCT, n=278, choroidal thickening predicts efficacy), Peng 2025 (retrospective, n=323).
How it may work
650 nm red light increases choroidal blood flow and thickness and modulates scleral growth/hypoxia signaling (dopamine-related pathways), slowing axial elongation; the same metabolic/photothermal load on the retina is the basis of safety scrutiny.
What complicates this
Rebound/regression after stopping; treatment-interruption effects (Xiang 2024); rare but serious retinal-safety case reports; long-term (multi-year) safety and optimal dosing still being defined.
Safety notes
Generally well tolerated in trials, but isolated case reports of retinal (OCT) changes and concern about cumulative retinal light dose mean treatment should be device-validated and ophthalmologist-supervised with periodic OCT; the effect can rebound after cessation. Adjunct/alternative within managed myopia-control care, not unsupervised home use.
Intra-oral PBM prevents and reduces severe oral mucositis — the strongest, guideline-grade indication in the PBM literature
Strong evidence· Points toward a benefit
This is PBM's most robust clinical application. Across a deep human evidence base (146 human studies of 254 total), red-light PBM (typically 660 nm intra-oral) prevents and reduces severe chemo/radiotherapy-induced oral mucositis: a Phase III double-blind RCT showed a six-fold drop in grade 3-4 mucositis (6.4% vs 40.5%; Antunes 2013), with consistent benefit on severity and quality of life across Martins 2020, Silva 2015 and others. The signal is strong and reproducible enough that PBM is endorsed in supportive-care guidelines (MASCC/ISOO).
Studied in Patients receiving chemotherapy/radiotherapy for head-and-neck cancer or conditioning for HSCTclinical studies
How strong the finding is
146 human studies (of 254), including a Phase III double-blind RCT (Antunes 2013, n=94: grade 3-4 OM 6.4% vs 40.5%), Martins 2020 (n=48, improved oral-health QoL), Silva 2015 (n=30, fewer grade 2-4 ulcers), and a multicenter sham-controlled trial (Nugent 2022, underpowered at 21% recruitment).
How it may work
PBM accelerates mucosal epithelial repair and angiogenesis, raises ATP via cytochrome c oxidase, and downregulates inflammatory cytokines (TNF-alpha, IL-6, IL-1beta) — blunting the ulcerative cascade triggered by chemo/radiotherapy.
What complicates this
Protocols vary (wavelength, dose, schedule) and some trials under-recruited (Nugent 2022); optimal dosimetry is still being standardized, but the direction of effect is consistent across the large body of RCTs.
Safety notes
Well established and well tolerated; eye protection during intra-oral delivery. There is a theoretical concern about light on residual tumor cells, but high-quality head-and-neck trials report favorable safety/oncologic outcomes; deliver per established protocols and oncology guidance. PBM is an adjunct, not a replacement for prescribed medical care.
pbm-001: PBM prevents/treats oral mucositis in oncology — Grade A Strong
Strong evidence· Points toward a benefit
PBM prophylaxis and treatment significantly reduces severity, incidence of Grade >=3 oral mucositis, and pain in head-and-neck cancer patients undergoing chemoradiotherapy; MASCC/ISOO guideline-endorsed.
Studied in Adults and pediatric head-and-neck cancer patients on chemo/radiationclinical studies
How strong the finding is
2024 meta-analysis 14 RCTs n=869 (Wiley Head & Neck); 2025 MDPI Biomedicines SR; MASCC/ISOO guidelines; pediatric SR/MA 2025. Source: DOI 10.1002/hed.27655; PMC8307997. Dossier claim id pbm-001. Best-evidenced PBM application. Requires intraoral clinical device.
How it may work
CCO photostimulation increases ATP and epithelial repair; reduced NF-kB lowers pro-inflammatory cytokines.
What complicates this
Consumer transfer N/A — intraoral clinical device only; consumer panels not applicable.
Safety notes
Eye protection mandatory; avoid direct thyroid irradiation; professional administration only.
Transcranial PBM enhances cognition in healthy adults — multiple RCTs and a meta-analysis, with high heterogeneity
Moderate evidence· Points toward a benefit
This is among PBM's better-supported brain claims: 8 human RCTs plus a meta-analysis (Salehpour 2019) report beneficial effects on cognitive performance in young, healthy individuals, with Barrett & Gonzalez-Lima 2013 showing improved sustained-attention reaction time and delayed-match memory after a single 1064 nm session — backed by animal work linking transcranial light to higher prefrontal oxygen consumption and better memory. The effect is real and replicated, but the meta-analysis flags high heterogeneity, and some single sessions (e.g., Chan 2021) showed no change on certain tasks. Net: moderate confidence, task- and dose-dependent.
Studied in Healthy adults (notably young) — attention, working memory, executive functionmixed
How strong the finding is
28 studies (19 human, incl. 8 RCTs; meta-analysis Salehpour 2019). Barrett 2013 (RCT, n=40, 1064 nm; improved PVT reaction time and DMS memory), Chan 2021 (RCT, n=33, 810 nm; mixed n-back results). Starred animal: Rojas 2012 (rat; higher prefrontal O2 consumption, better extinction memory), Salehpour 2018 (mouse; higher hippocampal ATP, better spatial memory).
How it may work
Transcranial NIR photostimulates cytochrome c oxidase in prefrontal cortex, raising oxygen consumption and ATP and improving cortical metabolic capacity — translating to gains in attention, working memory and executive function.
What complicates this
Meta-analytic heterogeneity is high; some single sessions show null effects on specific tasks; optimal wavelength/dose/timing not standardized. Benefit may be larger in high-novelty-seeking or lower-baseline individuals.
Safety notes
Single-session and repeated forehead protocols are well tolerated. Effects are task-specific and not universal; this is cognitive-enhancement/wellness use, not a medical treatment claim. PBM is an adjunct, not a replacement for prescribed medical care.
Low-level laser reliably blunts dentin hypersensitivity - a large, mostly-RCT human literature, though doses and devices vary
Moderate evidence· Points toward a benefit
A sizable human literature (~43 human studies, several double-blind RCTs, plus reviews) supports low-level laser for dentin hypersensitivity. Gerschman's double-blind RCT showed ~67% thermal-sensitivity reduction vs 17% placebo (p<0.001), and Ko's double-blind RCT of a 635 nm laser-emitting toothbrush cut pain scores significantly more than the LED control (5.8 to 2.3 vs 6.4 to 5.5, p<0.05). Results are consistent enough to call this a real, mechanism-plausible effect, though some head-to-head comparisons against fluoride varnish were a wash (Corona 2003) and protocols differ - best positioned as an effective adjunct.
Studied in Adults with cervical/exposed-dentin hypersensitivityclinical studies
How strong the finding is
50 studies (43 human, 4 reviews). Key: Gerschman 1994 (double-blind RCT, n=50, 67% vs 17% thermal-sensitivity reduction, p<0.001), Ko 2014 (double-blind RCT, n=96, 635 nm, significant pain drop), Corona 2003 (single-arm, no significant difference vs fluoride varnish).
How it may work
Two proposed routes: photo-biostimulation of odontoblasts promoting tertiary dentin and tubule occlusion, and a direct neural effect dampening A-delta fiber transmission in the dentin-pulp complex (mitochondrial ATP modulation), together raising the stimulus threshold for pain.
What complicates this
Wavelengths (635-830+ nm) and energy doses vary; some head-to-head trials found laser no better (and no worse) than fluoride varnish, and a few entries are case reports. Heterogeneity prevents a single recommended protocol.
Safety notes
Standard PBM safety with intra-oral delivery. Rule out caries/fracture first; use as an adjunct to desensitizing agents and proper technique.
Red/NIR PBM accelerated chronic venous leg ulcer healing across RCTs - moderate, localized-delivery evidence
Moderate evidence· Points toward a benefit
A substantial human literature (23 studies, including a double-blind RCT by Gupta 1998 where 660+880 nm reduced residual ulcer area to 24.4% vs 84.7% placebo, p=0.0008, and a sham-controlled RCT by Schumann 2011 where wIRA + visible light improved healing, p=0.012) supports PBM/photo-energy as an adjunct that accelerates chronic venous ulcer closure and reduces pain. The evidence is heterogeneous in wavelength and delivery (laser, LED, water-filtered IR-A, even blue light) and trials are mostly small, but the direction is consistently favorable. PBM is an adjunct to compression therapy and wound care - the standard of care - not a replacement.
Studied in Patients with chronic venous leg ulcers (typically alongside compression therapy).clinical studies
How strong the finding is
study_count 27 (23 human, 3 review); Gupta 1998 double-blind RCT (n=9/12 ulcers, 660+880 nm, residual area 24.4% vs 84.7%, p=0.0008); Schumann 2011 RCT (n=51, wIRA+VIS, VAS 85 vs 67.5 at 9 weeks, p=0.012); Sugrue 1990 (n=12, 780/904 nm, 44% more granulation, marked pain drop).
How it may work
Red/NIR drives cytochrome c oxidase to ATP, boosting fibroblast proliferation, collagen and granulation tissue, angiogenesis and modulated inflammation; wIRA additionally raises tissue oxygenation and perfusion.
What complicates this
Trials small and heterogeneous (wavelength, dose, device - laser vs LED vs wIRA vs blue light); some null trials exist in the broader literature; mostly localized delivery, so whole-body bed extrapolation is unproven; compression co-intervention confounds.
Safety notes
Eye protection; always combine with compression and wound care; rule out arterial insufficiency and infection; adjunct, not replacement.
Light therapy for acne has solid human support — especially blue+red combinations — with heterogeneous methods
Moderate evidence· Points toward a benefit
Acne is one of the better-validated light-therapy indications. In a double-blind RCT, a home blue (420 nm) + red (660 nm) LED device cut inflammatory lesions by 77% and non-inflammatory by 54% with reduced sebum (Kwon 2013); a randomized trial found combined blue-red phototherapy improved inflammatory lesions 76%, beating blue light and benzoyl peroxide (Papageorgiou 2000). Blue light alone reduced lesions ~64% and cut P. acnes in vitro (Kawada 2002), and red light alone reached a 77% response by week 10 (Pinto 2013). The evidence is encouraging and consistent in direction, though wavelengths, devices, and protocols vary widely — best regarded as a real adjunct for mild-to-moderate acne.
Studied in Patients with mild-to-moderate acne vulgaris.clinical studies
How strong the finding is
~51 studies incl. 7 human RCTs; Kwon 2013 RCT (420+660 nm; -77%/-54%), Papageorgiou 2000 RCT (76% inflammatory improvement, > blue/benzoyl peroxide), Kawada 2002 (blue ~64%, anti-P. acnes), Pinto 2013 (red 77% by week 10).
How it may work
Blue light (~415-420 nm) excites endogenous porphyrins in Cutibacterium acnes, generating singlet oxygen that kills the bacteria; red light (630-660 nm) penetrates deeper to reduce inflammation and modulate sebaceous activity via cytochrome c oxidase and cytokine effects.
What complicates this
Heterogeneous wavelengths, devices, and protocols; many studies in mild-moderate acne; blue vs red vs combination not standardized; some short follow-up.
Safety notes
Standard PBM safety; generally well tolerated (mild dryness reported). A reasonable adjunct or alternative for mild-to-moderate acne, but not a replacement for prescribed therapy in moderate-to-severe or scarring disease.
Red/near-infrared PBM meaningfully eases burning mouth syndrome pain - multiple RCTs converge, mostly with intra-oral diode lasers
Moderate evidence· Points toward a benefit
Across roughly 11 randomized trials plus non-RCTs and case series, photobiomodulation (largely 633-810 nm intra-oral diode laser) has repeatedly cut pain in burning mouth syndrome, a notoriously refractory neuropathic condition. Bardellini's double-blind RCT (n=85) showed significant symptom and oral-health-QoL gains (p=0.0008), Hanna's cohort dropped VAS pain from 7.6 to 3.9, and Lu's 2025 multicenter RCT reported an ~81% response rate when PBM was paired with oral cryotherapy. This is one of PBM's stronger oral-medicine signals; effect sizes and protocols still vary, and it should be offered as an adjunct rather than a sole therapy.
Studied in Adults with primary (idiopathic) burning mouth syndrome; some evidence in iatrogenic oral neuropathyclinical studies
How strong the finding is
43 studies (11 RCTs, ~30 human total, 11 reviews). Key: Bardellini 2019 (double-blind RCT, n=85, symptom p=0.0008, QoL p=0.0002), Hanna 2022 (VAS 7.6->3.9), Scardina 2020 (sham RCT, 800 nm, 50 J/cm2), Lu 2025 (multicenter RCT, 633 nm, ~81% response with adjunct cryotherapy).
How it may work
Light absorbed by cytochrome c oxidase in mitochondria of mucosal and small-fiber neural tissue raises ATP, lowers oxidative stress, and modulates pro-inflammatory and neuropathic signaling - plausibly desensitizing the nociceptors driving the burning sensation.
What complicates this
Wavelengths (633-970 nm), doses, and session counts differ widely; several trials are small, and some combine PBM with other modalities (e.g., cryotherapy), making the PBM-specific contribution harder to isolate. Delivery is targeted intra-oral diode laser, not full-body beds.
Safety notes
Standard PBM safety with intra-oral delivery (eye protection, controlled dose). Well tolerated in trials; use as an adjunct alongside, not instead of, evaluation for underlying causes and standard care.
Transcranial PBM for Alzheimer's: preliminary RCTs show cognitive gains and deep preclinical mechanism — moderate, hopeful, not definitive
Moderate evidence· Points toward a benefit
Alzheimer's is one of PBM's most developed brain indications: preliminary randomized trials report improved cognitive scores (MMSE, MoCA) versus placebo (Nizamutdinov 2021, Qi 2021, Nagy 2021, Chao 2019), backed by a deep mechanistic literature in animal models showing PBM reduces amyloid-beta, shifts microglia from inflammatory M1 to repair M2, restores mitochondrial dynamics, and improves memory. The mechanism-plus-early-human convergence is genuinely promising. Honest limits: the human RCTs are small and preliminary, and the strongest mechanistic detail is still animal — so 'moderate' confidence with confirmation pending.
Studied in Patients with Alzheimer's disease / cognitive decline (early human RCTs); rodent AD models for mechanismmixed
How strong the finding is
124 studies (24 human incl. 4 RCTs, 42 animal, 22 in-vitro, 31 reviews). Human RCTs report MMSE/MoCA gains vs placebo; starred preclinical: Chen 2023 (1070 nm, M1->M2 microglia, exosomal miR-7670-3p), Lu 2017 (808 nm, restored mitochondria), da Luz Eltchechem 2017 (627 nm, fewer plaques), Zhang 2019 (633 nm, less Abeta via SIRT1).
How it may work
Transcranial red/NIR light activates cytochrome c oxidase to restore neuronal ATP and mitochondrial dynamics, shifts microglia toward an anti-inflammatory M2 phenotype (with exosome/miRNA signaling), pushes amyloid-precursor processing down the non-amyloidogenic pathway (SIRT1/ADAM10 up, BACE1 down), and reduces amyloid plaque burden.
What complicates this
Human RCTs are small and described as preliminary; wavelengths, devices and protocols vary widely; the richest mechanistic data are animal, where skull penetration is far higher than in humans. Larger, longer RCTs are needed for a firm efficacy verdict.
Safety notes
Transcranial PBM has been well tolerated in AD trials; home-device and clinic protocols exist. Strictly an adjunct to standard dementia care — no claim of cure or disease arrest. Caution in patients with cerebrovascular disease (see brain-aging safety signal).
Near-infrared PBM measurably boosts skin microcirculation — real, but individual response and delivery matter
Moderate evidence· Points toward a benefit
Controlled human work shows near-infrared PBM genuinely increases microcirculatory blood flow: in a randomized trial, 830 nm over the wrist raised flow by 27% immediately and 54% at 20 minutes (p=0.004), while 633 nm red light did not (Gavish 2020) — and follow-up analysis tied response to baseline skin temperature, with only about half of people responding (Ovadia-Blechman 2023). LED phototherapy (625/660/850 nm) also improved blood flow at chronic-wound edges in a randomized trial (Frangez 2017). This is one of PBM's better-supported vascular effects, but it is wavelength- and person-dependent, and the evidence is for localized delivery, not whole-body beds.
Studied in Healthy adults and patients with chronic (including diabetic) wounds, localized treatment sites.clinical studies
How strong the finding is
~14 studies (11 human, incl. 2 RCTs); Gavish 2020 RCT (830 nm, +27% to +54% flow; 633 nm no effect), de Sa 2021 (660+850 nm LED foot), Frangez 2017 RCT (625/660/850 nm, improved wound-edge flow).
How it may work
NIR absorption releases nitric oxide from cellular stores and cytochrome c oxidase, producing local vasodilation and increased capillary perfusion; baseline skin temperature/vascular tone determines responder status.
What complicates this
Marked responder/non-responder variability driven by baseline skin temperature; red (633 nm) ineffective vs NIR; effects measured locally and short-term; small samples.
Safety notes
Standard PBM safety (eye protection). Effect is local and transient and varies between individuals; not everyone responds. A useful adjunct for perfusion/healing, not a replacement for vascular or wound care.
PBM is an evidence-backed option for tennis elbow - a meta-analysis plus multiple RCTs show real pain relief
Moderate evidence· Points toward a benefit
Lateral epicondylitis is one of PBM's better-supported musculoskeletal indications (16+ RCTs, ~28 human studies). Chang's 2010 meta-analysis found significant pain-relief effect sizes (pooled ES 0.71 post-treatment, 1.05 at follow-up) plus grip-strength and ROM gains when laser targeted tender/trigger points, Stergioulas 2007 (sham-controlled, 904 nm) reduced pain when added to exercise, and de Oliveira 2025 (sham RCT) showed a higher responder rate for PBM plus a static magnetic field (72% vs 40%). The convergence of a meta-analysis and consistent RCTs makes this a solid adjunct, with point-targeting and dose mattering.
Studied in Adults with lateral epicondylitis (tennis elbow)clinical studies
How strong the finding is
37 studies (28 human, 7 reviews). Key: Chang 2010 (meta-analysis, pooled ES 0.71 then 1.05 for pain; higher grip/ROM), Stergioulas 2007 (sham RCT, n=50, 904 nm plus exercise), de Oliveira 2025 (triple-blind sham RCT, n=50, PBMT-sMF 72% vs 40% responders).
How it may work
PBM reduces tendon inflammation and stimulates fibroblast/collagen remodeling and microcirculation (cytochrome c oxidase -> ATP), with analgesia from modulated nociception at tender/myofascial trigger points of the common extensor origin.
What complicates this
Earlier trials were contradictory and outcomes depend on irradiating tender/trigger points and using an adequate dose; wavelengths (810-905 nm) and co-interventions (exercise, magnetic field) vary.
Safety notes
Standard PBM safety with localized delivery. Most effective when targeting tender/trigger points alongside exercise; an adjunct rather than a sole treatment.
LLLT for myofascial pain: a large RCT base favors benefit, though not every trial agrees
Moderate evidence· Points toward a benefit
Myofascial pain syndrome is one of the most-studied PBM indications here (≈19 RCTs, 6 non-RCTs). Most trials applying low-level laser to trigger points report reduced pain and improved range of motion — Demirkol 2015 found LLLT (1064 nm) as effective as occlusal splints and superior to placebo, and Chang 2021 showed immediate relief — though some, like Altan 2005 (904 nm), found no advantage over placebo. The weight of evidence supports trigger-point LLLT as an effective adjunct when dosed correctly, within a broader pain-management plan.
Studied in Adults with myofascial pain syndrome (commonly cervical/trapezius and temporomandibular trigger points)clinical studies
How strong the finding is
Evidence base: 19 human RCTs + 6 non-RCTs + 1 animal (study_count 33; 30 human). Demirkol 2015 (RCT, 1064 nm): LLLT = splint > placebo. Chang 2021 (RCT, 810 nm, n=100): immediate pain relief at acupoints/trigger points. Simunovic 1996 (retrospective, >200 pts): 60-70% pain reduction. Counter: Altan 2005 (double-blind RCT, 904 nm): no benefit over placebo.
How it may work
PBM at trigger points is thought to relieve the ischemic, hypercontracted taut-band state by improving local microcirculation and ATP, reducing inflammatory/algogenic mediators, and modulating nociceptor activity via cytochrome c oxidase — restoring mobility and lowering pain.
What complicates this
Heterogeneous wavelengths (633-1064 nm), doses, and targets (acupoint vs trigger point); some well-designed RCTs are null, and Simunovic explicitly notes over/under-dosing reverses the effect — dosimetry drives the inconsistency.
Safety notes
Well tolerated; standard eye/skin precautions. Adjunct to stretching, exercise, and manual/trigger-point therapy — not a replacement; dose accuracy is decisive.
PBM matches or beats topical steroids for oral lichen planus pain and lesions - a solid mid-tier human literature
Moderate evidence· Points toward a benefit
Oral lichen planus has one of the better PBM evidence bases in oral medicine: ~23 human studies including randomized comparisons against the standard, topical corticosteroids. Dillenburg 2014 (660 nm) achieved higher complete-resolution rates than clobetasol with no recurrence at 90 days, Hemanth 2026 reported PBM superior to triamcinolone on pain and lesion severity (VAS p=0.002), and Mutafchieva 2024 showed PBM lowered salivary IL-1-beta, IL-6, and TNF-alpha alongside symptom relief. Consistent, mechanism-backed results make this a genuine steroid-sparing option - still best framed as an adjunct/alternative to be validated by larger trials.
Studied in Adults with symptomatic atrophic/erosive oral lichen planusclinical studies
How strong the finding is
34 studies (23 human, 10 reviews). Key: Dillenburg 2014 (randomized vs clobetasol, 660 nm, higher complete resolution, no recurrence to day 90), Hemanth 2026 (randomized, 660 nm, superior to TCS, VAS p=0.002), Mutafchieva 2024 (810 nm, lowered IL-1-beta/IL-6/TNF-alpha, 60% histologic improvement).
How it may work
PBM down-regulates the T-cell-driven inflammatory cascade of OLP - reducing pro-inflammatory cytokines (IL-1-beta, IL-6, TNF-alpha) and promoting mucosal healing and analgesia via mitochondrial photon absorption - without the mucosal-atrophy and candidiasis risks of chronic topical steroids.
What complicates this
Many comparators are active (topical steroids) rather than placebo, and wavelengths/doses (635-810 nm) vary; some entries are single-arm or case reports, and refractory cases sometimes needed combined PDT+PBM.
Safety notes
Standard PBM safety with intra-oral delivery. OLP warrants ongoing surveillance for malignant transformation; PBM is an adjunct/alternative within specialist care, not a reason to stop monitoring.
PBM accelerates burn-wound healing and reduces scarring — consistent human signal across RCTs and series
Moderate evidence· Points toward a benefit
Photobiomodulation has encouraging, fairly consistent human support in burn care. A double-blind RCT showed 655 nm LLLT significantly accelerated healing of skin-graft donor sites in burn patients (Vaghardoost 2018), polarized-light therapy shortened healing of deep dermal burns with almost no hypertrophic scarring (Monstrey 2002), fluorescent light energy healed all 18 acute second-degree burns without adverse effects (Mellergaard 2021), and a striking case series achieved complete healing in 13 diabetic grade-3 burn ulcers that were amputation candidates, using LLLT plus grafting (Dahmardehei 2016). The evidence spans wavelengths and devices but points the same way: PBM is a credible adjunct for burn healing and scar quality.
Studied in Patients with burns and burn-related wounds (incl. graft donor sites; diabetic burn ulcers).clinical studies
How strong the finding is
~20 human studies incl. 3 RCTs and case series; Vaghardoost 2018 RCT (655 nm, faster donor-site healing), Monstrey 2002 (polarized light, less hypertrophic scar), Mellergaard 2021 (FLE, 18/18 healed), Dahmardehei 2016 case series (13 diabetic grade-3 ulcers healed).
How it may work
Red/NIR raises fibroblast proliferation, collagen synthesis, angiogenesis, and tissue perfusion while modulating inflammation via cytochrome c oxidase/ATP, accelerating re-epithelialization and improving scar remodeling.
What complicates this
Heterogeneous wavelengths/devices (laser, polarized broadband, FLE); some uncontrolled series; varied burn depths and protocols.
Safety notes
Standard PBM safety; reported well tolerated without adverse events. A strong adjunct to burn wound care/grafting — not a replacement for surgical debridement, grafting, or infection management.
PBM reduces radiation-dermatitis severity in breast-cancer RT — multiple positive RCTs, one notable miss
Moderate evidence· Points toward a benefit
Photobiomodulation has solid randomized support for preventing acute radiation dermatitis. In the TRANSDERMIS RCT (808+905 nm), PBM significantly reduced skin-reaction severity at the end of radiotherapy (fewer grade 2/3 reactions, p=0.004) (Robijns 2018), and its objective sub-analysis showed moist desquamation in only 7% of the PBM group versus 30% of controls (Robijns 2018). A controlled study (660+805 nm) similarly cut grade 2/3 reactions and pain (Strouthos 2017). One trial using 590 nm LED found no benefit (Fife 2010), highlighting parameter dependence. On balance, the controlled evidence is positive enough for an honest moderate grade, with wavelength/dose clearly mattering.
Studied in Cancer patients (predominantly breast cancer) undergoing radiotherapy.clinical studies
How strong the finding is
~33 studies incl. several RCTs; Robijns 2018 TRANSDERMIS RCT (808+905 nm, less severe RD, p=0.004) and its sub-analysis (moist desquamation 7% vs 30%), Strouthos 2017 (660+805 nm, fewer grade 2/3, less pain); Fife 2010 (590 nm) negative.
How it may work
Red/NIR reduces inflammation and oxidative stress and accelerates wound healing in irradiated skin via cytochrome c oxidase/ATP and cytokine modulation, limiting acute radiodermatitis.
What complicates this
One RCT (590 nm) negative, underscoring wavelength/parameter dependence; mostly breast-cancer RT populations; protocol heterogeneity.
Safety notes
Standard PBM safety; well tolerated in oncology RT settings. Use under the radiation-oncology team's guidance; a preventive/supportive adjunct, not a replacement for standard RT skin care.
PBM is an effective adjunct for plantar fasciitis heel pain - most RCTs positive, high-intensity laser less clearly additive
Moderate evidence· Points toward a benefit
Plantar fasciitis is well-studied (6+ RCTs, ~20 human studies). Cinar 2017 (sham-controlled, 850 nm) improved function over usual care, Kiritsi 2010 (double-blind, 904 nm) reduced pain and fascia thickness, and Ulusoy 2017 reported the highest success rate for LLLT (70.6%) versus ESWT (65%) and ultrasound (23.5%). A 2026 trial found high-intensity laser no better than sham (both improved with stretching), so the strongest signal is for low-level laser as an adjunct to stretching/orthotics rather than high-intensity protocols alone.
Studied in Adults with plantar fasciitis / chronic heel painclinical studies
How strong the finding is
28 studies (20 human, 8 reviews). Key: Cinar 2017 (sham RCT, 850 nm, higher AOFAS-F), Kiritsi 2010 (double-blind RCT, 904 nm, lower pain and fascia thickness), Ulusoy 2017 (LLLT 70.6% vs ESWT 65% vs US 23.5%), Jitpimolmard 2026 (HILT 1064 nm equal to sham).
How it may work
PBM reduces inflammation and thickness of the plantar aponeurosis and provides analgesia via mitochondrial photon absorption (ATP), improved microcirculation, and modulated nociception at the enthesis.
What complicates this
Most positive trials combine PBM with stretching/orthotics; the recent high-intensity-laser RCT was negative against sham. Wavelengths/doses vary and some samples are small.
Safety notes
Standard PBM safety with localized delivery. Best paired with stretching and orthotic support; an adjunct, not a standalone cure.
PBM accelerates pressure-ulcer healing — a solid human RCT base, with dose and wavelength the key variables
Moderate evidence· Points toward a benefit
Pressure-ulcer healing is one of the better-supported PBM wound indications: roughly 10 human RCTs plus non-RCTs, with red/NIR (and even blue-light) phototherapy generally improving wound-area reduction versus standard care alone. A sham-controlled RCT of blue-light PBM nearly doubled mean area reduction (52% vs 30%), and red+NIR LED protocols improved healing in pilot RCTs, while animal work shows the effect hinges on getting irradiance/exposure right. The signal is real and clinically meaningful as an adjunct to pressure offloading, wound dressings, and infection control — not a replacement for them.
Studied in Patients with stage II-IV pressure ulcers (often immobile, hospitalized)clinical studies
How strong the finding is
Evidence base: 10 human RCTs + 2 non-RCTs + case report + 2 animal studies (study_count 23). Dollaku 2025 (sham-controlled RCT, n=48): 52.5% vs 29.8% area reduction with blue light. Baracho 2021 (RCT, 630+940 nm LED): improved healing. Lanzafame 2007 (mouse, starred): dose-reciprocity matters for the effect.
How it may work
PBM stimulates fibroblast and endothelial activity, angiogenesis, and collagen organization while modulating inflammation, via cytochrome c oxidase → ATP and redox signaling; blue light adds antimicrobial and distinct photoreceptor effects on healing.
What complicates this
Wavelengths span blue to NIR with differing mechanisms; many trials are small pilots with heterogeneous protocols and outcome measures, and dose-response is finicky (over/under-dosing can blunt the effect). Effect sizes vary by ulcer stage and care setting.
Safety notes
Well tolerated; standard skin/eye precautions. PBM is an adjunct to the pillars of pressure-ulcer care (offloading, nutrition, moisture/dressings, infection management) — never a substitute.
LLLT reduces Raynaud attack severity (less so frequency) — consistent intensity signal across RCTs
Moderate evidence· Points toward a benefit
Several randomized and crossover trials show low-level laser/light reduces the severity and, in some, the frequency of Raynaud attacks: al-Awami 2004 (double-blind RCT, n=47) found significantly greater improvement than placebo, while Hirschl 2002/2004 crossover studies reliably cut attack intensity (to ~82% of baseline) even when frequency was less affected. A single-arm MLS-laser study also showed clinical and microvascular gains. The evidence supports LLLT as a useful adjunct for symptom severity, with effects on attack frequency more variable.
Studied in Adults with primary and secondary Raynaud's phenomenonclinical studies
How strong the finding is
3 human RCTs + 2 non-RCTs (study_count 5, all human). al-Awami 2004 (double-blind RCT, 670 nm): greater reduction in frequency and severity than placebo. Hirschl 2002 & 2004 (crossover, double-blind): intensity reduced to ~82% of baseline, frequency less affected. Kuryliszyn-Moskal 2015 (single-arm MLS 808/905 nm): fewer/shorter attacks, improved capillaroscopy.
How it may work
PBM improves peripheral microcirculation and endothelial function — modulating vascular permeability, blood rheology, and angiogenic mediators (e.g., VEGF, angiopoietin-2) — via cytochrome c oxidase-mediated effects, easing vasospastic attack intensity.
What complicates this
Effects on attack frequency are inconsistent across trials and placebo responses are sizable; small samples, varied wavelengths/devices (laser vs LED, single vs multiwave), and no washout in the crossover designs temper certainty.
Safety notes
Non-invasive and well tolerated; standard precautions. Adjunct to cold-avoidance and pharmacologic management (e.g., calcium-channel blockers); secondary Raynaud needs management of the underlying disease.
Red LED/light therapy (610-630 nm) reduced primary-dysmenorrhea pain across multiple RCTs - moderate evidence
Moderate evidence· Points toward a benefit
Several randomized trials support PBM for primary dysmenorrhea: Shin 2012 (610 nm, double-blind) reported an 83% pain-reduction rate (p=0.001 over placebo), and a multicenter double-blind RCT (Hong 2016, n=88, 610 nm) showed significantly greater VAS reduction with active light (4.34 vs 1.79, p<0.001) and no serious adverse events; Wang 2023 (630 nm) matched combined oral contraceptives on relief while altering pain-related metabolites. The convergent RCT evidence is moderate and consistent. A well-tolerated, drug-sparing adjunct for menstrual pain - not a replacement for evaluating secondary causes.
Studied in Women with primary dysmenorrhea.clinical studies
How strong the finding is
14 studies (7 human, 2 review, 2 animal, 2 in vitro, 1 other); Shin 2012 (DB-RCT, 610 nm, 83% responders, p=0.001); Hong 2016 (multicenter DB-RCT, n=88, VAS 4.34 vs 1.79, p<0.001); Wang 2023 (RCT, 630 nm, comparable to COC, lower PGD2); Thabet 2021 (HILT approx LLLT, both reduced pain).
How it may work
Red light applied to the lower abdomen or acupoints improves local microcirculation to uterine smooth muscle and downmodulates prostaglandins (e.g., PGD2) and inflammation via cytochrome c oxidase to ATP, reducing cramping pain.
What complicates this
Devices/wavelengths and application sites (abdomen vs acupoints) vary; some trials small; subjective VAS endpoint; one comparison study (Thabet) lacked a true placebo arm; long-term effect unclear.
Safety notes
Eye protection; rule out secondary dysmenorrhea (endometriosis, etc.); adjunct or alternative to NSAIDs per preference; well tolerated in trials.
PBM speeds wrist/hand fracture recovery - small human RCTs show less pain, edema, and disability
Moderate evidence· Points toward a benefit
Several small human RCTs support PBM as an add-on in wrist/hand (and adjacent) fracture rehab. Chang 2014 (sham-controlled, n=50, 830 nm) improved healing parameters significantly versus placebo, Saebo 2022 (triple-blind, n=50, 904 nm) showed better PRWHE scores and less night pain/analgesic use out to 26 weeks after distal radius fracture, and Baek 2017 documented greater facial-fracture edema reduction (16.5% vs 7.3%, p<0.047). Encouraging and consistent for pain, edema, and function as an adjunct to standard fracture care, though samples are small and protocols vary.
Studied in Adults rehabilitating wrist/hand and related fractures (including distal radius)clinical studies
How strong the finding is
17 studies (7 human, 5 animal, 3 reviews). Key: Chang 2014 (sham RCT, n=50, 830 nm, all parameters improved), Saebo 2022 (triple-blind RCT, n=50, 904 nm, better PRWHE/night pain to 26 wk), Baek 2017 (590+830 nm, edema 16.5% vs 7.3%, p<0.047).
How it may work
PBM accelerates callus/bone and soft-tissue healing, reduces post-traumatic edema and inflammation, and provides analgesia via mitochondrial ATP production, angiogenesis, and osteoblast stimulation at the fracture site.
What complicates this
Small samples; some studies address facial or tibial/ankle fractures rather than wrist/hand specifically, and wavelengths/doses differ. Multiwavelength devices complicate attribution.
Safety notes
Standard PBM safety with localized delivery. Adjunct to immobilization, reduction/fixation, and exercise therapy; not a replacement for orthopedic management.
PBM helps shoulder pain - frozen shoulder and impingement RCTs mostly positive, a few neutral
Moderate evidence· Points toward a benefit
Shoulder pain has a robust PBM literature (17+ RCTs, ~36 human studies). Stergioulas 2008 (sham-controlled, n=63, 810 nm) significantly reduced pain and disability in frozen shoulder, and Santamato 2009 found high-intensity laser superior to ultrasound in subacromial impingement; results are not uniform - Bingol 2005 showed gains in some signs but not pain, and ESWT outperformed LLLT in one comparison. Overall the evidence supports PBM as an effective adjunct (often with exercise) for frozen shoulder and impingement, with device/dose heterogeneity the main caveat.
Studied in Adults with frozen shoulder, subacromial impingement, or rotator-cuff-related shoulder painclinical studies
How strong the finding is
50 studies (36 human, 11 reviews). Key: Stergioulas 2008 (sham RCT, n=63, 810 nm, lower pain/disability), Santamato 2009 (HILT 1064 nm > ultrasound), Bingol 2005 (mixed - signs improved, pain not), Guloglu 2020 (ESWT > LLLT on some scores).
How it may work
PBM reduces peri-articular inflammation and provides analgesia (cytochrome c oxidase -> ATP, reduced cytokines/oxidative stress), supporting capsular and rotator-cuff recovery and range-of-motion gains alongside rehab.
What complicates this
Wavelengths (810-1064 nm) and intensities (LLLT vs HILT) vary; some trials show no pain benefit or favor ESWT, and many combine PBM with exercise, complicating attribution.
Safety notes
Standard PBM safety with localized delivery. Best combined with exercise/physiotherapy; an adjunct, not a standalone cure.
Intranasal phototherapy/PBM reduces allergic-rhinitis symptoms - multiple RCTs positive, though many use UV-visible light
Moderate evidence· Points toward a benefit
Allergic rhinitis has a substantial human literature (13+ RCTs, ~30 human studies). Intranasal phototherapy improved nasal symptoms versus placebo (Kennedy & Robertson 2020, sham RCT, n=64), red/infrared PBM improved nasal inspiratory flow and obstruction (Oliveira 2025, RCT, n=62), and rhinophototherapy enhanced quality of life (Cingi 2009). A caveat for biohackers: several effective protocols use mixed UV-visible 'Rhinolight' light (immunomodulatory) rather than classic red/NIR PBM, so mechanism and device matter. Net: a genuinely supported, well-tolerated intranasal option as an adjunct to standard allergy care.
Studied in Adults and children with allergic rhinitis (seasonal/perennial)clinical studies
How strong the finding is
42 studies (30 human, 7 animal, 4 reviews). Key: Kennedy & Robertson 2020 (sham RCT, n=64, intranasal, lower TNSS), Oliveira 2025 (RCT, n=62, red+IR, higher nasal flow, less obstruction), Cingi 2009 (n=100, mixed UV-visible, higher QoL).
How it may work
Two overlapping routes: classic red/NIR PBM dampens local inflammatory mediators and mast-cell/eosinophil activity (mitochondrial ATP, anti-inflammatory signaling); mixed UV-visible rhinophototherapy adds direct immunosuppressive/immunomodulatory effects on nasal mucosal inflammatory cells.
What complicates this
Heterogeneous light sources - true red/NIR PBM vs mixed UV-visible phototherapy - with different mechanisms and safety profiles; some trials are single-arm and follow-up is often short.
Safety notes
Standard PBM safety; UV-containing rhinophototherapy devices require correct use to limit mucosal UV exposure. Adjunct to allergen avoidance and standard pharmacotherapy, not a replacement.
PBM for diabetic neuropathy: a large human evidence base with real but heterogeneous benefit
Moderate evidence· Mixed findings
Diabetic neuropathy has one of the deepest human PBM literatures here — 11 RCTs and 8 non-RCTs — and the results are genuinely mixed but lean positive. Yamany 2012 (850 nm, sham-controlled) showed significant pain reduction plus improved electrophysiology and foot microcirculation, and a pilot device study (Rajeswari 2024, 890 nm) reported large nerve-conduction gains; yet Swislocki 2010 found no difference in pain intensity, and Almasi 2025 saw reductions that didn't reach between-group significance. So PBM helps some patients with painful diabetic neuropathy — particularly via microcirculation and nerve conduction — but effects are inconsistent across protocols.
Studied in Patients with painful diabetic peripheral neuropathy / polyneuropathyclinical studies
How strong the finding is
41 studies (26 human, incl. 11 RCTs). Yamany 2012 (RCT, 850 nm; significant pain reduction + improved electrophysiology and microcirculation), Rajeswari 2024 (pilot, 890 nm; ~100% gains in nerve-signal amplitude/conduction velocity), vs Swislocki 2010 (RCT, 870 nm; no pain-intensity difference) and Almasi 2025 (RCT, 808+905 nm, 6 J/cm2; reductions not significant between groups).
How it may work
NIR light improves foot/limb microcirculation (nitric-oxide-mediated), supports peripheral nerve mitochondrial energy and repair, and modulates inflammation — improving nerve conduction, sensation and pain in diabetic peripheral nerves.
What complicates this
Substantial heterogeneity in wavelength, dose and outcomes; several rigorous RCTs are null on primary pain endpoints while others are clearly positive. Device/protocol standardization is lacking, so results don't pool cleanly.
Safety notes
Well tolerated across trials; localized lower-limb/foot delivery. Adjunct to glycemic control and standard neuropathy care — never a substitute for diabetes management or foot-care surveillance.
Low-level light therapy improves dry-eye and meibomian-gland dysfunction across many human studies — often paired with IPL
Moderate evidence· Points toward a benefit
Dry-eye disease has one of the larger ophthalmic PBM evidence bases (24 human studies): LLLT reduced dry-eye symptom (SPEED) scores more than IPL in a randomized comparison (Giannaccare 2023), combined IPL+LLLT lengthened tear break-up time even in Sjogren's patients (Di Marino 2021), and a 460-eye retrospective series showed OSDI and meibomian-gland improvements in patients who had failed conventional therapy (Stonecipher 2019). The direction is consistently positive, but many protocols pair LLLT with IPL, so the standalone PBM effect is partly entangled.
Studied in Patients with dry-eye disease and meibomian-gland dysfunction (incl. Sjogren's)clinical studies
How strong the finding is
33 studies (24 human): Giannaccare 2023 (randomized, n=40, LLLT > IPL on SPEED, p<0.001), Di Marino 2021 (n=20, IPL+LLLT, raised BUT, p<0.0001 at 3 mo), Stonecipher 2019 (retrospective, 460 eyes, reduced OSDI/MGD).
How it may work
Periocular PBM warms and restores meibomian-gland function, reduces ocular-surface inflammation, improves tear-film lipid quality and stability, and stimulates glandular/epithelial cell metabolism.
What complicates this
Frequent IPL co-treatment clouds PBM-specific attribution; several key studies are retrospective/single-arm; parameter reporting is inconsistent across devices.
Safety notes
Periocular light therapy is well tolerated with eye protection; no adverse events reported in comparison trials. Adjunct to lid hygiene, tear substitutes and prescribed therapy.
PBM (often with exercise) reduces fibromyalgia pain — a reasonably strong human signal, delivery varies widely
Moderate evidence· Points toward a benefit
Fibromyalgia has a solid PBM base (≈10 human RCTs), with phototherapy — alone, combined with exercise, or as laser acupuncture — repeatedly lowering pain and improving FIQ/quality-of-life versus controls. da Silva 2017 (double-blind RCT, n=160) found phototherapy plus exercise raised pain thresholds at multiple tender points, and De Lima 2025 (RCT) reported large effects on pain and symptom severity with pulsed laser acupuncture. Whole-body PBM is now being explored qualitatively. The evidence supports PBM as a worthwhile adjunct within multimodal FM care, not a stand-alone fix.
Studied in Adults (predominantly women) with fibromyalgia syndromeclinical studies
How strong the finding is
Evidence base: 10 human RCTs + 2 non-RCTs + case report (study_count 32; 25 human). da Silva 2017 (RCT, n=160, 640/875/905 nm, starred): improved pain thresholds, best with phototherapy+exercise. De Lima 2025 (double-blind RCT, n=20): pain NRS effect size 2.07, symptom severity 2.55. Fitzmaurice 2024: qualitative whole-body PBM experience study.
How it may work
PBM reduces local and systemic oxidative stress and inflammatory mediators and may modulate central pain processing via cytochrome c oxidase → ATP; combining it with exercise plausibly stacks mitochondrial and analgesic benefits.
What complicates this
Protocols are heterogeneous (localized cluster, laser acupuncture, whole-body, sometimes bundled with exercise or hyperthermia), making the PBM-specific contribution hard to isolate; several trials are small, and long-term durability is under-studied.
Safety notes
Well tolerated; standard eye/skin precautions. Adjunct to exercise, sleep, and pharmacologic/behavioral FM management — not a replacement; manage expectations about magnitude and durability.
Near-infrared PBM (820-850 nm) over the thyroid cut levothyroxine needs and TPO antibodies in Hashimoto's - moderate, neck-localized evidence
Moderate evidence· Mixed findings
In chronic autoimmune (Hashimoto's) hypothyroidism, near-infrared PBM applied over the thyroid (820-850 nm) has, across several human trials including a sham-controlled RCT (Hofling 2013), reduced levothyroxine requirements (38.6 vs 106.9 microg/day, p<0.001), lowered anti-TPO antibodies and improved gland echogenicity; a 350-patient study (Ercetin 2020) echoed higher T3 and reduced replacement needs. Results are encouraging and mechanism-consistent, though one RCT (Tunc 2024) found no change in thyroid function despite better oxidative-stress markers, so effects are not uniform. Human studies used neck-targeted delivery, not a full-body bed - applying bed delivery is a plausible extension to confirm, not a proven equivalence - and PBM remains an adjunct alongside endocrinology care, never a replacement for levothyroxine.
Studied in Adults with Hashimoto's thyroiditis / autoimmune hypothyroidism on levothyroxine.clinical studies
How strong the finding is
13 studies (10 human, 2 review, 1 animal); Hofling 2013 sham-RCT (n=43, 830 nm, 707 J/cm2, LT4 38.59 +/- 20.22 vs 106.88 +/- 22.90 microg/day, p<0.001, lower TPOAb); Ercetin 2020 (n=350, 850 nm, higher T3, lower TPOAb); Berisha-Muharremi 2023 (n=74, 820 nm, lower TSH/antiTPO/LT4); Tunc 2024 RCT (n=46, no thyroid-function change, higher glutathione/QoL).
How it may work
NIR photons absorbed by cytochrome c oxidase raise ATP and reduce oxidative stress in thyrocytes while modulating the autoimmune inflammatory milieu (lower TPOAb), potentially preserving residual follicular function.
What complicates this
Trials mostly from a few groups with modest n; one RCT showed no thyroid-function change; co-interventions (selenium, vitamin D, iron) in some studies confound; durability beyond follow-up uncertain; all neck-localized, not bed-delivered.
Safety notes
Neck PBM should be done under medical supervision with thyroid-function monitoring; never self-titrate or stop levothyroxine without labs and physician guidance; rule out thyroid nodules/malignancy before irradiating; adjunct only.
Laser acupuncture / PBM reduces headache frequency and intensity — several RCTs, mostly via acupoint delivery
Moderate evidence· Points toward a benefit
Multiple randomized trials support PBM for headache, most using low-level laser acupuncture: in children, Gottschling 2008 (double-blind, multicenter) cut headache days by 6.4/month vs 1.0 on placebo (P<0.001); Ebneshahidi 2005 significantly reduced tension-headache intensity and duration; and an ILIB study in migraine improved pain and raised regional cerebral blood flow. The replicated, placebo-controlled signal is encouraging for both migraine and tension-type headache. The main caveat is delivery: most positive trials use laser acupuncture or intravascular irradiation, not a simple topical or full-body protocol.
Studied in Adults and children with migraine and tension-type headacheclinical studies
How strong the finding is
11 studies (8 human). Gottschling 2008 (double-blind multicenter RCT, n=43 children, 830 nm; -6.4 vs -1.0 headache days, P<0.001), Ebneshahidi 2005 (RCT, n=50, 830 nm; significant intensity/duration reduction), Chen 2023 (controlled ILIB, 633 nm; pain reduction + 1.27-fold rCBF increase).
How it may work
PBM at acupoints/vasculature modulates pain pathways and inflammation and increases regional cerebral blood flow; for migraine, normalizing the rCBF drop during attacks is a plausible contributor, alongside mitochondrial/anti-inflammatory effects.
What complicates this
Most positive trials use laser acupuncture (TCM point selection) or intravascular ILIB rather than straightforward transcutaneous PBM, complicating mechanism attribution and generalization; some samples are small.
Safety notes
Well tolerated, including in children; laser acupuncture and ILIB require trained delivery. Adjunct to standard headache management and trigger control, not a replacement for acute or preventive medication when indicated.
Red/NIR PBM reduced post-cesarean pain and analgesic use across RCTs - moderate evidence
Moderate evidence· Points toward a benefit
Multiple randomized trials support PBM for post-cesarean pain: a double-blind RCT (Poursalehan 2018, n=80, 650+804 nm) significantly reduced pain at 1-24 h and total analgesic consumption, and a sham-controlled RCT (de Holanda Araujo 2019, n=88, 660 nm) showed meaningfully larger effect sizes for pain (0.71/0.69 active vs 0.11/0.43 placebo/control). A non-randomized study (Dehghanpour 2023) reported better wound recovery. The convergent RCT evidence is moderate-quality and consistent. PBM is a drug-sparing analgesic adjunct, not a replacement for obstetric/post-op care.
Studied in Women recovering from cesarean section.clinical studies
How strong the finding is
5 entries (3 human, 2 other incl. a protocol); Poursalehan 2018 (double-blind RCT, n=80, 650+804 nm, lower pain 1-24 h, lower analgesic p=0.006); de Holanda Araujo 2019 (sham RCT, n=88, 660 nm, 2 & 4 J/cm2, effect size 0.71/0.69 vs control); Dehghanpour 2023 (non-RCT, better recovery).
How it may work
Red/NIR via cytochrome c oxidase to ATP reduces local inflammation and prostaglandins, modulates nociceptor signaling and supports incisional healing, lowering pain and opioid need.
What complicates this
Trials modest in size, heterogeneous wavelengths/doses; some entries are protocols; blinding and measurement vary; mostly short follow-up.
Safety notes
Eye protection; apply over the incision per protocol; adjunct to standard post-cesarean analgesia and wound care.
Multiwavelength PBM improves visual acuity in dry AMD across multiple human trials — gains can be real but may be transient
Moderate evidence· Points toward a benefit
Photobiomodulation for dry AMD has a solid and growing human signal: Merry (2016) reported ~5.9 ETDRS-letter BCVA gains plus contrast-sensitivity and drusen improvements after a 3-week multiwavelength (590/670/790 nm) course, sustained at 3 months, and Nassisi (2024) saw BCVA peak at 12 weeks though it partially regressed by 24 weeks, with two patients developing neovascularization. Preclinical work (Begum 2013, 670 nm) anchors the mechanism in mitochondrial/anti-inflammatory effects. Net: a credible, repeatable functional benefit, with durability and retreatment cadence the open questions.
Studied in Adults with dry (non-exudative) age-related macular degenerationclinical studies
How strong the finding is
45 studies (22 human incl. 1 RCT, 6 non-RCT, 1 case report; plus LIGHTSITE-line multiwavelength data): Merry 2016 (n=24/42 eyes, +5.9 letters, p<0.001), Nassisi 2024 (n=38, BCVA up at W12, partial decline at W24, 2 MNV cases); Begum 2013 mouse mechanism.
How it may work
670 nm-class light raises cytochrome c oxidase activity and mitochondrial membrane potential in retinal pigment epithelium and photoreceptors, reduces complement-driven inflammation (e.g. C3) and oxidative stress, and may slow drusen-associated dysfunction.
What complicates this
Many trials are single-arm; benefit may be transient (W12 peak, W24 decline in Nassisi); incident neovascularization during follow-up needs scrutiny; wavelength/dose protocols differ across devices.
Safety notes
Retinal PBM at studied doses appears safe, but progression to neovascular AMD has been observed during follow-up (causation unclear) — ophthalmologic monitoring is essential. Adjunct to AREDS supplementation and standard AMD care, not a cure.
PBM meaningfully extends herpes-labialis recurrence-free intervals — among the better-controlled PBM dermatology claims
Moderate evidence· Points toward a benefit
Recurrent cold sores respond well to PBM in randomized trials. In a double-blind RCT, 690 nm laser extended the median recurrence-free interval to 37.5 weeks versus 3 weeks for placebo (p<0.0001) (Schindl & Neumann 1999); a large randomized comparison found 670 nm LLLT an effective treatment that lengthened recurrence intervals without side effects (Munoz Sanchez 2012); and a recent double-blind RCT showed 940 nm PBM added to acyclovir reduced pain and lesion size faster than acyclovir alone (Seyyedi 2024). The evidence converges on real benefit for recurrence prevention and symptom control, earning an honest moderate grade.
Studied in Patients with recurrent herpes labialis (HSV-1 cold sores).clinical studies
How strong the finding is
~23 studies incl. 4 RCTs; Schindl 1999 RCT (690 nm, recurrence-free 37.5 vs 3 wk), Munoz Sanchez 2012 RCT (670 nm), Seyyedi 2024 RCT (940 nm + acyclovir, less pain/smaller lesions).
How it may work
PBM modulates the local immune response and cytokine milieu and accelerates epithelial healing, reducing reactivation frequency, pain, and lesion duration of HSV-1.
What complicates this
Varied wavelengths/doses; some older trials; a few combined PBM with antivirals, complicating attribution.
Safety notes
Standard PBM safety; consistently well tolerated, no side effects reported. An effective adjunct (and recurrence-reducer) that pairs well with antivirals; not a replacement for antiviral therapy where indicated.
Laser/LED therapy helps radicular pain and function in disc herniation across several trials — heterogeneous and often adjunctive
Moderate evidence· Points toward a benefit
Three human trials point the same general direction: LED (945 nm) beat laser and placebo for radicular pain, claudication and disability when paired with positioning/exercises (de Carvalho 2016); HILT added to collagenase chemonucleolysis accelerated early VAS/ODI/SF-36 recovery (Song 2025); and HILT matched TENS/ultrasound for cervical disc herniation (Yilmaz 2020). The throughline is real benefit for pain and function, but modalities (LLLT vs LED vs HILT), wavelengths and co-interventions vary widely, so the effect is encouraging rather than locked in.
Studied in Adults with lumbar or cervical disc herniation and radiculopathyclinical studies
How strong the finding is
Three human RCTs/controlled trials: de Carvalho 2016 (904 nm laser vs 945 nm LED vs placebo; LED superior for radicular pain), Song 2025 (n=60, HILT+collagenase superior early, P<0.05), Yilmaz 2020 (n=40, HILT approx equal to TENS/US, both effective).
How it may work
Red/NIR light reduces perineural inflammatory cytokines and oxidative stress, raises local ATP and microcirculation, and modulates nociceptive signaling around the herniated disc and affected nerve roots.
What complicates this
Marked heterogeneity in device (LLLT/LED/HILT), wavelength and adjuncts; small samples; several positive results are equivalence to another active therapy rather than placebo-beating, and HILT effects may be partly photothermal.
Safety notes
HILT is more thermal than LLLT — dosimetry and training required. Adjunct to exercise, positioning and standard care; not a replacement for surgical evaluation in progressive deficit or cauda equina.
PBM curbs pain, swelling, and dry socket after tooth extraction - a large, mostly-positive human literature
Moderate evidence· Points toward a benefit
Tooth-extraction recovery is one of PBM's most-studied dental uses (~112 human studies, 20 reviews). Randomized trials show reduced post-extraction pain and complications: Nejat 2021 (double-blind, n=80, 660+810 nm) lowered alveolar osteitis incidence and pain on days 2-5, Intan 2018 showed faster pain decline (905 nm), and Abdel-Alim 2015 found immediate post-op application most effective. The weight of evidence supports PBM as an effective adjunct for post-extraction pain, edema, trismus, and dry-socket prevention, with heterogeneity in wavelength, dose, and timing the main caveat.
Studied in Patients undergoing tooth/third-molar extractionclinical studies
How strong the finding is
159 studies (112 human, 20 reviews, 23 animal). Key: Nejat 2021 (double-blind RCT, n=80, 660+810 nm, lower alveolar osteitis and pain), Abdel-Alim 2015 (randomized, n=80, 830 nm, immediate > delayed), Intan 2018 (RCT, n=42, 905 nm, faster pain reduction).
How it may work
PBM reduces post-surgical inflammation and edema, accelerates soft-tissue and bony socket healing, and provides analgesia via mitochondrial photon absorption (ATP), enhanced microcirculation, and modulated cytokine release.
What complicates this
Protocols vary widely (single vs multiple sessions, 660-970 nm, intra- vs extra-oral, immediate vs delayed), and effect sizes differ across endpoints; some studies combine PBM with other adjuncts (A-PRF, high-level laser).
Source-integrity update (checked 2026-09-07): Nejat et al. 2021 (DOI 10.1111/php.13457; PMID 34048061) has an Expression of Concern first published 2026-02-26 (DOI 10.1111/php.70086; PMID 41744481). The publisher reports unresolved ethics-approval, trial-registration, reporting and data-integrity concerns. Notice: https://onlinelibrary.wiley.com/doi/full/10.1111/php.70086 . Reassessment of this study's contribution to the efficacy summary and representative dose remains pending clinical review.
Safety notes
Standard PBM safety with intra-oral delivery. Adjunct to good surgical technique and standard post-op care.
PBM as an adjunct for Bell's palsy: RCT and controlled trials show better facial-nerve recovery, especially in slow-resolving cases
Moderate evidence· Points toward a benefit
Across 19 human studies (including 2 RCTs and 3 controlled non-RCTs), PBM applied to the facial nerve has improved recovery in Bell's palsy — Wu's controlled trial and RCT (808+905 nm) showed significantly better House-Brackmann and Sunnybrook grades at 6 months in patients whose palsy had lasted more than 8 weeks. Adding light to standard care looks like a reasonable, low-risk adjunct, particularly for cases that aren't resolving on their own. Heterogeneous devices and protocols (several use laser acupuncture) keep confidence at moderate rather than high.
Studied in Patients with Bell's palsy, including those with delayed recovery (>8 weeks duration)clinical studies
How strong the finding is
25 studies (19 human, incl. Wu 2024 RCT n=84 and Wu 2023 controlled trial n=54, both 808+905 nm, 8.35 J/cm2, class IV laser; significant House-Brackmann/Sunnybrook improvement at 6 months). Older controlled and case-series data (Yamada 1995, Bernal 1993) align directionally.
How it may work
PBM accelerates peripheral facial-nerve regeneration and reduces perineural inflammation via mitochondrial activation and improved microcirculation, supporting reinnervation of facial musculature.
What complicates this
Many studies combine PBM with laser acupuncture or other modalities; device classes and doses vary; some positive trials are non-randomized. Effect is most demonstrated in chronic/delayed cases rather than acute onset.
Safety notes
No clinically significant adverse effects reported across the literature; eye protection essential given facial/periorbital delivery. Adjunct to standard early corticosteroid/antiviral and physiotherapy management, not a replacement.
pbm-004: PBM reduces knee osteoarthritis pain and disability — Grade B Moderate
Moderate evidence· Points toward a benefit
PBM reduces pain (VAS) and disability in knee osteoarthritis with moderate-certainty evidence; best results at 904–905 nm or 785–808 nm, 4–8 J/cm2, 10–16 sessions. Overdosing above 4–8 J/cm2 reduces effect.
Studied in Adults with knee OA; older adults respond well; additive with exerciseclinical studies
How strong the finding is
2024 PTJ meta-analysis n=542 (pzae073); 2025 umbrella review PMC12326686 (PMID 40770824); 2024 ScienceDirect meta-analysis n=673. Source: PTJ pzae073; PMID 40770824. Dossier claim id pbm-004. Weak consumer transfer (contact device needed).
How it may work
Increased ATP in chondrocytes/synoviocytes; reduced NF-kB, IL-1b, TNF-a; reduced chondrocyte apoptosis.
What complicates this
Joints are deep targets; consumer panels at distance deliver uncertain joint-level fluence.
Safety notes
Eye protection; avoid direct popliteal artery irradiation.
pbm-007: PBM reduces tendinopathy and chronic neck pain — Grade B Moderate
Moderate evidence· Points toward a benefit
PBM reduces pain and improves function in tendinopathy across multiple sites; evidence for chronic neck pain is positive in controlled trials, though fewer large RCTs than for OA.
Studied in Adults with tendinopathy or chronic neck/shoulder painclinical studies
How strong the finding is
2021 tendinopathy meta-analysis PMC8364035; 2026 Frontiers chronic-pain SR PMC12909510; WALT Position Paper 2026 PMC12898000. Source: PMC8364035. Dossier claim id pbm-007. Weak consumer transfer.
How it may work
Increased collagen remodeling; reduced local inflammatory cytokines; modulated nociceptor thresholds.
What complicates this
Neck pain heterogeneous; low-dose protocols underperform (biphasic dose).
Safety notes
Eye protection; caution near thyroid when treating anterior neck.
pbm-005: PBM (pre-exercise) reduces DOMS and EIMD — Grade B Moderate
Moderate evidence· Points toward a benefit
Pre-exercise PBM significantly reduces muscle soreness and fatigue and limits EIMD (reduced CK and oxidative stress); post-exercise PBM improves functional recovery. IOC recognizes PBM for acute muscular recovery.
Studied in Athletes and active adults (strength and endurance)clinical studies
How strong the finding is
2025 whole-body PBM SR (34 RCTs, JBRA); 2024 meta-analysis PMID 38758297; 2025 athlete meta-analysis PMC12463863; 2025 SR PMID 40954632. Source: PMID 38758297. Dossier claim id pbm-005. Weak consumer transfer (clinical-grade devices used).
How it may work
CCO activation increases ATP and delays fatigue; reduces ROS and inflammatory cytokines.
What complicates this
Pre-exercise low-certainty; performance enhancement less consistent; protocol variability major confounder. Consumer panels deliver far lower tissue fluence.
Safety notes
Eye protection; avoid epiphyseal plates in adolescents.
Photobiomodulation effects on exercise performance are small and mode-specific, and were studied before exercise rather than after
Moderate evidence· Mixed findings
A meta-analysis of 37 studies and 586 participants found photobiomodulation improved muscle endurance in single-joint exercise (SMD 0.27) and time to exhaustion in cycling (SMD 0.35), with no effect on single-joint strength, running, or swimming performance. The irradiation was applied before exercise as a preconditioning method, which is the opposite of the Superhuman Protocol's placement of red light last.
Studied in Healthy and trained adults across single-joint, cycling, running, and swimming tasksclinical studies
How strong the finding is
Meta-analysis of 37 studies with mode-specific stratification, which is more informative than a single pooled estimate. Effect sizes are small where present, and clearly null in three of the tested modes.
How it may work
Red and near-infrared light is absorbed by mitochondrial cytochrome c oxidase, which is proposed to raise electron-transport efficiency and cellular energy availability. Where that translates into measurable performance appears to depend on how much of the working muscle mass the light actually reaches, which is why small single-joint tasks respond and whole-body running and swimming do not.
What complicates this
This literature tests light before exercise. Separate post-exercise recovery literature exists and reports reductions in soreness markers, but it is a different question with its own heterogeneity. Neither body of work evaluates a whole-body bed applied at the end of a three-modality sequence, which is a different geometry and a different timing.
Safety notes
Supports a modest, mode-specific performance framing for red light. It does not support presenting the final step of the protocol as amplifying or locking in the previous two steps.
LLLT helps Achilles tendinitis — a multi-RCT base, strongest in acute cases
Moderate evidence· Points toward a benefit
Achilles tendinopathy has a reasonable PBM base (about 7 human RCTs and 2 non-RCTs). An early large double-blind RCT (n=176) found laser therapy significantly outperformed placebo through one-month follow-up, with the biggest gains in acute tendinitis. The body of evidence supports LLLT as a useful adjunct — most convincing for acute presentations and when dosed correctly — within a rehab program rather than as a stand-alone treatment.
Studied in Adults with Achilles tendinitis/tendinopathy (acute and chronic)clinical studies
How strong the finding is
Evidence base: 7 human RCTs + 2 non-RCTs. Representative: Lögdberg-Andersson 1997 (double-blind RCT, n=176, 904 nm): significant benefit vs placebo sustained to 4 weeks post-treatment, most effective in acute tendinitis. (Grounding study lacks an indexed PubMed ID.)
How it may work
PBM in tendon reduces inflammatory mediators and oxidative stress and stimulates fibroblast activity/collagen organization and microcirculation via cytochrome c oxidase → ATP, supporting tendon repair and analgesia; the effect is strongly dose-dependent.
What complicates this
The single grounding study has no indexed PMID and is older; across the LLLT tendinopathy literature results hinge on dose and are more equivocal in chronic disease, so protocol heterogeneity limits certainty.
Safety notes
Well tolerated; standard eye/skin precautions. Adjunct to load management, eccentric exercise, and physiotherapy — not a replacement; correct dosimetry matters.
Androgenetic alopecia is PBM's strongest dermatology case — multiple RCTs show real terminal-hair gains
Moderate evidence· Points toward a benefit
For pattern hair loss, low-level laser/light therapy has the most robust evidence in PBM dermatology. Four pooled multicenter, double-blind, sham-controlled RCTs (269 subjects) with a 655 nm laser comb showed a statistically significant increase in terminal hair density in both men and women, with no serious adverse events (Jimenez 2014) — this device class is FDA-cleared. A randomized double-blind trial of a 650 nm home helmet likewise improved hair density and diameter versus sham (Suchonwanit 2018), and further RCTs combining red/green LED with microneedling show added benefit (Charoensuksira 2024). The honest grade is solidly moderate: consistent, controlled, reproducible gains — tempered by device heterogeneity and some industry funding.
Studied in Men and women with androgenetic (pattern) hair loss.clinical studies
How strong the finding is
~94 references incl. 14 human RCTs; Jimenez 2014 (4 RCTs, 269 subjects, 655 nm, significant terminal-hair density), Suchonwanit 2018 RCT (650 nm helmet), Charoensuksira 2024 RCT (red/green LED + microneedle), Lueangarun 2024 pilot.
How it may work
Red light (650-660 nm) absorbed by follicular cytochrome c oxidase raises ATP, prolongs the anagen growth phase, increases follicular blood flow, and counters miniaturization of androgen-sensitive follicles.
What complicates this
Device and protocol heterogeneity; some industry sponsorship; effect sizes modest and variable; long-term durability less characterized.
Safety notes
Standard PBM safety; consistently well tolerated with no serious adverse events across RCTs. An effective standalone or combination adjunct; works best alongside, not instead of, proven agents (minoxidil/finasteride) in appropriate patients.
pbm-003: PBM increases hair density in androgenetic alopecia — Grade B Moderate
Moderate evidence· Points toward a benefit
LLLT/PBM devices (630–680 nm; comb/helmet/cap) significantly increase hair density vs. sham in androgenetic alopecia; combination with topical minoxidil is superior to minoxidil alone.
Studied in Adults with AGA (Norwood II–V male; Ludwig I–II female)clinical studies
How strong the finding is
2022 meta-analysis FDA-cleared home devices PMID 34980962; 2025 Springer meta-analysis 7 RCTs; 2024 sham-controlled RCT; SR PMC11534645. Source: PMID 34980962. Dossier claim id pbm-003. Moderate consumer transfer (FDA-cleared devices studied directly).
How it may work
CCO activation in follicular keratinocytes extends anagen phase; increases local IGF-1.
What complicates this
Some consumer-device data exist but are primarily manufacturer-funded.
Safety notes
Avoid active scalp malignancy; well-tolerated in all RCTs.
PBM for low back pain is genuinely mixed - several positive RCTs, but the largest, cleanest trial was negative
Moderate evidence· Mixed findings
Low back pain has a large PBM literature (~49 human studies) with honestly conflicting results. Multiple RCTs are positive - Konstantinovic 2010 (n=546, 904 nm) and Vallone 2014 (980 nm, delta-VAS 3.96 vs 2.23) showed added benefit, often combined with NSAIDs or exercise - yet Guimaraes 2021, a well-designed double-blind RCT (n=148), found PBM no better than placebo for chronic nonspecific LBP. The fairest read: PBM may help as part of a multimodal program, especially in acute/radicular or inflammatory presentations, but it is not a reliable standalone fix and the best-controlled evidence tempers enthusiasm.
Studied in Adults with acute or chronic (often nonspecific) low back pain, with or without radiculopathyclinical studies
How strong the finding is
64 studies (49 human, 8 reviews). Positive: Konstantinovic 2010 (double-blind RCT, n=546, 904 nm, p<0.001 with nimesulide), Vallone 2014 (RCT, n=100, 980 nm, delta-VAS 3.96 vs 2.23), Holanda 2016 (808 nm, >=50% pain relief). Negative: Guimaraes 2021 (double-blind RCT, n=148, PBM equal to placebo).
How it may work
PBM exerts anti-inflammatory and analgesic effects on paraspinal muscle and nerve tissue (cytochrome c oxidase -> ATP, reduced oxidative stress and cytokines, possible direct neural modulation), most plausibly where an inflammatory component is present.
What complicates this
Large heterogeneity in wavelength (640-980 nm), dose, and co-interventions; the most rigorous standalone trial (Guimaraes) was negative, and many positive trials pair PBM with drugs or exercise, confounding the PBM-specific effect.
Safety notes
Standard PBM safety with localized paraspinal delivery. Best used within a multimodal program (exercise, education); not a substitute for evaluation of red-flag back pain. PBM is an adjunct, not a replacement for prescribed medical care.
Red/NIR PBM reduced breastfeeding nipple-trauma pain across RCTs - moderate evidence, healing signal mixed
Moderate evidence· Points toward a benefit
Multiple randomized trials support PBM for breastfeeding nipple pain/trauma: Coca 2016 (660 nm, double-blind) cut pain by about 2.0 cm at 24 h (p=0.016), Gaitero 2026 (660+808 nm, n=60) showed significant pain relief from 30 min through days post-treatment, and Chaves 2012 (860 nm LED) significantly improved both lesion healing (p<0.001) and pain (p<0.001). The pain-relief evidence is consistent and moderate-quality; effects on healing are positive but less uniform across trials. PBM is a painless adjunct that may help sustain breastfeeding - combined with latch/technique support, not a replacement.
Studied in Breastfeeding/postpartum women with nipple pain or trauma.clinical studies
How strong the finding is
11 studies (6 human, 3 review, 2 other); Coca 2016 (DB-RCT, 660 nm, pain -2.0 cm at 24 h, p=0.016); Gaitero 2026 (DB-RCT, n=60, 660+808 nm, significant pain relief 30 min to 12 h+); Chaves 2012 (RCT, 860 nm LED, healing and pain p<0.001); Buck 2016 (case series).
How it may work
Red/NIR via cytochrome c oxidase to ATP accelerates epithelial wound healing, modulates inflammation and provides analgesia at the nipple/areola.
What complicates this
Trials small-to-moderate; healing endpoints less consistent than pain; some broader-literature trials are null; co-intervention with latch education confounds; heterogeneous devices/wavelengths.
Safety notes
Eye protection; clean application; pair with lactation/latch support; adjunct, not a substitute for addressing the cause (poor latch, infection).
pbm-002: PBM reduces facial photoaging and periocular wrinkles — Grade B Moderate
Moderate evidence· Points toward a benefit
PBM (660 nm red, 590 nm amber) reduces periocular wrinkle volume ~30% vs. sham over 10 sessions, with histological evidence of increased Type I collagen and decreased metalloproteinases.
Studied in Women 40–65, skin phototypes II–IVclinical studies
How strong the finding is
2023 RCT n=137 PMID 36780572; 2025 JAAD consensus; MDPI IJMS 2024 review. Source: PMID 36780572. Dossier claim id pbm-002. Partial consumer transfer (lower irradiance/uncertain distance).
How it may work
Fibroblast photostimulation increases collagen I/III and elastin; decreases MMP (collagenase) expression.
What complicates this
Consumer LED masks use similar wavelengths at lower irradiance; likely some effect, magnitude uncertain.
Safety notes
Direct retinal hazard — fitted eye shields; caution with photosensitizing medications.
pbm-006: PBM accelerates diabetic/chronic wound healing — Grade B Moderate
Moderate evidence· Points toward a benefit
PBM accelerates healing and reduces wound size in diabetic and chronic wounds, with positive effects across inflammation, proliferation, and maturation phases; diverse device types show consistent directional benefit.
Studied in Adults with diabetic foot ulcers, venous leg ulcers, post-surgical woundsclinical studies
How strong the finding is
2023 SR PMID 38028869; 2024 Wiley gene-expression SR; 2025 PMC11628774; 2023 660nm Ras/MAPK study PMC10093328. Source: PMID 38028869. Dossier claim id pbm-006. Clinical contact application only.
How it may work
Increased ATP drives fibroblast/keratinocyte proliferation; increased VEGF/angiogenesis; Ras/MAPK wound-closure gene expression.
What complicates this
Consumer full-body panels are not appropriate for wound treatment.
Safety notes
Avoid suspected skin malignancy; standard wound care for infected wounds.
pbm-015: PBM modestly aids fat reduction only as lifestyle adjunct — Grade B Moderate (adjunct)
Moderate evidence· Points toward a benefit
PBM as adjunct to lifestyle intervention modestly reduces BMI (-1.18), body weight (-3.54 kg), and waist circumference (-7.28 cm) vs. control in obese patients (11 RCTs, n=569); fat mass % and waist-to-hip ratio were NOT significantly improved. Standalone consumer 'fat-melting' claims are not supported (D).
Studied in Obese adults (BMI >=30); predominantly femaleclinical studies
How strong the finding is
2025 BMC meta-analysis 11 RCTs n=569 PMC11992763 (PMID 40217252); 2025 LED abdominal adipose PMC11845923; 2022 histology PMID 36074934. Source: PMC11992763. Dossier claim id pbm-015. B adjunct / D standalone.
How it may work
Photon-induced transient adipocyte pore formation releases lipids; lipolysis requires metabolic clearance via exercise.
What complicates this
MARKETING RISK: 'fat-melting'/'body contouring' standalone panel claims (D) outrun evidence; only modest effect WITH lifestyle co-intervention.
Safety notes
Sessions must be combined with exercise for lipid clearance; no serious AEs in RCTs.
pbm-009: PBM reduces local inflammation (systemic-from-panels is D) — Grade B Moderate (local)
Moderate evidence· Points toward a benefit
PBM consistently reduces local and peripheral inflammatory markers at targeted sites (TNF-a, IL-1b, IL-6, CRP up to ~40%). Systemic whole-body anti-inflammatory benefit from consumer panels is mechanistically plausible but NOT established by large RCT (D-level).
Studied in Local inflammatory conditions; obese adults; cancer patients (mucositis)clinical studies
How strong the finding is
2023 cytokine study PMC10115964; 2025 immunomodulatory review PMC11991943; 2025 PBM obesity meta-analysis PMC11992763. Source: PMC11991943. Dossier claim id pbm-009. Grade B local/targeted; D systemic via consumer panels.
How it may work
Reduced NF-kB lowers pro-inflammatory cytokine genes; increased IL-10; local ROS modulation.
What complicates this
MARKETING RISK: 'full-body anti-inflammation' from standing near a panel is D-level and not supported; local-only is B.
PBM improves sleep quality across transcranial and whole-body delivery — multiple positive RCTs, some nuance
Moderate evidence· Points toward a benefit
Several RCTs report better sleep with PBM: transcranial 810 nm improved PSQI and Epworth scores with EEG delta changes in chronic insomnia (Mehdizadeh 2025), an 830 nm laser array improved PSQI/insomnia scores and quality of life in night-shift nurses (Lin 2025), and whole-body red light improved sleep in athletes. Effects can be conditional — Giménez 2023 saw benefits (mood, drowsiness) only at 6.5 J/cm² and only in winter, and Zhao 2022 found no between-group sleep-efficiency difference. Net: a generally positive, mechanism-plausible signal across both transcranial and whole-body delivery, best treated as an adjunct for sleep.
Studied in Adults with chronic insomnia, shift workers, athletes, and people with subjective cognitive declineclinical studies
How strong the finding is
Base study_count 13 (12 human). Mehdizadeh 2025 (RCT, 810 nm tPBM): PSQI −4.6, ESS −4.1, delta-power changes. Lin 2025 (RCT, n=60, 830 nm array, 252 J/cm²): improved PSQI/AIS and QoL. Giménez 2023 (double-blind RCT, 850 nm, starred): benefits only at 6.5 J·cm⁻², winter-only. Zhao 2022 (RCT, 1064 nm tPBM): no between-group sleep-efficiency difference.
How it may work
Transcranial NIR raises prefrontal cortex oxygenation and metabolism via cytochrome c oxidase, modulating EEG (e.g., delta power) and memory/mood circuits; whole-body/peripheral PBM may act systemically on circadian and inflammatory signaling (e.g., reduced IFN-γ, resting heart rate) to support sleep.
What complicates this
Outcomes are mostly subjective (PSQI/ESS), dose- and season-dependent (Giménez), and at least one RCT (Zhao) showed no group difference in objective sleep efficiency; wavelengths and delivery (transcranial vs whole-body vs palm/array) vary widely, complicating pooled claims.
Safety notes
Non-invasive, well tolerated; standard eye protection for transcranial use. Adjunct to sleep hygiene and evidence-based insomnia care (e.g., CBT-I) — not a replacement; dose and timing appear to matter.
Transcranial PBM for depression: a credible antidepressant signal that didn't fully replicate — promising but unsettled
Moderate evidence· Mixed findings
The flagship ELATED-2 RCT (Cassano 2018) found a sizable antidepressant effect of transcranial NIR (823 nm) in MDD (HAM-D17 effect size 0.75-1.5), and open/retrospective multi-watt NILT series report high response/remission rates — but the larger ELATED-3 trial did not confirm benefit, and an SAD light-visor RCT suggested even infrared light helps. Strong animal models (Salehpour 2019) show PBM reduces depressive-like behavior and oxidative stress. Net: a real, mechanism-backed signal that has not cleanly replicated at scale, so tPBM is a promising adjunct to confirm, not an established antidepressant or a substitute for proven care.
Studied in Adults with major depressive disorder; some seasonal affective disorder and TBI-associated depressionmixed
How strong the finding is
5 human RCTs + 4 non-RCTs + case reports (study_count 49; 18 human, 15 animal). Cassano 2018 (double-blind RCT, 823 nm, starred): HAM-D17 effect size 0.75-1.5. Henderson 2017 (retrospective, n=39, 810/980 nm): ~92% robust response. Counterweight: ELATED-3 reported no benefit. Salehpour 2019 (mouse, starred): antidepressant-like, antioxidant effects.
How it may work
NIR light absorbed by cortical cytochrome c oxidase boosts cerebral metabolism and ATP, promotes neuroplasticity, modulates endogenous opioids, and lowers neuroinflammation and oxidative stress; animal work links benefit to restored mitochondrial membrane potential and antioxidant capacity.
What complicates this
The positive RCT (ELATED-2) is small and was not confirmed by the larger ELATED-3; multi-watt open series lack blinding/controls; wide variation in wavelength, power (mW to multi-watt), and montage. Some 'light' effects (SAD) may not be PBM-specific.
Safety notes
tPBM was fairly well tolerated with no serious adverse events in trials; standard eye protection and dose limits apply. Adjunct only — does not replace antidepressants, psychotherapy, or crisis care; screen for bipolarity before antidepressant-type interventions.
pbm-008: Transcranial PBM reduces depression symptoms (not sleep) — Grade B Moderate
Moderate evidence· Mixed findings
Transcranial PBM significantly alleviated depression symptoms vs. sham across 11 RCTs (SMD -0.55); sleep outcomes were NOT significantly improved in the same meta-analysis. Requires skull-contact NIR device — not consumer panels.
Studied in Adults with depression; some treatment-resistantclinical studies
How strong the finding is
2024 Frontiers Psychiatry meta-analysis 11 RCTs PMC10866010; PMC12457395; PMC11671386. Source: PMC10866010. Dossier claim id pbm-008. POOR consumer transfer — skull-contact required.
How it may work
NIR penetrates skull, activates CCO in prefrontal cortex, increases BDNF and cerebral blood flow.
What complicates this
Sleep null finding — caution for sleep marketing. Consumer masks/panels do not deliver effective transcranial fluence.
Safety notes
Avoid cranial irradiation over known brain malignancy; active epilepsy near site.
PBM in multiple sclerosis: strong anti-inflammatory effect in EAE models, human benefit so far for muscle performance
Limited evidence· Mixed findings
In experimental autoimmune encephalomyelitis (the standard MS model), PBM consistently reduces clinical disease score, delays onset, lowers CNS nitric oxide, attenuates demyelination and boosts oligodendrocyte precursors (Gonçalves 2016, Muili 2012, Duarte 2018) — a robust disease-modifying signal in animals. In people, the controlled human evidence is narrower: a double-blind crossover RCT (Rouhani 2024) found high-dose PBMT improved muscle force recovery in pwMS, though fatigue didn't reliably change. So the honest claim is disease-modifying in animals, symptom-supportive (muscle performance) in early human data — not proven to alter MS itself in humans.
Studied in MS — EAE/cuprizone animal models (disease-modifying) and people with MS (muscle performance)mixed
How strong the finding is
18 studies (7 human, 5 animal). Starred animal: Gonçalves 2016 (660/904 nm; lower EAE score, less CNS NO), Muili 2012 (670 nm; reduced severity), Duarte 2018 (808 nm; attenuated demyelination, more OPCs). Human: Rouhani 2024 (double-blind crossover RCT; high-dose PBMT improved force recovery, fatigue unchanged); Silva 2020 (non-RCT; raised IL-10).
How it may work
PBM down-regulates CNS nitric oxide and pro-inflammatory signaling and supports remyelination (oligodendrocyte precursors) in EAE; in patients, improved mitochondrial function plausibly underlies better muscle force recovery.
What complicates this
Disease-modifying data are animal-only; the human RCT addresses muscle performance, not demyelination, and fatigue didn't improve. EAE penetration/dosing don't translate directly to human CNS.
Safety notes
Human PBMT for muscle performance was well tolerated. No human evidence that PBM modifies MS disease course — do not present it as disease-modifying. Strict adjunct to disease-modifying therapy and neurologic care.
PBM for Parkinson's: powerful neuroprotection in animal and primate models, but human RCTs so far are negative
Limited evidence· Mixed findings
Parkinson's is the clearest case of PBM's preclinical-vs-clinical gap. In MPTP mouse and macaque models, NIR light (670/810 nm) repeatedly rescued dopaminergic neurons in the substantia nigra and improved motor behavior — even in a primate model the authors framed as a template for clinical translation. Yet the human RCTs to date show no statistically significant effect on most clinical outcomes vs placebo (Bullock-Saxton 2021, Santos 2019). So the mechanism is robust and genuinely exciting, but human efficacy is unproven — an honest 'not yet,' not a dismissal.
Studied in Parkinson's disease — MPTP mouse/primate models (neuroprotection) and PD patients (human RCTs, largely null)mixed
How strong the finding is
67 studies (26 animal, 15 human incl. 2 RCTs). Starred preclinical: Darlot 2016 (macaque MPTP, 670 nm; reduced clinical signs, neuroprotection), Kim 2017 (mouse, 670 nm; ~half of dopaminergic neurons rescued), Reinhart 2016 x2 (mouse, 670/810 nm; combined wavelengths and broad time-window benefit). Human RCTs: no significant effect on most outcomes.
How it may work
NIR light protects nigral dopaminergic neurons via cytochrome-c-oxidase-driven mitochondrial support and reduced oxidative stress/apoptosis; remote (e.g., limb/dorsum) irradiation also appears to confer protection, suggesting a systemic 'remote conditioning' pathway alongside direct effects.
What complicates this
Human RCTs are largely negative on primary outcomes; the strongest animal data use deep/implanted or high-penetration delivery that doesn't translate to non-invasive human dosing through the skull. Mechanistic promise has not become clinical benefit.
Safety notes
Transcranial/remote PBM has been well tolerated in PD trials; deep midbrain delivery in animals used implanted fibers (invasive) not applicable to consumer use. Strict adjunct to dopaminergic and standard PD care, with no current proof of clinical benefit.
PBM for traumatic brain injury: robust neuroprotection in animals, but the human RCT signal is non-significant
Limited evidence· Mixed findings
Preclinical TBI work is strong and consistent — transcranial 810 nm light preserved mitochondrial membrane potential, cut apoptosis and reactive oxygen species, increased synaptic proteins and neuron survival, and improved neurological scores in rodent models (with a clear treatment-schedule dependence: 1-3 sessions helped, 14 did not). In humans, however, the controlled signal is weaker: in moderate TBI, PBM showed only statistically non-significant improvement over sham (Longo 2020). So the honest read is a compelling mechanism awaiting convincing human confirmation — direction mixed.
Studied in Traumatic brain injury — rodent models (strong) and patients with moderate TBI (non-significant human RCT signal)mixed
How strong the finding is
54 studies (24 animal, 17 human, 9 reviews). Starred animal: Dong 2015 (810 nm, reversed hypoxic apoptosis), Yang 2019 (808 nm, more synaptic proteins/neurons), Xuan 2013 (810 nm, 18 J/cm2; 1-3 sessions improved NSS, 14 did not), Moreira 2009 (660/780 nm, cytokine modulation). Human: Longo 2020 RCT (non-significant improvement vs sham).
How it may work
Transcranial NIR sustains mitochondrial membrane potential and cytochrome-c-oxidase-driven ATP under hypoxia, limits cytochrome-c leakage and apoptosis, lowers ROS, reduces reactive gliosis, and supports synaptic protein expression and neuronal survival in injured cortex.
What complicates this
The pivotal human RCT was non-significant; animal penetration vastly exceeds human; benefit is schedule-sensitive (more is not better). Mechanistic strength has not yet translated to a clear human outcome.
Safety notes
Transcranial PBM was well tolerated in human TBI studies; dosing schedule matters (over-treatment lost benefit in mice). Adjunct to standard neurocritical/rehabilitation care, not a replacement.
PBM gives meaningful symptom and pain relief in oral chronic GVHD - consistent case series, no RCT yet
Limited evidence· Points toward a benefit
Across ~7 human reports (case series and a retrospective cohort), photobiomodulation reduced pain and mucosal symptoms in oral chronic graft-versus-host disease, often refractory to topical steroids. Finfter 2021 found at least 50% pain reduction in 77% of 56 sessions (mean pain 5.2 to 1.4), and Epstein's series documented improved oral sensitivity, dryness, and even fibrotic changes. The consistency across independent groups is encouraging for this hard-to-manage, non-immunosuppressive adjunct, but the absence of randomized trials keeps the grade at limited - confirmatory controlled studies are explicitly called for.
Studied in Post-allogeneic-HSCT patients with symptomatic oral chronic GVHDclinical studies
How strong the finding is
8 studies (7 human, 1 review): Finfter 2021 (retrospective, 11 patients/56 sessions, >=50% pain relief in 77%, mean 5.2 to 1.4), Epstein 2016/2017/2020 (case series, 660-850 nm intra-/extra-oral).
How it may work
PBM modulates inflammatory cytokines, promotes mucosal repair, and provides analgesia via mitochondrial photon absorption (cytochrome c oxidase -> ATP) - offering symptom control without adding to the systemic immunosuppression these patients already carry.
What complicates this
All human evidence is uncontrolled (case series/retrospective); concurrent steroid use and small samples prevent causal attribution. Wavelengths and intra- vs extra-oral delivery vary.
Safety notes
Standard PBM safety with intra-/extra-oral delivery, under oncology/transplant team oversight. Adjunct to standard GVHD care, not a replacement for systemic management.
Sinus phototherapy for chronic rhinosinusitis: real 830 nm LLLT signals, but a mixed and partly UV-based trial record
Limited evidence· Mixed findings
Across several small human trials, light therapy to the sinuses has produced inconsistent results: an 830 nm LLLT sham-controlled trial improved total symptom scores (Cohen's d ≈ 0.69), and mixed UV/visible rhinophototherapy helped chronic rhinosinusitis with nasal polyps, yet a double-blind UV/VIS trial in CRS without polyps found no benefit over placebo. The honest read is encouraging-but-heterogeneous, and several 'positive' studies used ultraviolet/visible rhinophototherapy rather than pure red/NIR PBM. Treat sinus PBM as an adjunct to standard CRS management, not a replacement.
Studied in Adults with chronic rhinosinusitis (with and without nasal polyps); some acute/chronic maxillary sinusitisclinical studies
How strong the finding is
Evidence base: 2 human RCTs + 4 human non-RCTs (study_count 10). Naghdi 2022 (830 nm, n=20 crossover) improved TSS vs sham (d ≈ 0.69); Kiricsi 2017 (RCT, n=87 UV/VIS) improved polyp-associated CRS at 3 months; Dulguerov 2017 (double-blind RCT, n=50 UV/VIS) was negative; Kruchinina 1991 (He-Ne 633 nm) reported improved microcirculation.
How it may work
Red/NIR PBM acts via cytochrome c oxidase to lower mucosal oxidative stress and pro-inflammatory mediators and improve microcirculation; UV-containing rhinophototherapy works by a distinct, partly immunosuppressive/antimicrobial photomechanism on nasal mucosa.
What complicates this
Wavelength heterogeneity is the core caveat — UV/VIS rhinophototherapy is mechanistically different from red/NIR PBM, so pooling them overstates the PBM case. Trials are small, devices and delivery sites differ, and the best-designed UV/VIS RCT (Dulguerov) was null.
Safety notes
Pure red/NIR PBM is well tolerated; UV-containing rhinophototherapy carries the usual UV-exposure cautions for mucosa. Adjunct to saline, intranasal steroids, and ENT care — not a substitute.
LED and fluorescent-light-energy PBM eased rosacea erythema and inflammation in small uncontrolled studies
Limited evidence· Points toward a benefit
Across small case series and one 9-patient single-arm trial (Wade 2021), LED phototherapy - blue (~447-480 nm) plus red (650 nm) light and biophotonic fluorescent light energy (FLE/Kleresca) - reduced papulopustular inflammation, flushing and erythema in rosacea with good tolerability. The evidence is early: mostly uncontrolled case reports/series without blinding, so the true effect size is uncertain. A reasonable adjunct to standard anti-inflammatory rosacea therapy, not a replacement.
Studied in Adults with papulopustular or erythematotelangiectatic rosacea.clinical studies
How strong the finding is
9 studies in base (1 review, 5 human, 1 animal, 1 in vitro, 1 other); grounding = 4 human (Braun 2017, Sorbellini 2020, Wade 2021 n=9 single-arm, Sannino 2018), all directionally toward reduced erythema/inflammation.
How it may work
Red/NIR PBM modulates inflammatory cytokines and oxidative stress and supports barrier repair via cytochrome c oxidase to ATP; blue light adds antimicrobial/anti-inflammatory effects on the pilosebaceous unit; FLE re-emits converted wavelengths into the dermis.
What complicates this
Predominantly case reports/series, small n, no controls or blinding, heterogeneous devices and wavelengths (blue vs red vs FLE), short follow-up; placebo and regression-to-mean not excluded.
Safety notes
Eye protection; blue-light photosensitivity caution; adjunct to standard care; avoid heat that could trigger flushing.
Intravascular red/NIR light during stenting shows softening of restenosis markers — but the one RCT missed its primary endpoint
Limited evidence· Mixed findings
Catheter-delivered intravascular light therapy during coronary stenting has, in single-arm human series, produced low restenosis rates (~14.7% in De Scheerder 2000, n=68) and appeared feasible and safe. However, the lone randomized trial (Derkacz 2010, 808 nm, n=101) found the restenosis-rate difference non-significant (15.0% vs 32.4%) even while minimal lumen diameter and late lumen loss improved significantly. So the signal is real but unproven on hard endpoints. Note this is intravascular delivery during PCI — it has nothing to do with transdermal or full-body red-light devices.
Studied in Patients undergoing percutaneous coronary intervention / coronary stenting.clinical studies
How strong the finding is
1 human RCT (Derkacz 2010, 808 nm, primary endpoint non-significant) plus several single-arm human series (De Scheerder 2000 n=68 and n=81; Kaul 1998 n=22) at 650 nm, and supportive pig/rabbit data.
How it may work
Low-power red/NIR enhances endothelial cell growth and modulates smooth-muscle proliferation and inflammation at the injury site, theoretically limiting neointimal hyperplasia after balloon/stent injury.
What complicates this
Only one RCT, which was negative on its primary restenosis endpoint; single-arm series lack controls; results predate modern drug-eluting stents and may not generalize.
Safety notes
This is an invasive, catheter-based interventional procedure performed by cardiologists — not a consumer or self-administered therapy. No bearing on at-home PBM. Strictly an investigational adjunct to PCI, never a replacement for guideline-directed coronary care.
Diode-laser PBM helps clear denture stomatitis, but antifungals can still outperform it - small, mixed human studies
Limited evidence· Mixed findings
Five small human studies indicate low-level diode laser (typically 685/830 nm) can improve denture stomatitis, including fungicidal effects on Candida and superior mucosal healing versus conventional care (Marei 1997; Maver-Biscanin 2004/2005). The signal is real but modest, and not uniformly superior: Maciel 2015 found topical miconazole outperformed photodynamic therapy plus low-power laser (80% vs 40% cure). Reasonable as an adjunct - especially where antifungal tolerance or compliance is an issue - rather than a first-line replacement for antifungals and denture hygiene.
Studied in Denture wearers with Candida-associated (Newton type I/II) denture stomatitisclinical studies
How strong the finding is
5 human studies: Marei 1997 (controlled, 904 nm, superior healing), Maver-Biscanin 2004 (RCT, 685/830 nm, fungicidal, 3 J/cm2) and 2005 (case series), Maciel 2015 (miconazole 80% vs PDT+laser 40%).
How it may work
PBM accelerates mucosal wound healing and modulates local inflammation (cytochrome c oxidase -> ATP), and at certain parameters exerts direct photo-antimicrobial/fungicidal effects on Candida albicans colonizing the palate and denture base.
What complicates this
Studies are small and heterogeneous; one comparison favored a standard antifungal over PDT+laser. Several combine laser with photodynamic therapy, blurring the PBM-only effect.
Safety notes
Standard PBM safety with intra-oral delivery. Pair with denture disinfection/hygiene; not a substitute for antifungal therapy when indicated. PBM is an adjunct, not a replacement for prescribed medical care.
Infrared/NIR light softened skin and eased Raynaud in localized scleroderma - consistent case-series signal
Limited evidence· Points toward a benefit
Four human case reports/series report that infrared and near-infrared light - water-filtered IR-A plus visible (580-1400 nm), whole-body IR-A (800-1400 nm), and 940 nm NIR - improved skin sclerosis, cosmesis and Raynaud symptoms in cutaneous/linear/limited-systemic scleroderma, including 7 of 10 responders in von Felbert 2011 who had failed conventional therapy. All are uncontrolled, so this is a promising but unproven signal in a hard-to-treat fibrosing disease. PBM/IR is an adjunct to rheumatologic care, not a replacement.
Studied in Patients with cutaneous/linear morphea or limited systemic sclerosis (acrosclerosis/Raynaud).clinical studies
How strong the finding is
4 human reports; von Felbert 2011 (n=10, wIRA+VIS, 7/10 marked improvement), Barolet 2014/2020 (940 nm, lcSSc and linear morphea case reports), Meffert 1990 (whole-body IR-A, n=7, improved Raynaud).
How it may work
NIR/IR-A modulates TGF-beta (a key fibrotic cytokine), reduces oxidative stress, and raises tissue temperature and perfusion (whole-body IR-A), which together may reduce fibrosis and improve acral microcirculation.
What complicates this
All uncontrolled case series/reports; mixing thermal (whole-body IR-A) and non-thermal PBM mechanisms confounds interpretation; small n; no blinding; heterogeneous scleroderma subtypes.
Safety notes
Eye protection; whole-body IR raises core temperature - monitor; adjunct to rheumatology/immunotherapy; distinguish more-responsive localized morphea from systemic disease.
PBM protects/restores hearing in animals but human RCTs are negative - promising mechanism, no proven clinical benefit
Limited evidence· Mixed findings
Hearing loss shows a classic preclinical-clinical gap. Rat studies are encouraging - Lee 2016 (808 nm) and Rhee 2013 (830 nm) both improved hearing thresholds and hair-cell counts - but the two human RCTs here are negative: Williams 2024 (850 nm crossover) found no protection against noise-induced temporary threshold shift, and Goodman 2013 found no audiometric benefit. The honest read: a real, reproducible animal mechanism that has not translated to humans yet, likely due to inadequate light delivery to the cochlea; not a recommended therapy for hearing loss today.
Studied in Animal models (noise/ototoxic injury); adults with hearing loss or noise exposure (human RCTs)mixed
How strong the finding is
14 studies (9 animal, 2 human, 2 reviews). Animal-positive: Lee 2016 (rat, 808 nm), Rhee 2013 (rat, 830 nm, better threshold and hair cells). Human-negative: Williams 2024 (RCT crossover, n=30, 850 nm, no TTS protection), Goodman 2013 (double-blind RCT, n=33, no benefit).
How it may work
PBM may protect and regenerate cochlear hair and neural cells via mitochondrial photon absorption (ATP, reduced oxidative stress) - the bottleneck in humans is likely delivering adequate light energy to the cochlea through the temporal bone.
What complicates this
Strong animal signal contradicted by negative human RCTs; the human trials had poorly reported parameters and questionable energy delivery to the cochlea, so failure may reflect dosing rather than a true null.
Safety notes
Standard PBM safety. Not an evidence-based human treatment for hearing loss; do not use in place of audiologic evaluation and management. PBM is an adjunct, not a replacement for prescribed medical care.
PBM raises pain thresholds fast — strong animal mechanism plus early human experimental-pain support
Limited evidence· Points toward a benefit
In rodent models, red-to-NIR phototherapy produces rapid, robust analgesia: multisource 890 nm LED cut formalin/acetic-acid nocifensive behavior, and 810 nm PBM to the dorsal root ganglion more than tripled paw pain thresholds (de Sousa 2018). Human experimental-pain trials back this up — pulsed 830 nm raised Aδ- and C-fiber thresholds versus sham, and blue light reduced spontaneous pain and hyperalgesia. The mechanism is well-mapped and the early human signal is encouraging; PBM is a reasonable analgesic adjunct, with clinical (vs experimental) acute-pain trials still the gap to close.
Studied in Preclinical pain models (mice) and healthy adults in experimental acute-pain paradigmsmixed
How strong the finding is
Base study_count 9 (4 animal, 2 human, 3 review). Pigatto 2017 (mouse, 890 nm, starred) and de Sousa 2018 (mouse, 810 nm, starred): rapid analgesia, >3× threshold increase via DRG targeting. Reuss 2021 (human crossover RCT): blue light reduced spontaneous pain/hyperalgesia. Takeuchi 2026 (human sham-controlled RCT): higher Aδ/C-fiber thresholds (moderate effect sizes).
How it may work
PBM modulates nociception by acting on cytochrome c oxidase in neurons along the pain pathway (DRG, nerve, cortex), altering mitochondrial signaling, slowing conduction in small pain fibers, and reducing local inflammatory mediators; the location of irradiation (e.g., over the DRG) is critical.
What complicates this
Human data are experimentally induced pain in healthy volunteers, not clinical acute pain; wavelengths span blue to NIR with different mechanisms; effect sizes are moderate and short-lived, and optimal dose/location are still being defined.
Safety notes
Non-invasive and well tolerated at non-thermal doses; eye protection standard. Adjunct for acute pain — does not replace appropriate analgesia or work-up of the pain's cause.
Transcranial PBM measurably increases brain blood flow and oxygenation in humans — a reproducible physiologic effect
Limited evidence· Points toward a benefit
Multiple human studies converge on a real, measurable hemodynamic effect: a single transcranial PBM session increases oxygenated hemoglobin and decreases deoxygenated hemoglobin in both hemispheres (Tian 2016, 1064 nm), and transcranial LED therapy raised middle-cerebral and basilar artery flow velocities by 17-30% with lower pulsatility in older women (Salgado 2015). This is one of the better-documented mechanistic effects of brain PBM. The honest framing: these are short-term, mostly uncontrolled physiologic measurements — they establish the mechanism, not a clinical outcome.
Studied in Healthy adults and older adults (acute cerebral hemodynamic/oxygenation response)clinical studies
How strong the finding is
7 studies (4 human). Tian 2016 (1064 nm, 0.25 W/cm2; bilateral rise in HbO2, fall in Hb), Salgado 2015 (627 nm, 10 J/cm2; +25-30% MCA velocity, +17-25% basilar, lower pulsatility/resistance indices), Hu 2023 (1064 nm; cortical activation changes), Litscher 2019 (810 nm; increased regional oxygen saturation).
How it may work
NIR light stimulates nitric-oxide release (photo-dissociation from cytochrome c oxidase and intracellular stores), producing local vasodilation and increased regional cerebral blood flow and tissue oxygenation, measurable by fNIRS, transcranial Doppler and regional oxygen saturation.
What complicates this
Mostly single-session, uncontrolled or small; demonstrates a biomarker change (flow/oxygenation), not a downstream clinical benefit. Whether the hemodynamic boost translates to outcomes remains to be shown.
Safety notes
Acute exposures were well tolerated; note that strong PBM-induced vasodilation warrants caution in cerebrovascular disease (see brain-aging adverse case). This is a physiologic-effect claim, not a treatment for any specific disorder.
Laser/light for onychomycosis is genuinely mixed — open-label success, but a double-blind RCT found it ineffective
Limited evidence· Mixed findings
Onychomycosis is a cautionary tale in honest grading. Open-label and retrospective studies look good — 89% clinical improvement with a triple-wavelength (650/810/915 nm) laser plus abrasion (Aukstikalnyte 2022), reduced severity and positive-culture rates with Nd:YAG 1064 nm (Hees 2014), and 46.6% excellent improvement retrospectively (Kiran 2024). But the most rigorous test, a prospective double-blind randomized controlled trial, concluded that 1064 nm Nd:YAG laser was not effective for onychomycosis (Sabbah 2019). Importantly, much of this is photothermal Nd:YAG laser, not classic photobiomodulation. Net: encouraging uncontrolled data undercut by a negative RCT — direction mixed, grade limited.
Studied in Patients with toenail onychomycosis (often elderly or with thick nails).clinical studies
How strong the finding is
~7 studies incl. 2 RCTs; positive open-label/retrospective (Aukstikalnyte 2022 650/810/915 nm, 89%; Hees 2014 Nd:YAG; Kiran 2024) but negative double-blind RCT (Sabbah 2019, 1064 nm, not effective).
How it may work
Proposed mechanisms are photothermal (Nd:YAG heating to damage fungal elements) and, for lower-power devices, photobiomodulatory stimulation of nail-bed healing; mechanical abrasion often accompanies treatment.
What complicates this
Best-controlled trial negative; positive studies uncontrolled/retrospective and often combined with nail abrasion; much is photothermal Nd:YAG, not PBM; severity classification often unchanged.
Safety notes
Standard laser/PBM safety. Given the negative RCT, set expectations modestly; antifungal therapy remains primary. Laser/light is at most an adjunct, never a replacement for prescribed antifungal treatment.
Light therapy improves psoriasis plaques — mostly blue light evidence, with promising red/NIR series
Limited evidence· Points toward a benefit
Psoriasis responds to visible-light therapy, though the strongest controlled data are for blue light rather than classic red/NIR PBM. Randomized trials show high-dose blue (420 nm) and red (630 nm) both improved plaques, with blue continuing to reduce erythema (Kleinpenning 2012), and 453 nm blue light significantly improved the Local Psoriasis Severity Index versus untreated control plaques (Pfaff 2015). A red+NIR (633+830 nm) LED case series reported 60-100% clearance with high satisfaction (Ablon 2010), and a red/NIR-emitting fabric helped some patients (Pixley 2023). Honest read: real benefit for localized plaques, much of it blue-light-driven; red/NIR data are promising but smaller and partly uncontrolled.
Studied in Patients with mild, localized plaque psoriasis.clinical studies
How strong the finding is
~8 studies; Pfaff 2015 RCT (453 nm, significant LPSI improvement), Kleinpenning 2012 RCT (420 vs 630 nm, both improved), Ablon 2010 case series (633+830 nm, 60-100% clearance), Pixley 2023 case series (red/NIR fabric).
How it may work
Blue light (420-453 nm) reduces keratinocyte hyperproliferation and modulates T-cell-driven inflammation; red/NIR (630-830 nm) adds anti-inflammatory and healing effects via cytochrome c oxidase/ATP.
What complicates this
Strongest controlled data are blue light, not red/NIR; red/NIR evidence smaller and partly uncontrolled; small samples; localized plaques only.
Safety notes
Standard PBM safety; home blue-light treatment showed high compliance and satisfaction. A useful adjunct for limited plaques; not a replacement for systemic or biologic therapy in moderate-to-severe psoriasis.
Transcranial PBM improves cognition in mild cognitive impairment — consistent human gains, with notable responder variability
Limited evidence· Points toward a benefit
Several human studies in older adults with mild cognitive impairment show transcranial PBM improving global cognition, working memory and regional cerebral blood flow (Lee 2025 controlled, Baik 2021, Chun 2026), with effects tracked by fNIRS and SPECT. The signal across studies is encouraging for a population with few good options. Two honest caveats: many studies are single-arm or small, and a recurring theme is that a meaningful fraction of people are non-responders — so individual benefit is variable and not guaranteed.
Studied in Older adults with mild cognitive impairment / cognitive declineclinical studies
How strong the finding is
18 studies (10 human). Lee 2025 (non-randomized controlled, n=36, 810 nm; better visual working memory, MoCA, anti-saccade latency vs control), Baik 2021 (single-arm, n=14, 610 nm; rCBF and cognition trends), Lee 2024 and Chun 2026 (fNIRS-based responder/non-responder prediction).
How it may work
Transcranial NIR increases cytochrome-c-oxidase activity and regional cerebral blood flow (nitric-oxide-mediated), improving prefrontal/cortical bioenergetics and hemodynamic efficiency that underlie working memory and global cognition.
What complicates this
Many designs are single-arm or small with surrogate (fNIRS/SPECT) endpoints; explicit responder/non-responder split (e.g., ~half non-responders in some cohorts) limits generalizable efficacy. Wavelengths and durations vary.
Safety notes
Home-based and clinic transcranial protocols reported as well tolerated. Responder status varies — set realistic expectations. Adjunct/wellness use alongside, not instead of, medical cognitive evaluation and care.
PBM eases pain and swelling after total knee replacement - small RCTs positive, larger trials needed
Limited evidence· Points toward a benefit
Several small human RCTs support PBM after total knee arthroplasty. Bahrami 2022 (n=45, 804 nm) showed greater range of motion through 3 months, Chia 2025 (n=30) found less postoperative swelling and longer walking distance, and Huang 2022 (sham-controlled, n=82, 808 nm laser acupuncture) reduced pain and morphine use in the first 72 hours. Consistent early-recovery benefits make PBM a reasonable adjunct for post-TKA rehabilitation, though trials are small, sometimes unblinded, and parameters are inconsistently reported.
Studied in Patients recovering from primary total knee arthroplastyclinical studies
How strong the finding is
6 studies (4 human, 1 review). Key: Bahrami 2022 (RCT, n=45, 804 nm, higher ROM through 3 mo), Chia 2025 (RCT, n=30, less swelling, longer walk distance), Huang 2022 (sham RCT, n=82, 808 nm acupuncture, lower pain/morphine at 72 h).
How it may work
PBM reduces postoperative inflammation and edema and provides analgesia (ATP/anti-inflammatory and possible neural effects), supporting earlier mobilization and range-of-motion gains.
What complicates this
Small, single-center, sometimes non-blinded samples; one ROM advantage faded by 12 months and parameters are under-reported. Some benefit may overlap with concurrent analgesia/rehab.
Safety notes
Standard PBM safety with localized peri-knee delivery. Adjunct to multimodal analgesia and physiotherapy; not a replacement for standard perioperative care.
Transcranial PBM for bipolar disorder: early cognition and mitochondrial signals, evidence still small and uncontrolled
Limited evidence· Points toward a benefit
Small human studies suggest transcranial infrared laser (1064 nm) to the prefrontal cortex can raise oxidized cytochrome c oxidase and cerebral oxygenation and improve cognitive flexibility/impulsivity in older euthymic bipolar patients (O'Donnell 2021, small sham-controlled crossover), and a four-patient case series reported reduced anhedonia. The mechanistic rationale — targeting prefrontal mitochondrial hypometabolism — is strong, but the clinical evidence is preliminary (tiny samples, mostly single-arm). Position tPBM as an experimental adjunct for cognitive symptoms, never a replacement for mood stabilizers, and with caution given mania-activation theory.
Studied in Adults (often older) with bipolar disorder, primarily targeting cognitive symptoms; euthymic patients in the controlled workclinical studies
How strong the finding is
1 human non-RCT + 1 case series in the rating (study_count 4). O'Donnell 2021 (sham-controlled crossover, n=5): improved cognitive flexibility/impulsivity over 5 weekly 1064 nm sessions. O'Donnell 2023 (n=15) and Gonzalez-Lima 2025 (n=29) document CCO/oxygenation changes and response prediction. Mannu 2019 (4-case series): reduced anhedonia/apathy.
How it may work
1064 nm photons photo-oxidize cytochrome c oxidase in prefrontal mitochondria, increasing oxidized CCO and the oxygenated/deoxygenated hemoglobin balance (HbD), thereby boosting prefrontal metabolism and oxygenation — directly addressing the mitochondrial dysfunction and PFC hypometabolism seen in bipolar disorder.
What complicates this
Extremely small samples, single-arm or n=5 crossover designs, and surrogate (fNIRS/CCO) endpoints in the mechanistic studies; no adequately powered RCT, and durability/mood-safety during active episodes is untested.
Safety notes
Generally well tolerated in small studies; theoretical risk of mood activation/switch with any antidepressant-like neuromodulation warrants monitoring. Strict adjunct to mood-stabilizing pharmacotherapy and psychiatric care.
Laser-acupuncture PBM improved childhood asthma control in small RCTs; strong anti-inflammatory animal data — but never replace controllers
Limited evidence· Points toward a benefit
Small pediatric RCTs of low-level laser applied to acupuncture points report better asthma control, improved spirometry, and lower exhaled oxidative-stress markers versus sham (Dabbous 2017: 91.7% vs 25% improved control). This sits on a large, mechanistically rich animal literature where 660-780 nm LLLT reduces bronchial hyperresponsiveness, Th2 cytokines, and eosinophilia. The human signal is encouraging but comes mostly via laser acupuncture in children, so it is a limited-to-moderate adjunct case — and a hard safety line: PBM must never replace inhaled controllers or rescue therapy in asthma.
Studied in Children with bronchial asthma (human trials); allergic-asthma animal modelsmixed
How strong the finding is
2 human RCTs in the rating; base study_count 16 (10 animal, 3 human). Dabbous 2017 (RCT, n=48, 780 nm acupoints): 91.7% vs 25% improved control, better FENO/spirometry. Elseify 2013 and Elsheikh 2019: improved symptoms/airway resistance. Silva 2014 (mouse, 660 nm, starred): reduced BHR and Th2 inflammation.
How it may work
In airway models, PBM downregulates RhoA and NF-κB-driven Th2 cytokines (IL-4/5/13), ICAM-1, and eosinophil/eotaxin signaling and restores oxidant balance via cytochrome c oxidase-mediated effects; the human studies add a traditional acupoint-stimulation route.
What complicates this
Human evidence is small, mostly pediatric, and delivered as laser acupuncture (a different paradigm than direct chest PBM), raising risk of acupuncture/placebo confounding; the bulk of mechanistic data is animal. No large or adult RCTs.
Safety notes
PBM/laser acupuncture is non-invasive and well tolerated, but asthma is potentially life-threatening: PBM is strictly adjunctive and must not substitute for inhaled corticosteroids, bronchodilators, or emergency care. Any controller change needs physician oversight.
Transcranial PBM shows encouraging, replicated signals in autism — small RCTs positive, larger confirmation needed
Limited evidence· Points toward a benefit
Two randomized sham-controlled trials reported real improvements with PBM in ASD: Leisman 2018 cut Aberrant Behavior Checklist irritability (adjusted mean difference −15.17 vs placebo) with red-laser application to the skull/temporal areas, and Fradkin 2024 improved CARS scores (between-group difference 7.23) with 850 nm transcranial PBM in young children. Open-label and retrospective transcranial studies echo benefits on social responsiveness and rigidity. This is a genuinely promising, mechanism-plausible signal for a condition with few options — but samples are small and it must be framed as an adjunct under clinical supervision, not a cure.
Studied in Children, adolescents, and adults with autism spectrum disorderclinical studies
How strong the finding is
1 human RCT + 1 non-RCT in the rating; broader base study_count 10 (6 human). Leisman 2018 (RCT, n=40, 635 nm): large drop in ABC irritability. Fradkin 2024 (double-blind RCT, n=30, 850 nm, 40 Hz): improved CARS. Ceranoglu 2022 (open-label, n=10): SRS-2 −30.6. Pallanti 2022 (retrospective, n=21): lower CARS, better sleep.
How it may work
Transcranial NIR light penetrates to cortex where cytochrome c oxidase absorbs it, increasing neuronal ATP and cerebral oxygenation, promoting neuroplasticity, and reducing neuroinflammation and oxidative stress; EEG changes accompany clinical shifts in some trials.
What complicates this
Small samples, short durations, heterogeneous devices/protocols (wavelength, pulse frequency, montage) and outcome scales; open-label/retrospective designs are prone to expectancy effects. No large confirmatory RCT yet.
Safety notes
tPBM was well tolerated with no serious adverse events in these trials; standard eye protection applies. Adjunct to behavioral and clinical care — not a replacement, and families should avoid unproven 'cure' framing.
Red LED (630 nm) reduced disease-activity scores in scarring alopecia - single pilot trial, needs controls
Limited evidence· Points toward a benefit
A 16-patient single-arm pilot (Gerkowicz 2019) using 630 nm superluminescent LEDs as an adjuvant in frontal fibrosing alopecia and lichen planopilaris significantly reduced disease-activity scores (LPPAI p=0.012, FFASS p=0.017) and increased thick-hair counts over 10 weeks, well tolerated. This is a single uncontrolled pilot plus small case reports; a systematic review (Jafari 2024) notes most LLLT alopecia data are in androgenetic, not cicatricial, alopecia. Encouraging as an adjuvant to standard immunomodulatory therapy, not a stand-alone cure for scarring alopecia.
Studied in Patients with primary cicatricial (scarring) alopecia - FFA, LPP - on stable topical/systemic therapy.clinical studies
How strong the finding is
study_count 4 (3 human, 1 review); key = Gerkowicz 2019 pilot n=16, 630 nm, significant LPPAI/FFASS reduction; plus Cook 2023 case series and Larrondo 2025 brief report.
How it may work
Red PBM modulates perifollicular inflammatory cytokines and oxidative stress and may extend anagen via cytochrome c oxidase to ATP, potentially slowing follicular fibrosis.
What complicates this
Single small uncontrolled pilot, no sham; review evidence for LLLT in cicatricial alopecia is sparse and mostly extrapolated from androgenetic alopecia; heterogeneous subtypes.
Safety notes
Eye protection; adjunct to immunomodulatory therapy; scarring alopecia causes irreversible follicle loss, so set expectations - PBM aims to slow activity, not regrow scarred areas.
Low-level laser/red-light improved visual acuity in amblyopia — including in adults — but evidence is small and mixed in design
Limited evidence· Points toward a benefit
Amblyopia is classically treatable only in childhood, so the signal here is interesting: Ivandic (2012) reported visual-acuity gains in ~90% of treated eyes (>=3 lines in over half) in 178 mostly adult patients with 780 nm laser, and a 2025 pediatric randomized study found low-level red light accelerated acuity gains while slowing axial elongation in myopic amblyopia (Li 2025). A 2026 case report adds an anecdotal adult signal. Promising and mechanism-plausible, but built on one older RCT/comparison, a small pediatric trial and case-level data.
Studied in Children and adults with amblyopia (ametropic/strabismic/anisometropic)clinical studies
How strong the finding is
4 studies (3 human): Ivandic 2012 (n=178, 780 nm, ~90% eyes improved, p<0.001, +>=3 lines in ~54-56%, ~6-month durability), Li 2025 (randomized pediatric, n=66, 650 nm RLRL accelerated BCVA and retarded axial growth), Zhu 2026 (case report).
How it may work
Retinal/macular PBM may enhance photoreceptor and retinal-ganglion-cell mitochondrial function and neural plasticity, and (with red light) modulate axial-growth signaling — potentially improving acuity beyond the classical critical period.
What complicates this
Ivandic is partly retrospective/single-blinded; small samples; one positive trial bundles myopia-control effects with amblyopia; case-report-level adult evidence is hypothesis-generating only.
Safety notes
Direct ocular light exposure requires validated low-power dosimetry and ophthalmologic supervision; red-light devices have associated retinal-safety discussions in myopia care. Adjunct to refractive correction/occlusion, not a replacement.
PBM accelerates fracture/defect bone healing across a deep animal literature - human translation is early but plausible
Limited evidence· Points toward a benefit
Bone repair has a very large preclinical PBM literature (~187 animal studies) showing accelerated healing: Magri 2015 and Nascimento 2015 (rat, 780-808 nm) found more new bone, higher alkaline phosphatase, and healing in diabetic animals approaching that of healthy controls, and systematic reviews converge on roughly 5 J/cm2 at low irradiance as an effective dose window. Human data remain sparse (only ~3 studies here), so this is a strong, well-mapped mechanism with translation still in early stages - promising as an adjunct to fracture/graft healing to be confirmed in human trials, not yet a proven clinical standard.
Studied in Predominantly animal models (rat/rabbit/mouse/sheep); limited human fracture/graft-healing datamixed
How strong the finding is
205 studies (187 animal, 3 human, 7 in vitro, 6 reviews). Key: Magri 2015 and Nascimento 2015 (rat, 780-808 nm, more new bone/ALP), Bao 2025 and Dos Santos 2025 (systematic reviews: ~5 J/cm2 low-irradiance optimum; 780/808 nm common).
How it may work
PBM drives osteoblast proliferation/differentiation, angiogenesis, and inflammation resolution via mitochondrial (cytochrome c oxidase), opsin, and TRPV-channel signaling, raising ATP and remodeling activity at the repair site - most effective in a mid-dose window (~5 J/cm2, low irradiance), with excessive irradiance inhibitory.
What complicates this
Human evidence is minimal relative to the animal base; preclinical protocols vary enormously and excessive irradiance can be inhibitory. Reviews stress the need for standardized parameters and clinical trials.
Safety notes
Standard PBM safety with localized delivery. Human bone-repair use is early-stage and adjunctive at best; do not replace fixation, weight-bearing protocols, or standard fracture care.
PBM for chemo-induced alopecia improves quality of life and animal regrowth — but RCTs haven't proven hair-density gains
Limited evidence· Mixed findings
For chemotherapy-induced alopecia the signal is genuine but mixed. In a rat model, a 655 nm laser comb significantly accelerated regrowth without compromising chemotherapy efficacy (Wikramanayake 2013). Two human RCTs in breast-cancer patients consistently improved quality-of-life and global-health scores with PBM (Lodewijckx 2023, 678 nm; Claes 2025), yet neither showed a statistically significant difference in scalp coverage or hair thickness versus control. Honest read: encouraging animal data and reproducible QoL benefit, but human hair-regrowth efficacy is not yet demonstrated, and trials are small.
Studied in Cancer patients (mostly breast cancer) with chemotherapy-induced alopecia; plus a rat CIA model.clinical studies
How strong the finding is
~5 studies (2 human RCTs, 1 starred rat, commentary); Wikramanayake 2013 rat (655 nm, faster regrowth, chemo efficacy preserved), Lodewijckx 2023 RCT (678 nm, better QoL) and Claes 2025 RCT (PBM+scalp cooling, QoL up, no significant coverage gain).
How it may work
Red/NIR stimulates follicular cell proliferation and repair via cytochrome c oxidase/ATP, theoretically protecting and reactivating follicles stressed by cytotoxic chemotherapy.
What complicates this
RCTs positive on QoL but not on objective hair coverage/thickness; small samples; rat parameters poorly reported; combination with scalp cooling clouds attribution.
Safety notes
Standard PBM safety. A theoretical oncologic concern (light effects on residual tumor) means PBM over the scalp in active cancer should be clinician-supervised; animal data showed no loss of chemo efficacy but human reassurance is limited. Adjunct only, never a replacement for oncology care or scalp cooling.
Light therapy improved skin-graft donor-site outcomes - RCT positive on healing, controlled series shows mainly pain relief (mixed)
Limited evidence· Mixed findings
Four human studies address PBM/light for split-thickness skin-graft donor sites: a self- and sham-controlled RCT (Monstrey 2002, n=20, polarized 400-2000 nm light) showed significantly better donor-site healing across nearly all variables, while a controlled case series (Carboni 2021, 660 nm) found no change in re-epithelialization or wound area but a real reduction in pain. Case reports add that wIRA rescued infected donor sites. The evidence is encouraging but mixed across endpoints and small - a reasonable adjunct for donor-site comfort and possibly healing, not a guaranteed accelerator of closure.
Studied in Patients with split-thickness skin-graft donor sites (including burn patients).clinical studies
How strong the finding is
4 human studies; Monstrey 2002 (starred RCT, n=20, polarized 400-2000 nm, significantly better scores on nearly all variables); Carboni 2021 (controlled series, 660 nm, 1.53 J/cm2, no re-epith/area change but less pain); Aljasir 2018 (wIRA, infected donor site); Kiyoizumi 1988 (830 nm + in-vitro PGI2/vasodilation).
How it may work
Red/NIR/polarized light via cytochrome c oxidase to ATP enhances fibroblast/keratinocyte activity, angiogenesis (PGI2-mediated vasodilation shown in vitro) and analgesia, supporting donor-site repair; wIRA adds perfusion/oxygenation.
What complicates this
Small n; controlled studies disagree on re-epithelialization vs pain endpoints; heterogeneous devices (polarized broadband, wIRA, 830, 660 nm); some are case reports; placebo and co-care confound.
Safety notes
Eye protection; adjunct to standard donor-site dressing and wound care; rule out infection; results vary by endpoint.
PBM for blood pressure is a mixed bag — modest, often transient signals and at least one negative RCT
Limited evidence· Mixed findings
Human data on PBM and hypertension are genuinely mixed. An older single-arm study reported an 80% effectiveness rate (Umeda 1990, 830 nm), and a 635 nm course reduced daytime systolic/diastolic pressure by roughly 7% in patients with hypertension plus hyperuricemia (Kovalenko 2018); a large observational series found only minimal, transient BP reductions (Fatu 2025, n=268). But a randomized trial of intravascular laser (Pacheco 2024, 660 nm ILIB) found no significant effect on systolic or diastolic pressure. Net: an honest signal toward modest, possibly transient effects, not reliable antihypertensive efficacy — and several positive studies used systemic/intravascular delivery rather than a skin device.
Studied in Adults with hypertension (often with comorbidities such as hyperuricemia or musculoskeletal disease).clinical studies
How strong the finding is
~14 studies (5 human, 6 animal, 1 review, others); 1 RCT negative on BP (Pacheco 2024 ILIB 660 nm), single-arm/observational positive but modest (Umeda 1990; Kovalenko 2018 ~7%; Fatu 2025 minimal/transient).
How it may work
Proposed effects include NO-mediated vasodilation, improved endothelial function, and reduced uric acid / oxidative stress, lowering vascular tone and blood pressure.
What complicates this
Randomized data negative on BP; positive studies small, uncontrolled, or observational; heterogeneous delivery (ILIB vs transdermal); transient effects; confounding comorbidities.
Safety notes
Standard PBM safety. Effects on BP appear small and inconsistent; hypertension requires monitoring and proven therapy. PBM is at most an adjunct and must never replace antihypertensive medication or lifestyle management.
PBM for infertility shows positive but non-significant trends - promising leads, no controlled proof yet
Limited evidence· Mixed findings
Human infertility data for PBM are suggestive but not conclusive: a controlled study (Tsai 2020, 633 nm He-Ne before frozen-embryo transfer) found higher clinical-pregnancy (37.9% vs 35.5%), implantation and live-birth rates, but none reached statistical significance; retrospective (Ohshiro 2012) and case-series (Phypers 2024) reports describe pregnancies in difficult cases, and an old series (Hasan 1989) noted increased sperm counts in oligospermia. The direction is encouraging and mechanism-plausible (improved endometrial microcirculation, mitochondrial support of gametes), but controlled evidence is underpowered and non-significant. Strictly an adjunct to confirm - never a substitute for reproductive-medicine care.
Studied in Women with infertility / recurrent implantation failure or age-related infertility; men with oligospermia (older series).clinical studies
How strong the finding is
12 studies (5 human, 3 review, 1 animal, 1 in vitro, 2 other); Tsai 2020 (controlled, 633 nm, higher pregnancy/implantation/live-birth but non-significant p=.844/.518/.876); Ohshiro 2012 (830 nm, retrospective, severe infertility); Phypers 2024 (case series, multi-wavelength, live births); Hasan 1989 (male oligospermia, higher sperm count).
How it may work
PBM may improve uterine/ovarian microcirculation and release growth factors and cytokines to enhance endometrial receptivity, and support oocyte/sperm mitochondrial function (cytochrome c oxidase to ATP), potentially aiding implantation and gamete quality.
What complicates this
The best controlled study showed non-significant differences (underpowered/self-selected groups); others retrospective or case series without controls; heterogeneous protocols; strong placebo potential in fertility outcomes; publication bias toward successes.
Safety notes
Reproductive-endocrinology oversight; avoid unproven claims to vulnerable patients; investigational adjunct to ART, not a replacement.
For osteoporosis, PBM's bone-density signal is modest and mostly as an exercise add-on - strong in animals, thin in humans
Limited evidence· Mixed findings
Most osteoporosis evidence is preclinical (20 animal studies), with a handful of human trials. High-intensity laser combined with exercise modestly increased lumbar BMD beyond exercise alone (Alayat 2018, sham RCT, n=100), and a small spinal-cord-injury single-arm study (Mohammadzadeh 2024) saw site-specific BMD and vitamin-D gains - but laser alone was generally not enough. The honest read: a real osteogenic mechanism in animals and a modest human adjunct-to-exercise signal, not a standalone osteoporosis treatment; weight-bearing exercise and pharmacotherapy remain primary.
Studied in Adults with osteopenia/osteoporosis (including men; one spinal-cord-injury cohort), largely as an exercise adjunctmixed
How strong the finding is
25 studies (20 animal, 4 human, 1 in vitro). Key: Alayat 2018 (sham RCT, n=100, 1064 nm HILT+exercise > exercise for lumbar BMD), Alayat 2017 (sham RCT, n=100, lower pain/QoL), Mohammadzadeh 2024 (single-arm, n=8 SCI, 830 nm, site-specific BMD increase).
How it may work
PBM stimulates osteoblast activity, modulates the RANKL/osteoprotegerin balance, and improves bone microcirculation via mitochondrial photon absorption (ATP), favoring bone formation over resorption - additive to the mechanical loading of exercise.
What complicates this
Human trials are few and the additive BMD effect was modest and mostly seen only with concurrent exercise; laser alone was largely ineffective for BMD. Animal-to-human translation and protocol standardization remain open.
Safety notes
Standard PBM safety with localized delivery. Adjunct to weight-bearing exercise and prescribed osteoporosis therapy; not a substitute for pharmacologic management.
Red/yellow LED (590-630 nm) reduced sensitive-skin scores - one small RCT plus consistent open trials
Limited evidence· Points toward a benefit
One small randomized trial (He 2026, n=30, 590 nm and 590/630 nm LED) and two single-arm trials (Choi 2013 n=28; Sonbol 2020 n=30) showed LED phototherapy significantly reduced Sensitive Scale-10 scores and irritation markers (erythema, TEWL), with benefit persisting about 2 months. The randomized evidence is thin (one small RCT) but the direction is consistent and mechanism-plausible. A well-tolerated adjunct for sensitive-skin syndrome.
Studied in Adults with sensitive-skin syndrome, with or without associated facial dermatoses.clinical studies
How strong the finding is
3 human studies; He 2026 RCT (n=30, SS-10 p=0.0025/<0.0001; 590 nm reduced EI/MI/TEWL); Choi 2013 (n=28, mean 9.9 sessions, plus in vitro cytokine data); Sonbol 2020 (n=30, SS-10 54.7 to 13.9, benefit persisted 2 months).
How it may work
Red/yellow PBM dampens irritant-induced keratinocyte cytokine release and strengthens barrier function (reduced TEWL) via cytochrome c oxidase to ATP and anti-inflammatory signaling, shown in vitro on SLS-irritated keratinocytes.
What complicates this
Only one small RCT; others single-arm/unblinded; heterogeneous wavelengths (590 vs 630 nm) and devices; subjective primary endpoint (SS-10); short follow-up.
Safety notes
Eye protection; well tolerated with no adverse events reported; adjunct to barrier-supportive skincare.
PBM showed visual-acuity and field gains in retinitis pigmentosa — an exciting signal in an untreatable disease, but small and uncontrolled
Limited evidence· Points toward a benefit
RP has no approved therapy, which makes the PBM signal worth attention: a small comparison study recovered a mean 5.4 ETDRS letters at 8 weeks (Casson 2022), and several case reports/series describe improved acuity, visual fields and night vision, including durable gains over years with retreatment after relapse (Ivandic 2014; Koev 2015; Luque-Mialdea 2023). Encouraging and mechanism-plausible, but the evidence is dominated by case reports/series with small numbers and high variance — hope-worthy, not yet proven.
Studied in Patients with retinitis pigmentosaclinical studies
How strong the finding is
6 studies (5 human): Casson 2022 (comparison, n=12 + mouse, +5.4 letters at 8 wk, high variance), Ivandic 2014 (case report, 780 nm, VA to 20/20, relapse/retreatment over 7 yr), Luque-Mialdea 2023 (case report), Koev 2015 (case series, n=14, 633 nm, VA up over 3 yr, p<0.001).
How it may work
Red/NIR PBM supports photoreceptor and retinal-pigment-epithelium mitochondrial function and ATP, reduces oxidative stress and inflammation, and may slow degeneration or temporarily improve surviving photoreceptor performance.
What complicates this
Predominantly case reports/series; small samples, no robust controls, high inter/intra-subject variance (Casson); placebo/expectation effects hard to exclude in subjective vision outcomes.
Safety notes
Ocular PBM requires validated low-power dosimetry and specialist oversight; no adverse effects reported in these small studies. Adjunct/experimental — does not replace genetic counseling or emerging RP therapies.
670 nm-class PBM reduced diabetic macular edema and improved acuity across small human studies — non-invasive, but uncontrolled
Limited evidence· Points toward a benefit
Several human studies suggest PBM can reduce centre-involving diabetic macular edema without injections: a Phase II program (Shen 2020) paired mechanistic mouse/cell work with a 670 nm human trial showing improved mitochondrial function and reduced retinal vascular leakage; Chen (2022) saw BCVA rise (71.8 to 79.5) and retinal thickness fall over 12 months with no complications; and multiwavelength PBM (590/660/850 nm) reduced central retinal thickness and resolved intraretinal fluid in select patients (Kaymak 2023). All seven human studies point favorably, but most are single-arm/retrospective, so a non-invasive alternative to repeated injections is plausible, not proven.
Studied in Patients with (often early/centre-involving) diabetic macular edemaclinical studies
How strong the finding is
7 human studies: Shen 2020 (Phase II, n=21, 670 nm, + mechanistic animal/cell data), Chen 2022 (n=12/20 eyes, BCVA 71.8 to 79.5, reduced retinal thickness, no complications), Kaymak 2023 (n=19/30 eyes, multiwavelength, reduced CRT, IRF resolution, stable BCVA), Becker 2021 (single-arm).
How it may work
PBM enhances retinal mitochondrial membrane potential and ATP, protects Muller cells and photoreceptors from oxidative damage, and reduces vascular leakage and inflammatory edema — the targets of current intravitreal therapies, addressed non-invasively.
What complicates this
Mostly single-arm/retrospective with small samples and no sham control; durability and effect size vs anti-VEGF undefined; selection toward early/good-vision DME.
Safety notes
Retinal PBM at studied doses appears safe with no fundus complications reported; ophthalmologic monitoring required. Adjunct to glycemic control and standard DME care (anti-VEGF/laser) — not a replacement, especially in sight-threatening edema.
Red/NIR light shows promising regrowth signals in alopecia areata — small studies, spontaneous-remission caveat
Limited evidence· Points toward a benefit
Several reports suggest PBM can trigger hair regrowth in alopecia areata: a 660 nm laser used as monotherapy produced significant regrowth within days in a case report (Palma 2023), an incidental case showed terminal regrowth under a green/red-IR-emitting smartwatch (Duncan & Tziotzios 2025), and a self-controlled randomized study with infrared (Super Lizer) achieved regrowth in 7/15 irradiated areas versus 0/15 non-irradiated (Yamazaki 2003); a mouse model with a 655 nm laser comb corroborates the effect. The direction is encouraging and mechanism-consistent, but the human data are small and uncontrolled-to-semi-controlled, and AA's natural relapsing-remitting course is a real confounder.
Studied in Patients with alopecia areata (patchy autoimmune hair loss).clinical studies
How strong the finding is
~6 studies (3 human incl. a self-controlled RCT); Yamazaki 2003 (IR, 7/15 vs 0/15), Palma 2023 (660 nm case), Duncan 2025 (case), Wikramanayake 2012 (655 nm mouse).
How it may work
Red/NIR on the scalp boosts follicular cytochrome c oxidase/ATP, modulates the peri-follicular T-cell inflammation characteristic of AA, and may shift follicles from telogen into anagen.
What complicates this
Mostly case reports plus one small self-controlled trial; AA spontaneously remits/relapses, confounding attribution; heterogeneous devices.
Safety notes
Standard PBM safety; well tolerated in reports. A reasonable low-risk adjunct, but AA often needs immunomodulatory therapy — PBM is not a replacement for dermatologic care.
PBM in leprosy: no benefit for ulcer healing, but signals for neuropathic pain and function — genuinely mixed
Limited evidence· Mixed findings
The leprosy evidence cuts both ways. An early RCT (Barreto 2010, 660 nm) found no significant benefit of LLLT for wound healing, but more recent RCTs combining PBM with physiotherapy report reduced neuropathic pain and better functional capacity (SALSA scale) versus physiotherapy alone. So the honest claim is target-dependent: PBM does not appear to heal leprosy ulcers, yet may help the neuropathic pain and disability that follow nerve damage. All trials are small (25-30 patients).
Studied in Patients with leprosy sequelae — neuritis/neuropathic pain and functional limitation; not effective for ulcer wound healingclinical studies
How strong the finding is
3 human RCTs: Barreto 2010 (n=25, 660 nm; no wound-healing benefit), Duarte 2023 (n=30, 904 nm; improved SALSA function and reduced VAS pain) and Bonazza 2025 (n=30, physiotherapy+PBM; fewer patients with severe SALSA limitation, VAS improvement).
How it may work
For nerve-related symptoms, PBM reduces inflammation around peripheral nerves and supports nerve repair/regeneration via mitochondrial activation and anti-inflammatory cytokine shifts; this neural pathway is distinct from the skin-wound-healing endpoint where it failed.
What complicates this
Heterogeneous endpoints (wound healing vs neuropathic pain vs function) and small samples; positive trials bundle PBM with physiotherapy, so light's independent contribution is uncertain. The oldest, ulcer-focused RCT was frankly negative.
Safety notes
No notable adverse effects across trials; combined with physiotherapy in the positive studies. Strictly an adjunct — multidrug antibiotic therapy remains the cornerstone of leprosy treatment.
Helium-neon red light (633 nm) closed recalcitrant radiation ulcers in small case series - promising but uncontrolled
Limited evidence· Points toward a benefit
Three human case reports/series (Schindl, 1997-2000) using 632.8 nm He-Ne laser at about 30 J/cm2, three times weekly, achieved complete closure of chronic post-radiotherapy skin ulcers within 5-8 weeks, with no recurrence over 18-36 months in survivors. These are uncontrolled case reports, not RCTs, so causation versus natural healing cannot be cleanly separated - an encouraging signal that warrants controlled trials. PBM here is a localized-laser adjunct to standard wound care, not a replacement.
Studied in Patients with chronic recalcitrant skin ulcers following radiotherapy (e.g., post-mastectomy).clinical studies
How strong the finding is
3 human reports (study_count 3), all Schindl group, 633 nm at ~30 J/cm2; complete closure at 7/5/8 weeks; 18-36 month recurrence-free follow-up in survivors.
How it may work
Red light absorbed by cytochrome c oxidase raises ATP and drives fibroblast/keratinocyte proliferation, angiogenesis and modulated inflammation, accelerating re-epithelialization in hypoxic irradiated tissue.
What complicates this
Case-series only, single research group, no control arm, small n; spontaneous healing cannot be excluded; one patient died of tumor cachexia (unrelated to laser).
Safety notes
Standard PBM eye protection; in oncology patients coordinate with the oncology team and avoid irradiating active or suspected tumor tissue; PBM is an adjunct to wound care, never a replacement.
Near-infrared light to the legs eased restless legs symptoms in small RCTs — consistent short-term benefit
Limited evidence· Points toward a benefit
Three human trials show near-infrared light (650-940 nm) to the lower legs/acupoints significantly reduces restless-legs symptoms versus control over a 4-week course (Mohammadi 2018; Mitchell 2011 ×2), with two devices/wavelengths working comparably. Benefit was clear during treatment but tended to fade after stopping in the hemodialysis cohort. It is a low-risk, drug-sparing adjunct worth trying, with the caveat that durability and long-term data are limited.
Studied in Adults with restless legs syndrome, including hemodialysis patientsclinical studies
How strong the finding is
3 human RCTs (study_count 3, all human). Mohammadi 2018 (sham-controlled RCT, n=60, 940 nm acupoints): significant IRLS improvement (MD 3.8) that attenuated post-treatment. Mitchell 2011 (RCT, n=34, 890 nm): greater improvement than control, sustained 4 weeks post. Mitchell 2011 (comparison, n=25): two NIR devices both effective.
How it may work
NIR light to the legs is thought to enhance local microcirculation, nitric-oxide availability, and tissue oxygenation and modulate peripheral nerve signaling via cytochrome c oxidase → ATP, dampening the sensorimotor symptoms of RLS.
What complicates this
Small samples, short follow-up, and waning benefit after discontinuation (notably in dialysis patients); device/wavelength heterogeneity and possible placebo contribution; no large or long-term trials.
Safety notes
Non-invasive, well tolerated; standard precautions. Adjunct to standard RLS management (iron repletion, dopaminergic/alpha-2-delta agents as indicated); does not replace evaluation for secondary causes.
PBM for tinnitus: a large but contradictory trial record — some positive, several null
Limited evidence· Mixed findings
Tinnitus has one of the bigger PBM literatures here (12 human RCTs, 9 non-RCTs, a case series), but the results genuinely conflict. Some sham-controlled trials report meaningful VAS improvements (e.g., Demirkol 2017 with Nd:YAG 1064 nm), while well-designed double-blind trials (Mirz 1999, 830 nm transmeatal) and a recent RCT (Choi 2024, 830 nm) found no significant clinical benefit over placebo despite encouraging animal data. The signal is real enough to keep studying, but PBM is not a reliable tinnitus cure and should be framed as an experimental adjunct.
Studied in Adults with chronic subjective tinnitusclinical studies
How strong the finding is
Large heterogeneous base (study_count 38; 31 human). Positive: Demirkol 2017 (RCT, 810/1064 nm, up to ~100% VAS improvement with Nd:YAG). Null: Mirz 1999 (double-blind RCT, 830 nm, only 18% nonspecific improvement, no placebo separation) and Choi 2024 (RCT n=56 clinically negative though the mouse model was positive). Ali 2023 single-arm reported subjective benefit.
How it may work
NIR light reaching the cochlea/auditory pathway is proposed to upregulate cytochrome c oxidase and mitochondrial ATP in stressed hair cells and neurons, reduce oxidative stress, and modulate central auditory excitability — animal work shows reversal of tinnitus-associated VGLUT2 upregulation in the dorsal cochlear nucleus.
What complicates this
Marked heterogeneity in wavelength (650-1064 nm), delivery route (transmeatal vs external), dose, and outcome scales; baseline imbalances in some 'positive' trials (e.g., Demirkol diode arm) inflate apparent effects, and the best-blinded trials trend null.
Safety notes
Transmeatal/peri-auricular PBM is generally well tolerated; eye protection and avoiding excess power near the ear are standard. Adjunct only — sound therapy and CBT remain first-line, and PBM does not replace audiologic evaluation.
PBM relieves herpes-zoster and postherpetic-neuralgia pain — broad but largely uncontrolled evidence
Limited evidence· Points toward a benefit
A large body of human experience supports PBM for herpes-zoster pain, especially postherpetic neuralgia. A striking case documented a 15-year, treatment-resistant PHN dropping from 8/10 to 0/10 pain over 8 weeks of laser therapy (Knapp 2013); a 29-year retrospective series treated 123 PHN patients with 830 nm (Sasaki 2010); and a single-arm study reported final pain scores of 0 in 11 of 15 patients with 650 nm (Mukhtar 2020). The direction is consistently toward pain relief, but most studies are uncontrolled and an early crossover study itself noted a placebo effect — so the honest grade is limited despite the volume.
Studied in Patients with herpes zoster and postherpetic neuralgia (often older, with chronic pain).clinical studies
How strong the finding is
~18 human studies (2 RCTs, 9 non-RCTs, retrospectives, case reports); Knapp 2013 (810+980 nm PHN case), Sasaki 2010 (830 nm, n=123), Mukhtar 2020 (650 nm, pain 0 in 11/15).
How it may work
PBM reduces neurogenic inflammation, neurotoxic reactive oxygen species, and proinflammatory microglial activation while supporting nerve repair, dampening neuropathic pain signaling.
What complicates this
Predominantly uncontrolled; an early double-blind crossover noted a placebo effect; heterogeneous wavelengths/protocols; few RCTs.
Safety notes
Standard PBM safety; no attributable complications reported. A reasonable adjunct for zoster/PHN pain, used alongside antivirals and analgesics — not a replacement for prescribed care.
PBM for olfactory dysfunction: early human fMRI changes plus an animal recovery model — preliminary but intriguing
Limited evidence· Points toward a benefit
A small human non-RCT (Hosseini 2023, 660 nm) in traumatic anosmia/hyposmia found that LLLT increased activation in olfactory-related cortex and reshaped olfactory-network connectivity, and a mouse stroke model (Shalaby 2023, 808 nm) showed PBM to the olfactory bulb accelerated smell recovery by suppressing inflammatory cytokines and boosting glial/vascular repair factors. The convergence of a human neuroimaging signal with an animal recovery mechanism is encouraging for a hard-to-treat deficit. But the human study is small and uncontrolled by randomization, so this is an early lead.
Studied in Patients with traumatic olfactory dysfunction (anosmia/hyposmia); mouse stroke-induced olfactory model for mechanismmixed
How strong the finding is
2 studies: Hosseini 2023 (human, non-randomized controlled, n=24, 660 nm; increased cingulate/rectus/frontal activation, shorter pathlength and higher local efficiency in the olfactory network) and Shalaby 2023 (mouse, 808 nm to olfactory bulb; accelerated recovery via cytokine suppression and glial/vascular factors).
How it may work
PBM accelerates nerve regeneration and modulates microenvironmental inflammation (lower cytokines, higher GFAP/IBA-1/CD31 repair and vascular factors) in the olfactory pathway, supporting recovery of olfactory function after injury/ischemia.
What complicates this
Single small human study without randomized control; outcomes are largely neuroimaging/connectivity rather than validated smell-test endpoints. Animal model is ischemic, which may differ from human traumatic anosmia.
Safety notes
Reported as well tolerated in the human study. Adjunct to standard olfactory rehabilitation/training, not a replacement; persistent anosmia warrants ENT evaluation.
Low-intensity laser to the limbus lowered intraocular pressure in human eyes — small, older, mechanism-plausible studies
Limited evidence· Points toward a benefit
Brief low-intensity laser irradiation of the limbus reduced intraocular pressure in human eyes — by ~25.7% in ocular-hypertensive eyes and ~17.1% in normotensive eyes in a 211-eye case series (Ivandic 2009, p<0.001), with a smaller controlled study echoing an IOP drop (Dimitrova 2019) and a rat study showing red light protects the retina from a raised-IOP insult (Del Olmo-Aguado 2016). A real directional signal for IOP lowering, but the human work is uncontrolled/older, one study used a heat lamp (thermal confound), and the original framing was diagnostic rather than therapeutic.
Studied in Patients with ocular hypertension (and at-risk normotensive eyes)clinical studies
How strong the finding is
3 studies (2 human): Ivandic 2009 (case series, 123 pts/211 eyes, 780 nm, IOP -25.7% hypertensive / -17.1% normotensive, p<0.001), Dimitrova 2019 (non-randomized controlled, n=34, IOP down p=0.03; a Letter using a heat lamp), Del Olmo-Aguado 2016 (rat, red light retinal protection).
How it may work
PBM may transiently increase aqueous-humor outflow facility (trabecular-meshwork modulation) and, via cytochrome-oxidase stimulation, protect retinal ganglion cells from pressure-related mitochondrial stress.
What complicates this
Uncontrolled/case-series human data, older reports, a thermal-source confound (heat lamp) in one study, and a primarily diagnostic original intent; durability of IOP lowering unknown.
Safety notes
Ocular hypertension/glaucoma risk requires ophthalmologic management; PBM is an investigational adjunct, never a replacement for IOP-lowering therapy, and ocular dosimetry must be controlled.
Small split-body pilot shows PBM improved diabetic dermopathy lesions and skin blood flow
Limited evidence· Points toward a benefit
Diabetic dermopathy has limited but encouraging human data. In a placebo-controlled split-body pilot (12 type-2 diabetics), the 632 nm LLLT-treated side showed significant improvement in lesion diameter and in knee/ankle skin blood flow versus the placebo side (Abdelhalim 2020), and a case report described normalized skin color by day 21 alongside improved diabetic neuropathy with 830 nm (Hazari 2017). The within-patient control design is a strength for such a small study; the evidence is limited but points clearly toward benefit via improved microcirculation and healing.
Studied in Patients with type-2 diabetes and diabetic dermopathy.clinical studies
How strong the finding is
2 human studies; Abdelhalim 2020 placebo-controlled split-body pilot (n=12, 632 nm, significant lesion + blood-flow improvement), Hazari 2017 case report (830 nm, skin normalized in 21 days).
How it may work
Red/NIR improves cutaneous microcirculation and tissue repair via NO-mediated vasodilation and cytochrome c oxidase/ATP, addressing the impaired perfusion underlying diabetic skin lesions.
What complicates this
Very small pilot plus a single case; short follow-up; needs larger controlled trials.
Safety notes
Standard PBM safety. A reasonable adjunct for diabetic skin lesions, but glycemic control and diabetic skin/foot care remain primary; PBM is not a replacement for prescribed diabetes management.
PBM for childbirth/postpartum analgesia is mixed - negative perineal RCT, but endorphin and animal-pain mechanisms support further study
Limited evidence· Mixed findings
For childbirth-related analgesia the human evidence is mixed-to-negative: a triple-blind RCT (Alvarenga 2016) found LLLT gave no benefit for post-episiotomy perineal pain with the parameters tested, while older human work (Laakso 1994) showed PBM raised ACTH and beta-endorphin, and animal studies (de Oliveira 2021, starred) demonstrate dose-dependent antinociception via peripheral opioid and endothelin-B receptors. So the mechanism is real but a key human obstetric trial was null - likely a dosing/protocol problem rather than absence of effect. Limited overall; PBM is at most an adjunct, and optimal obstetric analgesia protocols are unproven.
Studied in Postpartum women (perineal/episiotomy pain); supported by animal antinociception and human neuroendocrine data.mixed
How strong the finding is
31 entries (7 review, 10 human, 13 animal, 1 in vitro); Alvarenga 2016 (triple-blind RCT, 780 nm, no perineal-pain benefit); de Oliveira 2021 (starred mouse, 630 nm, irradiance-dependent antinociception via opioid/ETB-R); Laakso 1994 (human RCT, higher ACTH/beta-endorphin); Kulkarni 2024 (human, dental-pulp analgesia - different application).
How it may work
PBM modulates nociception via peripheral opioid (endorphin/ACTH) and endothelin-B receptor pathways and reduces local inflammation (cytochrome c oxidase to ATP); analgesia is dose-dependent (irradiance matters).
What complicates this
The principal obstetric RCT was negative (parameter-dependent); the strongest mechanistic data are animal; one human study is off-topic (dental); heterogeneous endpoints; optimal dose unestablished.
Safety notes
Eye protection; adjunct only; the negative trial suggests parameters matter - do not rely on PBM as sole analgesia; follow obstetric guidance.
Case series suggest PBM calms lichen planopilaris — but ex-vivo transcriptomics found no significant change
Limited evidence· Mixed findings
For lichen planopilaris, a scarring alopecia with few good options, two case series report meaningful benefit: a significant mean drop of 0.87 in the LPP Activity Index after six months of 630 nm light (Fonda-Pascual 2017) and dramatic responses with reduced inflammation, symptom resolution, and hair regrowth in four patients (Randolph 2020). However, an ex-vivo transcriptomic study found no significant differentially expressed genes in the LLLT arm before versus after treatment (Yildiz-Altay 2025), leaving the mechanism unconfirmed. Honest read: clinically promising in small uncontrolled series, but the molecular evidence is so far neutral — a mixed, limited picture.
Studied in Patients with lichen planopilaris (lymphocytic scarring alopecia).clinical studies
How strong the finding is
~3 studies; Fonda-Pascual 2017 case series (630 nm, LPPAI -0.87, p=0.012), Randolph 2020 case series (650/660 nm, 4 patients, marked response), Yildiz-Altay 2025 ex vivo (no significant DEGs with LLLLT).
How it may work
PBM is proposed to reduce the lymphocytic peri-follicular inflammation of LPP and support follicular survival via mitochondrial/anti-inflammatory effects, though gene-expression data have not yet confirmed a clear molecular signature.
What complicates this
Only small uncontrolled case series support benefit; ex-vivo molecular study neutral; case-series improvement may reflect concurrent treatments or natural variation.
Safety notes
Standard PBM safety; reported without side effects. A low-risk adjunct, but LPP usually needs anti-inflammatory/immunomodulatory therapy — PBM is not a replacement for dermatologic management.
Red-light PBM to the larynx eases vocal fatigue — small but consistent human signal
Limited evidence· Points toward a benefit
In a randomized study of vocal-loading-induced fatigue, red-wavelength LLLT (628 nm) significantly normalized phonation threshold pressure and related measures versus infrared, heat, and control, and a single-arm study of 41 teachers found immediate acoustic and respiratory gains after one PBM session (largest in those with severe fatigue). The evidence is early — small samples, mostly single-session, partly confounded by surface heating — but consistently points toward benefit. PBM looks like a promising rapid adjunct for professional voice users, not a stand-alone voice therapy.
Studied in Vocally healthy adults and professional voice users (e.g., teachers) with task-induced or occupational vocal fatigueclinical studies
How strong the finding is
1 human RCT plus supporting human data (study_count 3). Kagan & Heaton 2016 (RCT, n=16): red 628 nm normalized PTP/IPSV/RFF better than IR/heat/control. Garrido 2025 (single-arm, n=41): immediate improvements, strongest in severe vocal fatigue. A 2023 SLP survey shows wide clinical adoption.
How it may work
PBM to the laryngeal muscles/mucosa is thought to reduce inflammation and oxidative stress and support tissue recovery via cytochrome c oxidase → ATP, easing the neuromuscular cost of phonation; note red settings also warm the neck surface, so a thermal contribution cannot be fully separated.
What complicates this
Very small samples, mostly immediate/single-session outcomes with no durability data; the red setting heats the neck to ~43°C, so part of the effect may be thermal rather than photobiomodulatory. Triple-blind work in healthy voices (Torres 2025) found only discreet effects.
Safety notes
Laryngeal-region PBM is non-invasive and well tolerated; keep within non-thermal dosing and protect the eyes. Adjunct to vocal hygiene and speech-language-pathologist-directed therapy — not a replacement.
Adjunct NIR LED PBM sped pneumonia recovery in a small RCT — promising, must complement antibiotics
Limited evidence· Points toward a benefit
In community-acquired pneumonia, a 940 nm LED vest added to standard care (a small RCT, n=30) improved pulmonary recovery and SpO2 (88→98%) and shortened hospital stay (9.3 vs 7.3 days; p=0.0015), echoed by an earlier non-randomized study from the same group. The signal is encouraging and the delivery (a thoracic LED vest) is practical, but the evidence is one small RCT plus a non-RCT. PBM here is a plausible adjunct to confirm — strictly alongside antibiotics and physiotherapy, never instead of them.
Studied in Hospitalized adults with community-acquired pneumoniaclinical studies
How strong the finding is
1 human non-RCT in the rating; base study_count 3. Pereira 2026 (RCT, n=30, 940 nm vest, starred): shorter stay (9.3 vs 7.3 d), higher SpO2, fewer symptoms. Pereira 2022 (non-randomized, n=21): improved hematologic recovery. (Geralde 2017 is photodynamic therapy, a different antimicrobial modality.)
How it may work
Transcutaneous NIR LED over the thorax is proposed to reduce pulmonary inflammation and oxidative stress and support tissue repair and microcirculation via cytochrome c oxidase → ATP, improving ventilation-perfusion and recovery.
What complicates this
Small single-group RCT plus a non-randomized study from one team; no multicenter replication, and one grounding study is PDT rather than PBM. Generalizability and durability unknown.
Safety notes
Non-invasive, well tolerated; standard precautions. PBM is an adjunct to antibiotics and physiotherapy and must not delay or replace antimicrobial treatment of pneumonia.
PBM as an osteomyelitis adjunct: bactericidal and healing signals from a rat model plus a small human series
Limited evidence· Points toward a benefit
In experimentally induced rat tibial osteomyelitis, 808 nm laser cut infection levels dose-dependently (up to ~93% reduction with debridement plus light), and a small human series in jaw osteomyelitis (n=8, 635 nm) reported better clinical outcomes and significantly less pain than controls after surgery. The combined picture is encouraging for PBM as a post-surgical, anti-infective adjunct. But the human data are tiny and non-randomized, so this is a promising lead rather than proof.
Studied in Osteomyelitis (experimental rat model; jaw osteomyelitis in a small post-surgical human series)mixed
How strong the finding is
2 studies: Kaya 2011 (rat, 808 nm, 7.64-22.93 J/cm2; infection reduced 37-93% with debridement+laser) and Kekovic 2023 (human, non-randomized controlled, n=8, 635 nm LED; better clinical achievement and significantly greater pain resolution at 3-6 months).
How it may work
PBM has a documented photo-eradication/bactericidal effect on Staphylococcus aureus at certain wavelengths and doses, and separately accelerates bone and mucosal healing and reduces pain via mitochondrial activation and anti-inflammatory signaling in the irradiated tissue.
What complicates this
Human evidence is a single 8-patient non-randomized series in jaw osteomyelitis; bactericidal data are largely preclinical/in-vitro. Generalization across bones and organisms is not established.
Safety notes
No adverse effects reported in the human series; used after surgical debridement and alongside antibiotics. PBM is a strict adjunct to surgery and antimicrobial therapy for a serious bone infection, never a replacement.
PBM for pediatric sleep bruxism: small RCTs show symptom relief, evidence still thin
Limited evidence· Mixed findings
Small pediatric RCTs suggest photobiomodulation (often over masticatory muscles or acupoints) can ease sleep-bruxism-associated symptoms — Salgueiro 2020 (n=76) significantly reduced headache frequency, comparable to occlusal splints, and Kobayashi 2022 examined EMG/dopamine effects with infrared LED. The findings are encouraging and PBM sidesteps the cooperation problems of splints in children, but the trials are small and outcomes heterogeneous. Reasonable as an adjunct to confirm, alongside standard bruxism/dental management.
Studied in Children with sleep bruxism (plus some adult insomnia/acupuncture data)clinical studies
How strong the finding is
1 human RCT in the rating; base study_count 7 (3 human + protocols). Salgueiro 2020 (RCT, n=76, 787 nm): reduced headache frequency, on par with occlusal splint. Kobayashi 2022 (RCT, n=30, 850 nm LED): masticatory EMG/dopamine effects. (Chen 2019 addressed insomnia, not bruxism.)
How it may work
PBM over the masseter/temporalis or acupoints is proposed to reduce muscle tension, inflammation, and pain and modulate stress-related signaling (e.g., salivary cortisol/dopamine) via cytochrome c oxidase-mediated ATP and analgesic effects.
What complicates this
Small pediatric samples, mixed/indirect endpoints (headache, EMG, cortisol rather than polysomnographic bruxism), and one grounding entry is a study protocol and another targets insomnia; some studies lacked between-group analyses. Diagnosis of pediatric SB is itself difficult.
Safety notes
Non-invasive, well tolerated, and easier than splints in young children; standard precautions. Adjunct to dental evaluation and occlusal-splint/behavioral care — not a replacement.
PBM for cerebral palsy: decades of practitioner series plus a small RCT suggest reduced spasticity and better motor function
Limited evidence· Points toward a benefit
The cerebral-palsy evidence is largely observational but consistent: Asagai's series reported improved gross motor function in a subset of 73 children and suppressed myotonia in 19 of 20 patients, and a more recent small RCT (Abdelhalim 2023, 810 nm) showed power gains in quadriceps and dorsiflexors in children with spastic diplegia. PBM appears most useful as a pre-stretching/pre-training adjunct that lowers pain and muscle tone so functional therapy can do more. The evidence base is thin and mostly non-randomized, so confidence is limited but the direction is encouraging.
Studied in Children with cerebral palsy (notably spastic diplegia) undergoing functional/physical therapyclinical studies
How strong the finding is
5 studies (3 human). Abdelhalim 2023 (RCT, n=40, 810 nm; power gains in quadriceps/dorsiflexors, lower pain and lactate), Asagai 2005 (controlled, n=73; motor-function improvement in 23) and Asagai 1995 (n=20; myotonia improved in 19).
How it may work
PBM reduces muscle spasticity/myotonia and pain — plausibly via lowered lactate, anti-inflammatory effects and modulation of neuromuscular tone — improving the imbalance between antagonistic muscles and enabling more effective stretching and strength training.
What complicates this
Mostly single-practitioner non-randomized series; the one RCT is small with a noted dose-reporting discrepancy. Outcome measures and protocols are heterogeneous, and randomized evidence remains scarce.
Safety notes
Reported as free of pain or serious adverse reaction across decades of use; not effective where irreversible joint contracture exists. Adjunct that enhances physiotherapy, never a replacement for it.
PBM for concussion/post-concussion symptoms: positive case and animal data, but the human RCT was negative
Limited evidence· Mixed findings
The concussion evidence is genuinely mixed. A detailed case report (Chao 2020) documented behavioral and neuroimaging improvement after 8 weeks of home transcranial PBM in a player with chronic post-concussion symptoms, and recent mouse studies show PBM improves cortical perfusion, oxygenation and brain waste-clearance after repeated concussion. But the controlled human test (Taylor 2023 RCT) found no benefit of transcranial PBM over placebo for persistent post-concussion symptoms. So mechanism and anecdote are encouraging while the best human evidence to date is null.
Studied in Patients with concussion / persistent post-concussion symptoms (human); repeated-concussion rodent models for mechanismmixed
How strong the finding is
4 studies (2 human, 2 animal). Chao 2020 (case report, 810 nm home LEDs; behavioral + neuroimaging gains over 8 weeks/14-month follow-up); Taylor 2023 (RCT, n=48 completers; no benefit over placebo). Mouse: Bragin 2026 (1267 nm) and Kibria 2026 (1270 nm) improved perfusion, oxygenation and brain clearance.
How it may work
Transcranial NIR improves regional cerebral blood flow, tissue oxygenation and meningeal-lymphatic clearance and supports mitochondrial energy in injured cortex — plausibly aiding recovery, per rodent microcirculation/clearance data.
What complicates this
The only RCT was negative for persistent symptoms; positive human data are a single case; animal models use longer wavelengths (1267-1270 nm) and far higher penetration. Timing (acute vs chronic) may matter and isn't resolved.
Safety notes
Home LED and clinic transcranial PBM were well tolerated, including self-administered use in the case report. Adjunct to standard concussion management and graded return-to-activity, not a replacement.
Laser for degenerative disc disease: one trial showed MRI disc-signal recovery, a placebo-controlled RCT showed no edge over sham
Limited evidence· Mixed findings
The signal here is genuinely mixed. Borshchenko (2022) reported a 14% rise in MRI disc-signal intensity after 1560 nm Er-fiber laser irradiation of lumbar discs (p<0.001), suggesting a regenerative/reshaping effect on cartilage, while Taradaj's (2018) placebo-controlled trial found laser improved patients but no better than placebo. So there is a provocative imaging signal for disc regeneration, but clinical superiority over sham is unconfirmed.
Studied in Adults with degenerative lumbar disc disease / discogenic low back painclinical studies
How strong the finding is
Two human studies: Borshchenko 2022 (single-arm, n=28, 1560 nm, +14% disc MRI signal, p<0.001) and Taradaj 2018 (placebo-controlled RCT, 786/1064 nm — improvement in all arms, no significant difference vs placebo).
How it may work
PBM may stimulate disc-cell/chondrocyte metabolism and matrix synthesis and reduce inflammatory cytokines; higher-energy fiber-laser protocols are proposed to induce cartilage reshaping and a regenerative healing reaction.
What complicates this
Borshchenko is uncontrolled and uses an imaging surrogate, not clinical outcomes; Taradaj's controlled design found no advantage over placebo. Different wavelengths/energies (1560 nm fiber vs 786/1064 nm) make the two hard to reconcile.
Safety notes
Higher-intensity intradiscal/fiber-laser delivery is an invasive procedure with distinct risks vs surface LLLT; standard PBM cautions otherwise. Adjunct to conservative spine care, not a replacement.
wIRA and 980 nm PBM eased cancer-related dysphagia and secretions in case reports - anecdotal
Limited evidence· Points toward a benefit
Two human case reports describe symptomatic relief of cancer-related dysphagia with PBM: water-filtered IR-A (Hoffmann 2017) reduced viscous secretions and dramatically improved sleep and quality of life within days, and 980 nm PBM (El Mobadder 2019) improved swallowing in hormonal-therapy-related dysphagia. These are single-patient anecdotes in palliative/supportive-care contexts - genuinely encouraging for symptom relief but not generalizable evidence. PBM is a supportive adjunct under oncology/supportive-care guidance, not a treatment for the underlying disease.
Studied in Patients with cancer- or treatment-related dysphagia (supportive/palliative care).clinical studies
How strong the finding is
2 human case reports; Hoffmann 2017 (wIRA, esophageal-cancer dysphagia, rapid QoL/secretion improvement); El Mobadder 2019 (980 nm, breast-cancer hormonal-therapy dysphagia, improved swallowing scale).
How it may work
PBM/IR-A modulates inflammation, supports mucosal/salivary tissue and may improve local perfusion and tissue comfort via cytochrome c oxidase to ATP and thermal effects (wIRA).
What complicates this
Single-case anecdotes, no controls, heterogeneous etiologies and devices; placebo and natural fluctuation unaccounted; not generalizable.
Safety notes
Oncology/supportive-care oversight; avoid direct irradiation of active tumor without sign-off; adjunct for symptom relief only.
PBM rapidly resolved refractory oral mucosal necrosis in small case reports - promising adjunct in oncology
Limited evidence· Points toward a benefit
Two human reports (Epstein 2016 case series of 3; de Bataille 2017 case report) describe rapid resolution of persistent, symptomatic oral mucosal necrosis - including post-radiation ulceration - after adding photobiomodulation, with notable pain relief (one patient cut analgesic use threefold). For a difficult oncologic complication with few options this is an encouraging adjunct, but the evidence is anecdotal and uncontrolled.
Studied in Patients with refractory oral mucosal necrosis/ulceration, including post-radiotherapyclinical studies
How strong the finding is
2 human reports: Epstein 2016 (starred case series, 3 cases, 660 nm intra-oral + 660/850 nm extra-oral, rapid resolution), de Bataille 2017 (case report, 660 nm, pain and analgesic-use reduction, healing by ~6 weeks).
How it may work
PBM stimulates angiogenesis and fibroblast-driven tissue repair while reducing inflammation and pain (cytochrome c oxidase -> ATP), helping re-epithelialize compromised, hypovascular mucosa.
What complicates this
Few uncontrolled cases; concurrent care and spontaneous healing cannot be excluded. No randomized data in this setting.
Safety notes
Standard PBM safety with intra-/extra-oral delivery, under oncology oversight; avoid directly irradiating known/suspected malignant tissue without specialist guidance. Adjunct, not a replacement for cancer care.
LLLT for cubital tunnel syndrome: short-term superiority over sham that fades by the medium term
Limited evidence· Mixed findings
Two human trials suggest LLLT helps cubital tunnel syndrome in the near term but not durably. Yağcı 2024 (sham-controlled RCT, n=64) found laser superior to placebo at 3 weeks but equivalent by 3 months, and a randomized comparison (Wieczorek 2025) showed electrophysical modalities including LLLT improved nerve-conduction and ultrasound measures comparably to manual neurodynamic therapy. So LLLT looks like a reasonable short-term adjunct for symptom relief, with benefit that converges with controls over time.
Studied in Adults with cubital tunnel syndrome (conservative management)clinical studies
How strong the finding is
2 human studies: Yağcı 2024 (RCT, sham-controlled, n=64, LLLT+splint+exercise; superior to placebo at 3 weeks, equivalent at 3 months) and Wieczorek & Wolny 2025 (randomized comparison, 82 limbs, 658+808 nm; electrophysical modalities incl. LLLT improved nerve conduction and ultrasound metrics on par with neurodynamics).
How it may work
PBM reduces perineural inflammation and edema around the ulnar nerve at the elbow and supports nerve conduction via mitochondrial activation and microcirculatory improvement — giving early symptom relief that standard conservative care eventually matches.
What complicates this
Benefit is short-term only and converges with controls by 3 months; LLLT is bundled with splinting/exercise or compared against another active therapy, limiting attribution to light alone. Small samples.
Safety notes
Combined with splinting and nerve-glide exercises in the trials; no significant adverse effects reported. Adjunct to conservative therapy; surgical referral remains appropriate for severe or progressive nerve compromise.
PBM for provoked vestibulodynia: real pain reduction in two RCTs, but the edge over sham is modest
Limited evidence· Mixed findings
Two randomized, sham-controlled trials of NIR/red PBM for provoked vestibulodynia both moved pain in the right direction: Lev-Sagie 2017 found 78% of LLLT (820 nm) patients improved vs 44% on sham (P=0.042), and Antonio 2025 found greater vulvar-pain reduction with real PBM than sham. The honest caveat is that Antonio's patients did not perceive real PBM as clearly better than sham, and psychological and sexual-function outcomes didn't move. So PBM looks like a reasonable, low-risk option for vulvar pain with a genuine but modest effect.
Studied in Women with provoked vestibulodynia (localized vulvar pain)clinical studies
How strong the finding is
2 human RCTs: Lev-Sagie 2017 (double-blind, n=34, 820 nm, 12 sessions; 78% vs 44% improved, P=0.042) and Antonio 2025 (RCT, n=30, 660+840 nm, 15 sessions; greater pain reduction than sham but no perceived superiority and no psychological/sexual benefit).
How it may work
PBM lowers inflammatory mediators and modulates the neural proliferation documented in vestibulodynia tissue, while raising local tissue ATP — reducing the peripheral pain signal from the vulvar vestibule.
What complicates this
Small samples; the larger-effect trial (Lev-Sagie) wasn't reproduced in magnitude, and patient-perceived benefit in Antonio matched sham — a hint of placebo contribution. Effect is real but modest.
Safety notes
Adverse events were minimal in both trials; trained vulvar/vestibular delivery required. Adjunct to multidisciplinary vulvodynia care (pelvic floor, psychosexual), not a standalone cure.
PBM may cut vertigo spells in Meniere's disease, but without hearing change and from weak, uncontrolled pilots
Limited evidence· Points toward a benefit
Two small human reports suggest possible benefit in Meniere's disease. Teggi 2008 (randomized vs betahistine, ~10-20 patients) found PBM reduced the number and duration of vertigo spells - though more slowly than betahistine, with no audiometric improvement and no placebo arm - and a 2026 case report described vertigo resolution with combined electroacupuncture and LLLT. This is a weak, preliminary signal for vertigo control only; PBM is at most an adjunct to test, not a substitute for established Meniere's management.
Studied in Adults with Meniere's disease and recurrent vertigoclinical studies
How strong the finding is
2 human studies: Teggi 2008 (randomized vs betahistine, 650 nm, fewer vertigo spells, no audiometric change, no placebo), Hsu 2026 (case report, LLLT plus electroacupuncture, vertigo eliminated).
How it may work
Proposed: PBM increases inner-ear microcirculation and modulates local inflammation (mitochondrial ATP), potentially reducing the endolymphatic/vestibular dysfunction that drives vertigo - without restoring cochlear (hearing) function.
What complicates this
No placebo-controlled data; tiny samples, an active comparator only, and benefit limited to vertigo (not hearing). The combined-modality case cannot isolate PBM.
Safety notes
Standard PBM safety with localized delivery. Adjunct only; does not improve hearing and should not replace dietary, medical, or surgical Meniere's management.
PBM shows early signals for sexual dysfunction — transcranial NIR for desire, intra-vaginal red/blue for pain — but trials are tiny
Limited evidence· Points toward a benefit
Two small human studies point in a hopeful direction: transcranial NIR PBM (823 nm) improved sexual function as a secondary outcome of a depression trial, and intra-/extra-cavitary PBM (440 + 660 nm) sharply reduced vaginal pain and raised sexual-function scores in breast-cancer survivors on hormone therapy. The mechanism plausibly differs by site — central (brain/desire) versus local (tissue/pain) — and a mouse study reinforces a central dopaminergic pathway for desire. Encouraging but preliminary: samples are 20-32 people, one is a non-randomized secondary analysis, so this is a signal to pursue, not a settled treatment.
Studied in Adults with sexual dysfunction — including depression-associated low desire (transcranial) and hormone-therapy-induced vaginal pain/dysfunction in breast-cancer survivors (local)clinical studies
How strong the finding is
Cassano 2018 (RCT secondary analysis, n=20, 823 nm: SAFTEE sex score improved -2.55 vs -0.45 sham, P=0.011) and Vieira & Rezende 2026 (quasi-experimental, n=32; 79% pain-free, VAS 9.46->1.04, QS-F 23->87, P<0.0001) plus Liu 2025 (mouse, transcranial NIR improved stress-induced low desire).
How it may work
Locally, red light raises mitochondrial ATP and dampens inflammation in vulvovaginal tissue, easing dyspareunia; centrally, transcranial NIR appears to drive dopaminergic activity in hypothalamic nuclei (AVPV/PVpo) linked to sexual desire, consistent with the cytochrome-c-oxidase energy pathway.
What complicates this
Very small samples; Cassano is a secondary analysis of a depression trial, not a primary sexual-function RCT; Vieira is non-randomized with a self-selected control. Local and central effects are distinct and shouldn't be pooled as one claim.
Safety notes
Both human studies reported good tolerability; intra-cavitary delivery requires trained administration. Standard eye protection for laser work. Adjunct to gynecologic, oncologic and psychosexual care, not a replacement.
PBM eases pain and may shrink oral leukoplakia lesions - small human studies, two different roles
Limited evidence· Points toward a benefit
Two small human studies point in a positive direction for oral leukoplakia. Ribeiro's RCT (n=18) used 660 nm laser to reduce pain after cryosurgical removal of leukoplakia, and Jagtap's 4-case series reported lesion-area shrinkage (437 to 223 mm2 after at least 10 treatments). One study is an analgesic adjunct to a destructive procedure, the other suggests direct lesion regression - both encouraging but preliminary. Given leukoplakia's premalignant potential, PBM should sit alongside, not replace, surveillance and definitive management.
Studied in Adults with oral leukoplakia (peri-procedural pain; possible lesion reduction)clinical studies
How strong the finding is
2 human studies: Ribeiro 2011 (RCT, n=18, 660 nm, less post-cryosurgery pain) and Jagtap 2018 (case series, n=4, lesion area 437 to 223 mm2).
How it may work
PBM reduces post-procedural pain and supports mucosal healing (ATP and anti-inflammatory effects); a direct lesion-reduction mechanism is less established and may involve modulation of dysplastic epithelial and inflammatory activity.
What complicates this
Tiny samples; the RCT addresses procedural pain rather than lesion clearance, and the case series lacks controls. No long-term malignant-transformation data.
Safety notes
Standard PBM safety with intra-oral delivery. Because leukoplakia is premalignant, PBM must not delay biopsy/surveillance or definitive treatment; use only as an adjunct.
A pre-emptive laser pass lowers drilling pain during cavity prep - two small human studies agree, both with limited reporting
Limited evidence· Points toward a benefit
Two small human studies suggest that pre-treating a tooth with low-level laser before cavity preparation reduces procedural pain. Femiano's sham-controlled trial (24 subjects, 88 teeth) found roughly 42% pain reduction in the laser group versus 16% in controls (p<0.0001), and Tanboga's non-randomized pediatric study reported lower VAS scores (median 1 vs 3, p<0.01). Encouraging and mechanistically reasonable for analgesia, but the trials are small with under-reported parameters, so treat this as a promising adjunct to confirm rather than a substitute for local anesthesia where indicated.
Studied in Adults and children undergoing cavity preparation, including without local anesthesiaclinical studies
How strong the finding is
2 human studies: Femiano 2018 (sham-controlled, 24 subjects/88 teeth, 42% vs 16% pain reduction, p<0.0001) and Tanboga 2011 (non-RCT, 10 children/20 molars, VAS 1 vs 3, p<0.01).
How it may work
PBM can reduce nerve excitability and the local inflammatory/nociceptive response (mitochondrial ATP modulation, altered fast axonal flow in A-delta/C fibers), raising the pain threshold of dentin-pulp afferents before mechanical insult.
What complicates this
Both studies are small; Tanboga is non-randomized and both report laser parameters incompletely (the listed 2940 nm is an Er:YAG cutting laser, not the LLLT analgesic source), limiting reproducibility.
Safety notes
Standard PBM safety with intra-oral delivery. An adjunct for comfort; do not withhold local anesthesia where clinically indicated.
980 nm diode laser cleared facial telangiectasias - but this is photothermal vessel ablation, not low-level PBM
Limited evidence· Points toward a benefit
A 12-subject single-arm trial (Dudelzak 2009) found a 980 nm diode laser at high fluences (22-147 J/cm2) effectively treated facial telangiectasias without complications. Important caveat: at these energies the mechanism is selective photothermal coagulation of vessels - fundamentally different from low-level photobiomodulation - so this does not support red-light/NIR PBM (or full-body beds) for telangiectasia. Vascular laser treatment is a procedural dermatology intervention requiring a trained operator.
Studied in Adults with facial telangiectasias (Fitzpatrick I-III).clinical studies
How strong the finding is
1 human single-arm trial (Dudelzak 2009, n=12, 980 nm, 22.2-146.9 J/cm2, 1-3 monthly sessions); effective with no observed complications.
How it may work
Photothermal: selective absorption by oxyhemoglobin at 980 nm coagulates target vessels. This is ablative/thermal, not the sub-thermal cytochrome c oxidase photobiomodulation pathway.
What complicates this
Small uncontrolled trial; the mechanism is photothermal ablation, not PBM - labeling it photobiomodulation would overstate the low-level-light evidence; results do not transfer to LED beds.
Safety notes
Operator-administered medical laser; risk of burns or pigment change at high fluence; eye protection mandatory; not a home or PBM-bed indication. PBM is an adjunct, not a replacement for prescribed medical care.
Transcranial PBM shows large working-memory and attention gains in adult ADHD — but the human trial is uncontrolled
Limited evidence· Points toward a benefit
A 48-adult single-arm study of transcranial PBM (1064 nm) in ADHD reported significant working-memory and attention gains with sizable effect sizes (Cohen's d 0.84-1.26), peaking 2-3 weeks post-intervention, and a rat ADHD model showed PBM reduced hyperactivity while increasing prefrontal connectivity and dampening neuroinflammation. The convergence of a strong human signal with a mechanistic animal model is exciting for a condition where non-drug options are wanted. The catch: the human study had no control arm, so expectation and practice effects can't be separated yet.
Studied in Adults with ADHD (working memory and attention); rat ADHD model for mechanismmixed
How strong the finding is
2 studies: Lai 2025 (human single-arm, n=48, 1064 nm, 250 mW/cm2, 720 s/day x7; N-back and CPT improvements, d=0.84-1.26, peak at 2-3 weeks) and Huang 2025 (rat SHR model, 808 nm; reduced track length/speed, higher prefrontal anisotropy, fewer Iba-1+ cells).
How it may work
Transcranial NIR reaches prefrontal cortex, boosting cytochrome-c-oxidase-driven ATP and cerebral blood flow; the rat data add reduced microglial (Iba-1) activation and increased prefrontal fractional anisotropy, i.e., less neuroinflammation and better connectivity underpinning attention/impulse control.
What complicates this
The human trial is uncontrolled and short; large effect sizes from single-arm designs often shrink under sham control. Animal-to-human dose translation for ADHD is unestablished.
Safety notes
Safety was formally assessed in the human study with no major issues at 1064 nm/250 mW/cm2. Transcranial PBM is an adjunct to evaluate, not a replacement for established behavioral or pharmacologic ADHD care.
LLLT reduced post-varicocelectomy orchialgia in a double-blind RCT — promising adjunct for a tough post-surgical pain
Limited evidence· Points toward a benefit
A double-blind, placebo-controlled trial in 60 men found that red (650 nm) and infrared (820 nm) LLLT significantly reduced chronic groin/scrotal pain after varicocelectomy and increased sexual satisfaction over a 12-week follow-up. Post-surgical orchialgia is stubborn and under-served, so a positive sham-controlled result is genuinely encouraging. As a single trial, it should be confirmed independently before being treated as standard care.
Studied in Men with chronic orchialgia following varicocelectomyclinical studies
How strong the finding is
1 human RCT: Momenzadeh 2024 (double-blind, n=60; 650 nm/50 mW + 820 nm/100 mW, 6-25 J/cm2/day, 15 min, 3x/week x12) showed significant pain reduction and improved sexual satisfaction vs placebo.
How it may work
Localized PBM dampens post-surgical inflammation and neurogenic pain signaling and improves microcirculation and tissue energy metabolism in the affected groin/scrotum, reducing chronic nociceptive input.
What complicates this
Single trial from one group; same protocol family as their testicular-pain study, so independent replication and longer follow-up are needed.
Safety notes
No significant adverse effects reported; trained delivery and standard eye protection. Adjunct to surgical/urologic management, not a replacement; persistent or escalating pain warrants re-evaluation.
Polychromatic visible+IR light sharply lowered pro-inflammatory cytokines in a human RCT - limited but striking signal
Limited evidence· Points toward a benefit
A randomized, double-blind, placebo-controlled trial (Zhevago & Samoilova 2006, n=62) found transcutaneous polychromatic visible+infrared light (480-3400 nm, 12 J/cm2) dramatically reduced circulating pro-inflammatory cytokines in people with elevated baselines - TNF-alpha, IL-6 and IFN-gamma fell roughly 34x, 12x and 1.5x at 30 minutes - with a mouse study (Fukuda 2013, 780 nm) echoing reduced TNF-alpha/IFN-gamma. The human signal is striking but rests on a single RCT, so it is limited pending replication. Supports PBM as a systemic immunomodulatory adjunct, not a replacement for treating the underlying driver of inflammation.
Studied in Adults with elevated systemic inflammatory markers (human RCT); supported by animal data.mixed
How strong the finding is
2 studies (1 human RCT, 1 animal); Zhevago 2006 (starred, n=62, 480-3400 nm, 12 J/cm2 transcutaneous + 2.4 J/cm2 ex vivo; TNF-alpha/IL-6/IFN-gamma down ~34x/12x/1.5x in those above-normal at baseline); Fukuda 2013 (mouse, 780 nm, lower TNF-alpha/IFN-gamma, no change IL-6/TGF-beta1).
How it may work
Light modulates immune-cell signaling via cytochrome c oxidase to ATP and redox shifts, downregulating pro-inflammatory cytokine release (TNF-alpha, IL-6, IFN-gamma) and rebalancing toward anti-inflammatory mediators - demonstrable both transcutaneously and ex vivo on blood.
What complicates this
Single human RCT; effects measured mainly in subjects with elevated baselines and at short timepoints (durability unclear); broadband source mixes thermal and photobiomodulatory effects; animal data partial (no IL-6 change); needs replication.
Safety notes
Eye protection; broadband sources include IR heat - avoid overheating; adjunct for immunomodulation, not a replacement for diagnosing and treating the inflammatory cause.
830 nm PBM improved post-inguinal-hernia scar quality and pain - single small RCT
Limited evidence· Points toward a benefit
A sham-controlled RCT (Carvalho 2010, n=28) found infrared 830 nm LLLT after inguinal-hernia surgery (applied 24 h post-op then days 3, 5, 7) significantly improved Vancouver Scar Scale scores, reduced scar thickness, increased malleability and roughly halved pain versus control. Promising and mechanism-consistent, but a single small trial - replication needed. PBM is a post-surgical adjunct, not a substitute for surgical technique.
Studied in Patients recovering from inguinal-hernia repair.clinical studies
How strong the finding is
1 human RCT (Carvalho 2010, n=28, 830 nm GaAlAs, 40 mW CW; VSS 2.14 +/- 1.51 vs 4.85 +/- 1.87; thickness 0.11 vs 0.19 cm; ~50% less pain).
How it may work
NIR via cytochrome c oxidase to ATP improves collagen organization and remodeling, modulates inflammation and provides analgesia during incisional scar formation.
What complicates this
Single small RCT; surrogate scar/pain endpoints; short follow-up; no replication.
Safety notes
Eye protection; adjunct to standard post-op care; begin per protocol after wound assessment.
PBM plus antimicrobial photodynamic therapy supported perianal-abscess healing post-drainage - single case report
Limited evidence· Points toward a benefit
A single case report (Campos 2021) describes antimicrobial photodynamic therapy plus PBM after incision and drainage of a perianal abscess, with no signs of infection or inflammation by day 5 and no fistula or recurrence at 3 months. This is one anecdote combining two light modalities, so attribution to PBM specifically is not possible. An encouraging hypothesis for adjunctive post-surgical care, not evidence of efficacy; standard surgical management remains primary.
Studied in Patients post incision-and-drainage of perianal abscess.clinical studies
How strong the finding is
1 human case report (Campos 2021); aPDT + PBMT post-drainage; no infection by day 5, no fistula at 3 months.
How it may work
PBM modulates inflammation and supports tissue repair (cytochrome c oxidase to ATP), while antimicrobial PDT contributes a photodynamic antibacterial effect - distinct but complementary light mechanisms.
What complicates this
Single case, no control; combined aPDT+PBM confounds attribution; natural post-drainage healing expected; not generalizable.
Safety notes
Surgical evaluation essential (sepsis/fistula risk); aPDT and PBM are distinct modalities; investigational adjunct only, not a substitute for drainage or antibiotics where indicated.
Infrared light improved sensation and blood flow in acromegaly-related neuropathy — a single well-instrumented case
Limited evidence· Points toward a benefit
A single-subject A-B-A case report used monochromatic infrared light (890 nm, Anodyne system) in a man with acromegaly-related sensorimotor polyneuropathy and documented behavioral/sensory improvement that appeared only during the intervention phases, alongside laser-Doppler-measured changes in red-blood-cell flux. The A-B-A design strengthens causal inference for an n-of-1, which is meaningful. But it remains one patient — a hypothesis-generating signal, not generalizable evidence.
Studied in Adults with acromegaly-related (and analogous) sensorimotor peripheral neuropathyclinical studies
How strong the finding is
1 human case report: Newton & Marshall 2021 (single-subject A-B-A, 890 nm MIRE via Anodyne Therapy System; behavioral/sensory change present only during intervention, with laser-Doppler flow changes over 5-week treatment).
How it may work
NIR light raises local nitric-oxide-mediated microcirculation and mitochondrial energy in peripheral nerve and surrounding tissue, plausibly improving nerve perfusion and sensory function in the feet.
What complicates this
n-of-1; no group data, no blinding beyond the A-B-A structure, and acromegalic neuropathy is rare, so external validity is unknown.
Safety notes
No adverse effects reported; home/clinic infrared pad delivery. Adjunct to endocrine management of acromegaly and standard neuropathy care, not a replacement.
808 nm PBM improved early nerve reinnervation after brachial plexus surgery - single small RCT
Limited evidence· Points toward a benefit
A small randomized controlled trial (Foo 2020, n=14) found that 808 nm PBM (4 J/cm2, 50 mW, daily x10) after Oberlin-procedure neurotization for brachial plexus injury produced more signs of reinnervation and significantly higher mean muscle power by 3 months, with no adverse effects. This is one small RCT - promising and mechanism-consistent, but underpowered and in need of replication. PBM is a surgical adjunct to support nerve regeneration, not a substitute for neurosurgical repair.
Studied in Patients undergoing surgical neurotization for traumatic high brachial plexus injury.clinical studies
How strong the finding is
1 human RCT (Foo 2020, n=14, 808 nm, 4 J/cm2, daily x10); more reinnervation and significantly higher muscle power at 3 months in the PBM arm; no adverse effects.
How it may work
NIR PBM on regenerating nerve upregulates Schwann-cell activity and neurotrophic factors, raises mitochondrial ATP (cytochrome c oxidase), reduces oxidative stress and supports axonal sprouting.
What complicates this
Single very small RCT (n=14), short follow-up, no replication; surgical and rehab co-factors; outcome blinding not uniform.
Safety notes
Eye protection; apply over the repair site per protocol; adjunct to surgical and rehabilitation care.
650 nm LLLT sped graft vascularization and reduced socket contraction in a small randomized trial
Limited evidence· Points toward a benefit
After allogeneic scleral grafting for contracted sockets, 650 nm LLLT significantly accelerated conjunctival vascularization (p=0.003) and reduced fornix contraction versus controls in a 39-patient randomized, double-blind study (Huang 2023). A clean directional result for a reconstructive challenge — limited by small size and some methodological ambiguity in the report.
Studied in Patients with contracted sockets undergoing allogeneic scleral graft transplantationclinical studies
How strong the finding is
One human randomized double-blind trial (Huang 2023, n=39, 650 nm, 10 mW, 3.8 J/cm2, 5 min/day x 7 days): faster conjunctival vascularization (p=0.003), less fornix contraction (p approx 0.000).
How it may work
PBM enhances angiogenesis and fibrovascular healing of the graft by stimulating endothelial and fibroblast activity and ATP synthesis while modulating the postoperative inflammatory response.
What complicates this
Small single-center trial; the report mixes 'retrospective chart review' and 'randomized' language, raising design-clarity questions; no replication.
Safety notes
Postoperative periocular LLLT well tolerated; standard PBM/surgical cautions. Adjunct to surgical socket reconstruction.
Laser plus Traditional Chinese Medicine reported 94% effectiveness in cervical radiculopathy — uncontrolled and confounded
Limited evidence· Points toward a benefit
An early single-arm series of 90 patients reported a 94.4% effective rate for radicular cervical spondylosis treated with laser therapy combined with Traditional Chinese Medicine (Li 1992). The number is eye-catching, but with no control group and laser bundled with TCM, it cannot isolate a PBM effect — this is a historical signal worth testing properly, not evidence of efficacy.
Studied in Patients with radicular cervical spondylosisclinical studies
How strong the finding is
One uncontrolled human single-arm series (Li 1992, n=90): 94.4% total effective rate (11 full recovery, 28 markedly effective, 46 improved), laser combined with TCM.
How it may work
PBM may reduce perineural inflammation and edema around compressed cervical roots and stimulate local microcirculation and tissue repair, plausibly easing radicular symptoms.
What complicates this
No control or randomization, a subjective composite endpoint, and co-administered TCM make attribution to PBM impossible; old report with sparse parameter details and no abstract.
Safety notes
Standard PBM safety; cervical radiculopathy with progressive neurological deficit needs surgical evaluation. Adjunct only, not a replacement for prescribed care.
LLLT aided conjunctival graft survival and healing in socket reconstruction — small case series with animal support
Limited evidence· Points toward a benefit
Combined with hydroxyapatite orbital implantation, 650 nm LLLT promoted conjunctival graft survival, incision healing and early vascularization in a 10-patient case series, with a companion rabbit model probing mechanism (Xu 2021). A reasonable wound-healing signal for a niche surgical problem, but the human evidence is a small uncontrolled series.
Studied in Patients undergoing conjunctival/scleral grafting for conjunctival sac stenosis with orbital implantationclinical studies
How strong the finding is
One human case series (Xu 2021, n=10, 650 nm) plus a rabbit mechanistic model: improved graft survival, incision healing and early HA-implant vascularization.
How it may work
PBM accelerates fibrovascular ingrowth and wound healing by boosting fibroblast/endothelial activity, angiogenesis and ATP production, and modulating inflammation at the graft/implant interface.
What complicates this
Tiny uncontrolled case series; outcomes partly mechanistic/animal; no randomization or comparator.
Safety notes
Postoperative periocular LLLT is well tolerated; standard surgical and PBM cautions. Adjunct to surgical reconstruction.
PBM of salivary glands nudges caries-risk markers, but it doesn't replace fluoride - human signal thin, animal data flat
Limited evidence· Mixed findings
Direct evidence that photobiomodulation prevents dental caries is weak. One human RCT (Nemeth 2019) found that irradiating major salivary glands shifted caries-risk markers favorably - lower Streptococcus mutans and Lactobacillus counts and higher salivary buffering (p<0.05) - while a rat study (Mueller 2007) showed laser alone added nothing to fluoride. The honest read is a plausible salivary/antimicrobial mechanism with one supportive human trial, not a caries-prevention therapy; fluoride and standard preventive care remain the foundation and PBM at most an adjunct to confirm.
Studied in High-caries-risk adults (salivary-gland-targeted PBM)mixed
How strong the finding is
2 studies: Nemeth 2019 (human RCT, n=36, polychromatic/LED light to salivary glands, reduced S. mutans/Lactobacillus and increased buffering, p<0.05) and Mueller 2007 (rat, 660 nm, laser alone no caries benefit; slight gain only when applied before fluoride).
How it may work
Light may stimulate salivary gland secretory cells (cytochrome c oxidase -> ATP) to improve salivary flow and buffering capacity, plus exert photo-antimicrobial effects on cariogenic flora - indirectly lowering caries risk rather than remineralizing enamel directly.
What complicates this
Only one human RCT, measuring surrogate risk markers rather than cavity incidence; the animal study was essentially negative for laser alone. No evidence PBM substitutes for fluoride.
Safety notes
Standard PBM safety. Does not substitute for fluoride, diet control, and oral hygiene; position only as an adjunct under dental supervision.
Laser phototherapy may calm oral cicatricial pemphigoid lesions as a steroid adjunct - one case only
Limited evidence· Points toward a benefit
Evidence for PBM in oral cicatricial pemphigoid is a single case report (Oliveira 2009): 660 nm laser phototherapy added to systemic steroids was associated with better lesion control, oral health, and quality of life. This is anecdotal - one patient, no control - so it can only be framed as a plausible, low-risk adjunct to standard immunosuppression in this rare autoimmune blistering disease, never a replacement for it.
Studied in Patients with oral cicatricial pemphigoid, alongside systemic steroidsclinical studies
How strong the finding is
1 case report (Oliveira 2009, Brazil): GaAlAs 660 nm laser (30 mW) plus systemic steroids over a 6-month course, with positive lesion and QoL outcome.
How it may work
PBM promotes wound healing and analgesia via mitochondrial photon absorption (cytochrome c oxidase -> ATP), enhanced fibroblast/keratinocyte activity, and dampened local inflammation - supportive for fragile, ulcerated mucosa.
What complicates this
A single uncontrolled case cannot separate the laser's effect from concurrent steroid therapy or natural disease fluctuation; no comparative data exist.
Safety notes
Standard PBM safety with intra-oral delivery. Strictly adjunctive to systemic immunosuppression; do not taper prescribed therapy on the basis of PBM.
Postoperative UV-visible phototherapy reduced nasal-polyp recurrence in one RCT - promising but single-study and UV-based
Limited evidence· Points toward a benefit
Evidence is a single multicenter RCT (Kiricsi 2022, n=30): adding mixed ultraviolet-visible (280-650 nm) phototherapy to intranasal steroids after endoscopic sinus surgery significantly reduced nasal-polyp recurrence, size, and obstruction. A genuinely encouraging result - but note it uses immunomodulatory UV-visible light rather than classic red/NIR PBM, and one trial cannot establish the effect. Reasonable as an adjunct to surgery plus steroids, pending replication.
Studied in Post-FESS patients with chronic rhinosinusitis with nasal polypsclinical studies
How strong the finding is
1 multicenter RCT (Kiricsi 2022): n=30, mixed UV-visible 280-650 nm plus intranasal steroid over 12 weeks, significantly reduced recurrence/size/obstruction vs steroid alone.
How it may work
Mixed UV-visible phototherapy exerts local immunosuppressive/immunomodulatory effects - reducing inflammatory cells and mediators in the nasal mucosa - counteracting the chronic inflammation that drives polyp regrowth (a different mechanism than red/NIR mitochondrial PBM).
What complicates this
Single small trial; it uses UV-visible (not red/NIR PBM) light, and the open design plus concurrent steroids limit attribution. Long-term recurrence data are lacking.
Safety notes
Standard phototherapy safety; UV-containing light requires correct use to limit mucosal UV exposure. Adjunct to surgery and intranasal steroids, not a replacement.
One small RCT suggests laser plus eccentric exercise beats laser alone for patellar tendinopathy
Limited evidence· Points toward a benefit
Evidence is a single small RCT (Liu 2014, n=21, 810 nm): low-level laser combined with eccentric exercise outperformed laser alone (and exercise comparators) on most outcomes, though pain relief between laser+exercise and laser alone was similar. This is consistent with PBM's role as an exercise-potentiating adjunct for tendinopathy, but with only one small trial here, it is a promising lead to confirm rather than established practice.
Studied in Adults with patellar tendinopathy (jumper's knee)clinical studies
How strong the finding is
1 human RCT (Liu 2014): n=21, 810 nm; laser plus eccentric exercise superior to other groups on most outcomes.
How it may work
PBM modulates tendon inflammation and stimulates fibroblast/collagen activity and microcirculation (cytochrome c oxidase -> ATP), plausibly enhancing the remodeling driven by eccentric loading.
What complicates this
Single very small trial; the pain difference vs laser-alone was nonsignificant, and the additive effect cannot be separated from exercise. No PMID/abstract available for independent dosimetry verification.
Safety notes
Standard PBM safety with localized delivery. Best paired with eccentric exercise; an adjunct, not a replacement for loading rehabilitation.
Low-level laser sped healing of traumatic lip lesions in a small case series - analgesia plus faster repair
Limited evidence· Points toward a benefit
Evidence is a two-case series (Moreira 2004) in cerebral-palsy patients with traumatic lip ulceration, where 685 nm laser accelerated healing, reduced secondary contamination, and provided analgesia. This is consistent with PBM's well-documented soft-tissue wound-healing effects, but it is anecdotal - useful as a supportive adjunct for difficult-to-manage labial trauma, not an evidence-backed standalone therapy.
Studied in Patients with traumatic lip/labial soft-tissue injury (here, spastic cerebral palsy)clinical studies
How strong the finding is
1 case series (Moreira 2004): 2 cases, 685 nm InGaAlP, 190 J/cm2, 14-day course; accelerated healing and analgesia.
How it may work
PBM enhances fibroblast proliferation, collagen deposition, and microcirculation while reducing inflammation and pain (cytochrome c oxidase -> ATP), speeding closure of mucosal/labial wounds.
What complicates this
Two uncontrolled cases; the high reported fluence (190 J/cm2) and special population limit generalization.
Safety notes
Standard PBM safety with localized delivery. Adjunct to wound care and management of the underlying cause (e.g., spastic bite); not a replacement for definitive treatment.
PBM shows early promise for the painful oral lesions of dystrophic epidermolysis bullosa - one small case series
Limited evidence· Points toward a benefit
Evidence is limited to a single case series (Sindici 2017): 904 nm laser treated 19 oral lesions across 7 patients with dystrophic epidermolysis bullosa, with reported clinical benefit over follow-up. For a rare, blistering, exquisitely fragile-tissue disease with few good options, this is an encouraging, low-trauma adjunct worth formal study - but it remains anecdotal and is not a disease-modifying therapy.
Studied in Patients with dystrophic epidermolysis bullosa and oral mucosal lesions (pediatric to young adult)clinical studies
How strong the finding is
1 case series (Sindici 2017): 7 patients (mean age 19.8), 19 oral lesions, 904 nm, 3-day treatment with 6-month follow-up.
How it may work
PBM supports epithelial wound healing and analgesia (mitochondrial photon absorption -> ATP, enhanced keratinocyte/fibroblast activity, reduced inflammation), attractive where mechanical dressings or topical agents risk further blistering.
What complicates this
Uncontrolled case series with small numbers and no comparator; natural lesion fluctuation cannot be excluded.
Safety notes
Standard PBM safety with non-contact intra-oral delivery to avoid mechanical trauma to fragile mucosa. Strictly adjunctive to specialist EB care.
PBM aided healing of necrotizing sialometaplasia in a single case - supportive, anecdotal
Limited evidence· Points toward a benefit
Evidence is one case report (Leite 2020): 660 nm PBM supported healing of palatal necrotizing sialometaplasia, a rare, self-limiting but locally destructive benign lesion. PBM's regenerative wound-healing profile makes this a reasonable supportive adjunct, but with a single uncontrolled case - and a condition that often resolves on its own - this is anecdotal and hypothesis-generating only.
Studied in Patients with necrotizing sialometaplasia of the palateclinical studies
How strong the finding is
1 case report (Leite 2020): 660 nm, 2 sessions, 3-month follow-up with healing.
How it may work
PBM accelerates the regenerative wound-healing cascade (fibroblast activity, angiogenesis, ATP-driven repair) and provides analgesia, supporting mucosal recovery of the ulcerated palatal lesion.
What complicates this
Single case; necrotizing sialometaplasia is typically self-resolving over weeks, so spontaneous healing cannot be excluded.
Safety notes
Standard PBM safety with intra-oral delivery. Confirm the benign diagnosis (it can mimic malignancy histologically); PBM is supportive only. PBM is an adjunct, not a replacement for prescribed medical care.
Combined red/blue light therapy eased Demodex blepharitis symptoms — one small human series plus supportive animal data
Limited evidence· Points toward a benefit
For treatment-resistant Demodex blepharitis, combined IPL + low-level red/blue light significantly improved symptom scores (12.0 to 7.8, p=0.003) with no adverse events in a 17-patient retrospective series (Farrant 2025), and an 808 nm PBM rat model showed reduced eyelid inflammation and improved tear volume/break-up time (Kim 2020). A reasonable, low-risk adjunct signal — but the human data are retrospective and bundled with IPL, so the PBM-specific contribution is not isolated.
Studied in Patients with blepharitis (incl. Demodex-associated) and meibomian-gland dysfunctionclinical studies
How strong the finding is
2 studies: Farrant 2025 (human retrospective, 17 pts/34 eyes, blue+red IPL/LLLT, symptom score 12.0 to 7.8, p=0.003, no adverse events) and Kim 2020 (rat, 808 nm, reduced inflammation, raised tear volume/TBUT).
How it may work
PBM reduces eyelid and meibomian-gland inflammation, supports glandular epithelial function and tear-film stability, and (with blue light) may exert antimicrobial/anti-Demodex effects; red light drives the mitochondrial/anti-inflammatory side.
What complicates this
Human evidence is a small retrospective series with IPL co-treatment, so PBM's standalone effect is unclear; the supporting mechanistic study is animal.
Safety notes
Periocular light therapy is well tolerated with eye shields; standard PBM cautions. Adjunct to lid hygiene and prescribed therapy.
Early signals for PBM in hidradenitis suppurativa — one retrospective series plus anti-inflammatory in-vitro work
Limited evidence· Points toward a benefit
Hidradenitis suppurativa has preliminary but interesting PBM support. A retrospective series of 16 patients treated with an 808 nm diode laser showed a significant drop in disease severity (median modified HS score 20 to 9 at six months) (Ozdemir & Tamer 2024), and in-vitro work on HS genetic cell models shows PBM reduces inflammatory IL1B expression and supports cell metabolism and migration (Zupin 2020; Ferri 2019). A note of honesty: much laser use in HS is photothermal follicle-targeting rather than classic photobiomodulation, so mechanism attribution is mixed. The direction is supportive; the human evidence is limited and uncontrolled.
Studied in Patients with hidradenitis suppurativa (plus HS in-vitro cell models).mixed
How strong the finding is
~4 studies (1 retrospective human, 2 in vitro, 1 review); Ozdemir & Tamer 2024 (808 nm, MHSS 20 to 9), Zupin 2020 / Ferri 2019 (in-vitro anti-inflammatory PBM).
How it may work
PBM exerts anti-inflammatory effects (reduced IL1B and other cytokines) and promotes wound healing, angiogenesis, and pain relief; in HS, photothermal follicle targeting may also contribute when higher-energy diode lasers are used.
What complicates this
Only one small uncontrolled human series; mechanism ambiguous (photothermal follicle ablation vs photobiomodulation); rest is in vitro/review.
Safety notes
Standard PBM safety. HS is a chronic inflammatory disease usually needing antibiotics, biologics, or surgery; light therapy is at most an adjunct, never a replacement for prescribed care.
Low-level light therapy resolved recalcitrant chalazia, especially after a second session — small retrospective signal
Limited evidence· Points toward a benefit
In 26 eyes with chalazia unresponsive to prior pharmaceutical or surgical treatment, a single 15-minute LLLT session (with standard meds) resolved 46%, rising to 92% after a second session (Stonecipher & Potvin 2019). For lesions already failing conventional care, that is an encouraging, low-risk option — though it is a retrospective chart review with concurrent pharmacotherapy, so controlled confirmation is needed.
Studied in Patients with recalcitrant chalazia (failed prior pharmaceutical/surgical therapy)clinical studies
How strong the finding is
One human retrospective series (Stonecipher & Potvin 2019, 22 pts/26 eyes): 46% resolution after one 15-min LLLT session, 92% after a second, only 2/26 unresolved; all on concurrent standard pharmaceutical regimen.
How it may work
PBM warms and stimulates meibomian-gland function, reduces local inflammation, and may promote drainage and resolution of the granulomatous chalazion.
What complicates this
Retrospective, uncontrolled, and combined with pharmacotherapy — cannot isolate LLLT; no sham arm; modest numbers.
Safety notes
Periocular LLLT is well tolerated; eye protection standard. Adjunct to lid hygiene/warm compress and prescribed therapy; surgical drainage remains an option.
650 nm PBM improved acuity and retinal function in Stargardt disease over a year — single uncontrolled study, no other options
Limited evidence· Points toward a benefit
In 90 eyes of 45 Stargardt patients, a year of twice-daily 650 nm PBM improved best-corrected visual acuity (0.7 to 0.4, p<0.001), PERG amplitude and microperimetry (Scalinci 2022). For an inherited macular dystrophy with no approved treatment, a functional-improvement signal is meaningful — but it is a single-arm, uncontrolled study, so the result is promising rather than established.
Studied in Patients with Stargardt disease (STGD1)clinical studies
How strong the finding is
One human single-arm trial (Scalinci 2022, n=45/90 eyes, 650 nm, 10 Hz, twice daily 10 min, 5 days/week x 12 months): BCVA 0.7 to 0.4 (p<0.001), improved PERG N35-P50 amplitude and microperimetry.
How it may work
PBM may bolster macular photoreceptor/RPE mitochondrial function and ATP and reduce oxidative stress and lipofuscin-related damage, temporarily improving or stabilizing residual macular function.
What complicates this
Single-arm and uncontrolled; subjective/functional endpoints susceptible to learning/placebo effects; no comparator or follow-up beyond a year.
Safety notes
Ocular PBM at studied doses appeared safe; validated dosimetry and specialist oversight required. Adjunct/experimental; does not replace genetic counseling or low-vision support.
Red laser (635 nm) cleared early cutaneous leishmaniasis lesions in 91% — striking but uncontrolled single-arm data
Limited evidence· Points toward a benefit
In a 53-patient, 123-lesion single-arm trial, red LLLT (635 nm, 75 J/cm2) produced complete response in 91% of early-stage (low-grade) cutaneous leishmaniasis lesions at 10 months, while high-grade lesions did not respond. For a disfiguring infection with toxic standard treatments, that is a genuinely promising signal. But it is a single uncontrolled study, so spontaneous healing and selection can't be excluded — a controlled trial is the necessary next step.
Studied in Patients with early-stage (low-grade) cutaneous leishmaniasis lesionsclinical studies
How strong the finding is
1 human single-arm trial: Khan 2020 (n=53, 123 lesions, 635 nm, 75 J/cm2, 300 mW, 4 weekly sessions) with 91% complete and 9% partial response in low-grade disease, no response in high-grade, at 10-month follow-up.
How it may work
Red light may act through photo-eradication and immune/wound-healing modulation — stimulating local immune clearance of the parasite and accelerating tissue repair via mitochondrial activation — though the precise anti-leishmanial pathway in vivo is not fully resolved.
What complicates this
No control or placebo group, so natural lesion regression can't be ruled out; benefit limited to early-stage disease. Single-center result awaiting randomized confirmation.
Safety notes
Well tolerated at the reported dose; ineffective for advanced/ulcerated high-grade lesions, which still need standard antiparasitic therapy. PBM is an adjunct/alternative to evaluate, not a confirmed replacement for established CL treatment.
Localized red/IR laser eased chronic testicular pain in a double-blind RCT — encouraging single-trial signal
Limited evidence· Points toward a benefit
In a 60-patient double-blind, placebo-controlled trial, both red (650 nm) and infrared (820 nm) LLLT significantly reduced chronic testicular pain at 6 and 12 weeks versus sham, and also improved sexual satisfaction. That is a clean, placebo-controlled result for a notoriously hard-to-treat condition. It is one trial, so confirmation in independent cohorts is the next step before calling it established.
Studied in Men with chronic testicular pain (orchialgia)clinical studies
How strong the finding is
1 human RCT: Momenzadeh 2024 (double-blind, n=60; 650 nm/50 mW and 820 nm/100 mW, 6-25 J/cm2/day, 15 min, 3x/week x12 sessions) showed significant pain reduction vs placebo at 6 and 12 weeks and improved sexual satisfaction.
How it may work
PBM reduces local inflammatory mediators and modulates peripheral nociceptor signaling while improving microcirculation and mitochondrial energy in the irradiated scrotal tissue, lowering chronic pain transmission.
What complicates this
Single trial, single center; durability beyond 12 weeks and the relative value of red vs infrared remain open. Replication is needed before firm recommendation.
Safety notes
No significant adverse effects reported in the trial; standard laser eye protection and trained delivery. PBM is an adjunct within a urologic work-up that should rule out treatable structural causes first.
High-intensity laser plus decompression improved function in lumbar disc protrusion — pain relief was less clear
Limited evidence· Mixed findings
In a 63-patient RCT, adding high-intensity laser therapy to spinal decompression significantly improved disability (ODI), lumbar flexion and straight-leg-raise versus decompression alone, though VAS pain (low back and radicular) did not reach significance (Chen 2018). Encouraging for function, honest about the pain endpoint — and note this is high-intensity laser, not classic low-level PBM, so the mechanism leans toward a biostimulatory/photothermal hybrid.
Studied in Adults with lumbar disc protrusionclinical studies
How strong the finding is
One human RCT (Chen 2018, n=63): significant gains in ODI, lumbar flexion and straight-leg-raise at 2 weeks (p<0.05); VAS pain not significantly different (p>0.05).
How it may work
HILT combines photobiomodulatory and mild photothermal effects — stimulating cellular metabolism, microcirculation and analgesic pathways while decompression unloads the nerve root; together they may reduce inflammation and improve mobility.
What complicates this
Single RCT, short follow-up (1 month); the non-significant pain result tempers the functional gains, and HILT was bundled with spinal decompression, so the laser's independent contribution is uncertain.
Safety notes
High-intensity laser delivers more thermal energy than LLLT — operator training and dosimetry matter to avoid burns. Adjunct to spinal decompression/physiotherapy, not a replacement for surgical evaluation when indicated.
Repeated low-level red light eased eye strain and improved accommodation in presbyopia — promising first RCT
Limited evidence· Points toward a benefit
In a double-blind RCT of 66 adults with presbyopia and eye strain, short-term 650 nm repeated low-level red light significantly reduced asthenopic symptoms (CVS-Q) and improved accommodative amplitude versus sham (Song 2026). A clean, blinded positive result for an everyday complaint — limited by short duration and single-trial status, so durability and longer-term safety remain to be shown.
Studied in Adults with presbyopia and asthenopia (eye strain)clinical studies
How strong the finding is
One human double-blind RCT (Song 2026, n=66/64 completed, 650 nm): significant reduction in CVS-Q asthenopia score and improved accommodative amplitude at day 31 vs sham.
How it may work
Red light may enhance ciliary-muscle and retinal mitochondrial function and choroidal perfusion, improving accommodative capacity and reducing visual fatigue.
What complicates this
Single short-term (1-month) trial; durability beyond a month and long-term retinal safety untested; modest sample.
Safety notes
Same retinal-safety vigilance as other red-light/RLRL eye applications; device-validated dosing and ophthalmologic oversight advised. Adjunct to refractive correction, not a replacement.
LED red light increased eyebrow hair count in frontal fibrosing alopecia — a small but sustained single-arm signal
Limited evidence· Points toward a benefit
In a first-of-its-kind single-arm study, 16 women with frontal fibrosing alopecia received 630 nm LED therapy weekly for 10 weeks; total eyebrow hair count rose significantly, as did thick and mid-thick hairs, and the gain in total eyebrow hairs was still significant at 6-month follow-up (Gerkowicz 2021). Eyebrow loss in FFA is notoriously hard to treat, so a durable, well-tolerated regrowth signal is encouraging — but this is a small, uncontrolled study, so the grade stays limited.
Studied in Older women with eyebrow loss due to frontal fibrosing alopecia.clinical studies
How strong the finding is
1 human single-arm study (Gerkowicz 2021, n=16, 630 nm LED, weekly x10) with significant, partly sustained eyebrow-count increase.
How it may work
Red LED light stimulates follicular cytochrome c oxidase/ATP and modulates peri-follicular inflammation, promoting regrowth in fibrosing-alopecia-affected eyebrow follicles.
What complicates this
Single-arm, small N, no control; FFA course variable; needs randomized confirmation.
Safety notes
Standard PBM safety; therapy was well tolerated. Use caution around the eyes (appropriate eye protection). A low-risk adjunct, not a replacement for FFA disease-directed therapy.
Red light gave 86% symptom relief in corticosteroid-addiction dermatitis — but the data are uncontrolled
Limited evidence· Points toward a benefit
In a retrospective series of 170 patients with corticosteroid-addiction (topical-steroid-withdrawal) dermatitis, 633 nm red light was associated with clinical relief in 85.9% — reduced lesion area and improved symptoms — with healing of the epidermis and reduced dermal inflammation on histology and no adverse events (Luan 2014). For a condition where stopping the offending steroid is itself the therapy, the lack of a control group is a serious limitation: improvement over time is expected. The signal is encouraging and the mechanism plausible, but this is uncontrolled evidence.
Studied in Patients with corticosteroid-addiction / topical-steroid-withdrawal dermatitis (mainly facial).clinical studies
How strong the finding is
1 human retrospective study (Luan 2014, n=170, 633 nm) with 85.9% clinical relief and supportive histology, no control group.
How it may work
Red light reduces cutaneous inflammation and supports epidermal barrier repair via cytochrome c oxidase/ATP and cytokine modulation, easing the rebound inflammation of steroid withdrawal.
What complicates this
Single uncontrolled retrospective study; no comparator; spontaneous improvement after stopping steroids confounds the result.
Safety notes
Standard PBM safety; no adverse events reported. A plausible adjunct during steroid withdrawal, but the core management is supervised cessation of topical steroids — PBM is not a replacement for dermatologic guidance.
Near-infrared stellate-ganglion irradiation eased induced breathlessness in one crossover RCT — early proof-of-concept
Limited evidence· Points toward a benefit
In a sham-controlled crossover trial of 28 healthy adults, linear-polarized near-infrared irradiation of the stellate ganglion significantly lowered the perceived dyspnea of resistive-load breathing across multiple loads (p ≈ .005-.009). It is a clever, mechanism-plausible proof-of-concept borrowing from pain-management practice, but it is a single small study in healthy volunteers with experimentally induced (not clinical) dyspnea. Worth following up in real respiratory disease; for now an experimental adjunct only.
Studied in Healthy adults with experimentally induced dyspnea (resistive loading); clinical dyspnea not yet testedclinical studies
How strong the finding is
1 human RCT (Izukura 2019, crossover, sham-controlled, n=28): significant reductions in modified Borg dyspnea at 10/20/30 cm H2O/L/s resistive loads with stellate-ganglion NIR vs sham.
How it may work
NIR irradiation of the stellate ganglion is thought to modulate sympathetic autonomic tone (analogous to a stellate ganglion block), altering the central perception of breathing effort; dyspnea and pain share processing pathways the device was originally designed to target.
What complicates this
Single small study in healthy subjects with induced dyspnea — no patient population, no durability data, and the polarized-NIR device differs from typical PBM emitters; effect on clinical dyspnea is unknown.
Safety notes
Non-invasive and well tolerated in the study; neck/ganglion targeting should be done knowledgeably. Adjunct/experimental — does not replace bronchodilators, oxygen, or work-up of the cause of breathlessness.
PBM linked to clinical improvement in vascular parkinsonism in one non-randomized study — intriguing, far from proven
Limited evidence· Points toward a benefit
In a single non-randomized controlled study, photobiomodulation was associated with good or satisfactory clinical improvement in 36 of 37 patients versus 6 of 25 controls (Maksimovich 2019) — a striking effect size for vascular parkinsonism, where options are limited. But without randomization, blinding, or replication, this is hypothesis-generating: encouraging enough to warrant controlled trials, not enough to claim efficacy.
Studied in Patients with vascular parkinsonismclinical studies
How strong the finding is
One human non-RCT (Maksimovich 2019): 36/37 treated vs 6/25 controls improved. No randomization, no blinding, single center.
How it may work
Cerebrovascular PBM (often delivered intravascularly/transcranially in this line of work) is proposed to improve cerebral microcirculation, stimulate angiogenesis and mitochondrial function, and reduce the ischemic burden underlying vascular parkinsonism.
What complicates this
Uncontrolled allocation and unblinded outcome assessment inflate apparent effect; a very large effect from one group is a classic small-study red flag. No independent replication.
Safety notes
Standard PBM safety; intravascular/transcranial delivery techniques carry their own procedural risks and must be clinician-supervised. Adjunct to standard neurological care, not a replacement.
Intranasal PBM (with methylene blue) coincided with Kleine-Levin remission — a single confounded case
Limited evidence· Points toward a benefit
In a treatment-refractory Kleine-Levin syndrome patient, intranasal red-light PBM combined with methylene blue was followed by remission of hypersomnia and cognitive/behavioral symptoms, with no relapse over 2 years. For an orphan disorder with no reliable treatment, that is a notable observation worth pursuing. But it is a single case in which PBM was co-administered with methylene blue, so the light's independent contribution cannot be isolated — purely hypothesis-generating.
Studied in Patients with Kleine-Levin syndrome (single refractory case)clinical studies
How strong the finding is
1 human case report: Hamper 2021 (intranasal PBM, 633 nm, + methylene blue; symptom remission within ~1 week and no further KLS episodes over ~2-year follow-up).
How it may work
Intranasal NIR/red light may reach basal brain regions and, together with methylene blue (a mitochondrial electron-transport enhancer), support neuronal bioenergetics in thalamic/hypothalamic circuits implicated in KLS — a plausible but unproven combined pathway.
What complicates this
n-of-1 and confounded by concurrent methylene blue; KLS is naturally remitting/relapsing, so spontaneous remission can't be excluded. No controlled data.
Safety notes
No adverse effects reported; intranasal device plus oral methylene blue. Methylene blue has its own interactions (e.g., serotonergic). Strictly investigational and adjunctive within specialist neurologic care.
Intra-oral 660 nm PBM preserved taste and tongue papillae during stem-cell transplant — a clean sham-controlled win
Limited evidence· Points toward a benefit
In an 85-patient sham-controlled RCT, intra-oral 660 nm PBM to the tongue dorsum significantly reduced hypogeusia, ageusia and parageusia and prevented lingual papillae atrophy across the neutropenic and engraftment phases of hematopoietic cell transplant (Ferreira 2024). For a side effect with no well-established remedy, that is a meaningfully positive result — still a single trial, so replication would cement it.
Studied in Patients undergoing hematopoietic cell transplantation (HCT/HSCT)clinical studies
How strong the finding is
One human sham-controlled RCT (Ferreira 2024, n=85, 660 nm, 100 mW, 8.8 J/cm2): significant reductions in taste disturbance at neutropenia (T1) and post-engraftment (T2) and prevention of papillae atrophy.
How it may work
PBM supports survival and regeneration of taste-bud and lingual papillae epithelium by boosting mitochondrial ATP, reducing oxidative damage from conditioning chemo/radiotherapy, and modulating local inflammation.
What complicates this
Single trial; taste outcomes are partly subjective and patient numbers per arm modest. No long-term or multi-center confirmation yet.
Safety notes
Intra-oral PBM is well tolerated and already standard for oral mucositis in this population; eye protection during delivery. Adjunct to supportive transplant care.
A single case suggests adjunctive red light helped pemphigus vegetans — anecdotal and combined with steroids
Limited evidence· Points toward a benefit
In one case report, a patient with pemphigus vegetans showed rapid improvement of cerebriform plaques when treated with low-dose systemic corticosteroid plus high-fluence 640 nm visible red light (Wang 2020). Because PBM was combined with corticosteroid, its independent contribution cannot be isolated. It is a hopeful anecdote in a difficult autoimmune blistering disease, but single-case, adjunctive evidence only.
Studied in Patients with pemphigus vegetans (single reported case).clinical studies
How strong the finding is
1 human case report (Wang 2020, 640 nm high-fluence red light, 120 mW/cm2, 210 J/cm2) with rapid plaque improvement alongside corticosteroid.
How it may work
High-fluence red light may exert local anti-inflammatory and pro-healing effects on the vegetating plaques via cytochrome c oxidase/redox modulation, complementing systemic immunosuppression.
What complicates this
Single case; PBM combined with corticosteroid, so effect cannot be attributed to light alone; no controlled data.
Safety notes
Standard PBM safety. Pemphigus is a serious autoimmune blistering disease requiring systemic immunosuppression; PBM here was strictly adjunctive to corticosteroid and is never a replacement for prescribed care.
A single case of refractory acrodermatitis continua cleared with polarized light — intriguing but anecdotal
Limited evidence· Points toward a benefit
In one case report, a pregnant woman with acrodermatitis continua refractory even to the most potent topical steroid was successfully treated with low-level polarized polychromatic non-coherent light, with no side effects (Choi 2011). It is a genuinely encouraging anecdote in a hard-to-treat inflammatory dermatosis where steroid-sparing options matter, but it is a single case — hypothesis-generating, not evidence of efficacy.
Studied in Patients with refractory acrodermatitis continua (single reported case, in pregnancy).clinical studies
How strong the finding is
1 human case report (Choi 2011) of complete response to low-level polarized polychromatic light.
How it may work
Broadband polarized light is thought to exert anti-inflammatory and pro-healing effects on keratinocytes and immune cells via mitochondrial/redox signaling, dampening the localized pustular inflammation.
What complicates this
Single case; uncontrolled; spontaneous fluctuation of the disease cannot be excluded.
Safety notes
Standard PBM safety; reported well tolerated including in pregnancy in this case. Single-case evidence only — a possible adjunct for refractory disease, never a replacement for dermatologic management.
A single case suggests adjuvant red light helped salvage a digitally ischemic finger — encouraging but anecdotal
Limited evidence· Points toward a benefit
In one published case, an elderly patient with atherosclerotic risk factors developed digital gangrene after a tourniquet procedure and recovered near-complete skin color and digit function within three months using a regimen that included adjuvant low-level light therapy (633 nm) alongside wound dressing and medication (Lueangarun & Tempark 2019). The PBM was one component of multimodal wound care, so its independent contribution cannot be isolated. This is a hopeful, mechanism-consistent anecdote — a single case report, not evidence of efficacy.
Studied in Patients with digital ischemia / threatened digit (single elderly case with atherosclerotic risk factors).clinical studies
How strong the finding is
1 human case report (Lueangarun & Tempark 2019, 633 nm) with near-complete recovery at 3 months as adjuvant LLLT.
How it may work
Red light (633 nm) enhances cytochrome c oxidase activity, ATP, angiogenesis, and microcirculation, supporting perfusion and wound healing in compromised tissue.
What complicates this
Single case; PBM combined with standard wound care so effect cannot be attributed to light alone; no controlled data.
Safety notes
Standard PBM safety. Digital ischemia/gangrene is limb-threatening and demands urgent vascular and wound care; PBM was used purely as an adjuvant to dressing and medication. Never a replacement for prescribed care.
830 nm laser eased post-stroke shoulder-hand pain and swelling in a controlled trial — encouraging, single-study
Limited evidence· Points toward a benefit
In post-stroke shoulder pain and hemiplegic hand edema, 830 nm laser therapy outperformed electrotherapy on pain, swelling, disability and independence in a 70-patient controlled clinical trial (Karabegovic 2009). It is a genuine human signal for a common, hard-to-treat complication, but it rests on one non-randomized comparison, so confirmation in blinded RCTs is the next step.
Studied in Post-stroke patients with hemiplegic shoulder pain and hand edemaclinical studies
How strong the finding is
One human controlled clinical trial (Karabegovic 2009, n=70, 830 nm, 6 weeks): laser group significantly better than electrotherapy controls on VAS pain (p<0.0001), swelling, DASH, Barthel and FIM.
How it may work
NIR light stimulates cytochrome c oxidase to raise local ATP, improves microcirculation and lymphatic drainage, and reduces inflammatory mediators — plausibly easing pain and edema in the paretic limb.
What complicates this
Single non-randomized comparison; both arms also received kinesitherapy and ice massage (co-interventions). No sham/placebo arm and no replication.
Safety notes
Standard PBM safety; avoid irradiating over malignancy or directly into the eye. Adjunct to rehabilitation (kinesitherapy, positioning), not a replacement for stroke rehab.
660 nm PBM reduced post-bichectomy swelling and pain in a tiny case series — proof of concept only
Limited evidence· Points toward a benefit
In six bichectomy patients (three treated, three controls), intra- and extra-oral 660 nm PBM reduced postoperative facial edema and pain (Bernal Rodriguez 2018). It fits PBM's well-established post-surgical recovery profile, but with n=6 and a descriptive design this is proof-of-concept, not evidence of efficacy.
Studied in Patients recovering from bichectomy (buccal fat pad removal)clinical studies
How strong the finding is
One human case series (Bernal Rodriguez 2018, n=6: 3 treated/3 controls, 660 nm intra+extra-oral, 3 sessions at 0/24/48 h): descriptive reduction in edema and pain.
How it may work
PBM accelerates post-surgical recovery by boosting cellular ATP and microcirculation, modulating inflammatory mediators and lymphatic drainage, and engaging analgesic pathways — reducing edema and pain.
What complicates this
Extremely small (n=6), descriptive comparison without statistics or blinding; first report for this surgery — needs adequately powered trials.
Safety notes
Intra-/extra-oral PBM is well tolerated; eye protection during delivery. Adjunct to standard post-operative care.
Intracerebral transcatheter PBM improved Binswanger's disease in one non-RCT — striking results, but an invasive delivery that doesn't generalize
Limited evidence· Points toward a benefit
Maksimovich's non-randomized controlled study reported good or satisfactory clinical improvement in nearly all treated Binswanger's disease and vascular-parkinsonism patients (~92%), with reduced dementia and motor impairment and recovered daily function over long follow-up. The effect size is dramatic, but the delivery is the crucial caveat: this used intracerebral transcatheter laser PBM — an invasive endovascular procedure — not transcranial or full-body light. It is a single uncontrolled-randomization study with a delivery route that cannot be assumed equivalent to non-invasive PBM.
Studied in Patients with Binswanger's disease and vascular parkinsonism (treated via intracerebral transcatheter laser)clinical studies
How strong the finding is
1 human non-randomized controlled study: Maksimovich 2019 (633 nm, intracerebral transcatheter PBMT; 27 BD + 62 VP patients; good/satisfactory results in ~92% with persistent cognitive and motor gains over 12-24+ month follow-up).
How it may work
Intracerebral laser delivery is proposed to improve perfusion and stimulate repair in ischemic/neurodegenerative cerebral white matter — angiogenesis and tissue regeneration in the affected vascular territory — bypassing the scalp/skull attenuation that limits transcranial light.
What complicates this
Single center, non-randomized, no blinding; the invasive transcatheter route makes the results non-transferable to transcranial or full-body PBM, where penetration to deep white matter is far lower.
Safety notes
Delivery is an invasive endovascular/intracerebral procedure carrying procedural risk — fundamentally different from non-invasive PBM and not self-administrable. Single-operator data; independent replication and safety auditing are essential. Adjunct within specialist neurovascular care only.
A single small RCT shows laser shortens the painful stomatitis of hand-foot-and-mouth disease
Limited evidence· Points toward a benefit
One double-blind, placebo-controlled RCT (Toida 2003, n=20) found 830 nm low-level laser shortened the painful period of hand-foot-and-mouth stomatitis from 6.7 to 4.0 days (p<0.005), with 90% acceptability and no adverse events. A clean, mechanism-consistent result for symptom relief - but it is one small trial, so the finding is promising and worth replicating rather than established.
Studied in Patients (including children) with painful oral stomatitis from hand-foot-and-mouth diseaseclinical studies
How strong the finding is
1 double-blind RCT (Toida 2003): n=20, 830 nm, 30 mW, 1.1 J/cm2; painful period 4.0 +/- 1.3 vs 6.7 +/- 1.6 days (p<0.005).
How it may work
PBM provides mucosal analgesia and accelerates epithelial healing of viral ulcers via mitochondrial photon absorption (ATP) and reduced local inflammatory signaling.
What complicates this
Single small trial with no replication; the symptom-duration endpoint is subjective and the self-limiting nature of HFMD complicates interpretation.
Safety notes
Standard PBM safety with intra-oral delivery; no adverse events reported. Symptomatic adjunct for a self-limiting viral illness, not an antiviral cure.
PBM and tumors: conflicting preclinical data — some wavelengths inhibit, at least one shows tumor stimulation — treat as a caution, not a therapy
Limited evidence· Mixed findings
The evidence on photobiomodulation and tumor growth genuinely cuts both ways, which is exactly why caution is warranted. Some preclinical work shows inhibition — 465 nm blue light arrested papillary-thyroid-carcinoma proliferation (Zhao 2024) and 980 nm pulsed PBM delayed early tumor growth by reinvigorating CD8+ T-cell antitumor immunity (Wang 2026) — while Rhee (2016) found 650 nm LLLT increased anaplastic thyroid tumor size via TGF-beta1 and Akt/HIF-1alpha. A human case report describes PBM within a combined regimen for advanced NSCLC (Su & Wu 2022). Bottom line: direct irradiation of malignant or suspicious tissue can plausibly stimulate as well as suppress tumors depending on wavelength, dose and tumor type, so it should be treated as a relative contraindication pending human data.
Studied in Patients with known or suspected malignancy (preclinical models predominate)mixed
How strong the finding is
46 studies, overwhelmingly preclinical (28 animal, 11 in-vitro; 1 human case report): inhibition in Zhao 2024 (465 nm, PTC) and Wang 2026 (980 nm, immune-mediated), but stimulation in Rhee 2016 (650 nm, anaplastic thyroid, raised TGF-beta1/Akt/HIF-1alpha); Su & Wu 2022 human case report within combined therapy.
How it may work
Light-cell interactions are dose-, wavelength- and context-dependent: PBM can drive proliferation/angiogenesis (e.g. TGF-beta1, Akt/HIF-1alpha, VEGF) in some tumor cells, induce cell-cycle arrest in others, or act indirectly by modulating the tumor immune microenvironment (CD8+ T-cell reinvigoration) rather than direct cytotoxicity.
What complicates this
Directly contradictory outcomes by wavelength/dose/tumor type; almost no human data (one case report). PBM failed against pigmented B16 melanoma (Wang 2026), underscoring tumor-type dependence and the danger of generalizing.
Safety notes
Avoid direct PBM over known/suspected malignant lesions unless under oncologic supervision and an evidence-based protocol (as in oral-mucositis care). Effects are unpredictable across tumor types — a relative contraindication, never a cancer therapy.
PBM for zygomatic (cheekbone) fracture recovery is unproven - the single trial showed no clear benefit
Limited evidence· Mixed findings
The lone available trial of photobiomodulation after zygomatic (cheekbone) trauma (Bashiri 2021) did not demonstrate a clear benefit over control, despite a more upbeat author interpretation. With only one small study and no replication, there is no honest basis yet to recommend PBM specifically for zygomatic fracture recovery. The biological rationale - light-driven reductions in edema and inflammation that help other facial-bone injuries - remains plausible, so this is a 'not yet shown' rather than a 'doesn't work', and well-designed trials are needed.
Studied in Adults recovering from zygomatic (cheekbone) fracturesclinical studies
How strong the finding is
Evidence base is a single trial (Bashiri 2021, Iran) whose data did not show a clear benefit; no meta-analysis and no replication.
How it may work
Proposed: red/NIR photons absorbed by cytochrome c oxidase raise ATP and modulate inflammatory cytokines and post-traumatic edema, which could in theory speed soft-tissue recovery around the fracture - but this pathway was not borne out as a measurable clinical benefit here.
What complicates this
A single small study can neither establish nor exclude an effect; the authors' positive framing appears to outrun their data. Adjacent facial-bone and post-surgical edema studies are more encouraging, so absence of evidence here is not evidence of absence.
Safety notes
Standard PBM safety: eye protection in the facial/periorbital field, avoid direct irradiation of the eye. PBM is at most an adjunct to standard maxillofacial fracture care, never a replacement for it.
Red/NIR light protects and helps regenerate corneal tissue — strong preclinical case, thin but positive human data
Limited evidence· Points toward a benefit
The mechanistic case for PBM in corneal injury is strong: red light (625-635 nm) attenuated pressure-induced corneal endothelial damage and sustained mitochondrial activation (Nunez-Alvarez 2017), red light blunted blue-light toxicity in corneal epithelial cells (2019), and NIR (600-1200 nm) reduced opacity and neovascularization and improved regeneration in injured rat corneas (Uysal 2024). One human non-randomized controlled study reported ~42% faster healing after corneal foreign-body removal (Koev 2011). Encouraging and mechanism-rich, but the human evidence is a single study that is uncontrolled by modern standards.
Studied in Patients with corneal injury/abrasion (human evidence limited; strong preclinical support)mixed
How strong the finding is
7 studies (3 in-vitro, 3 animal, 1 human): Nunez-Alvarez 2017 (starred, rat+in-vitro, 625-635 nm protection), Uysal 2024 (rat NIR, reduced opacity/neovascularization), Nunez-Alvarez 2019 (in-vitro, red blunts blue-light toxicity), Koev 2011 (human non-RCT, n=80, ~42% faster healing, p<0.001).
How it may work
Red/NIR light activates cytochrome c oxidase to protect corneal endothelial/epithelial mitochondria from oxidative and mechanical insult, promotes epithelial proliferation and matrix repair, and counteracts blue-light-induced apoptosis.
What complicates this
Predominantly preclinical; the single human study is non-randomized with limited parameter reporting and no PubMed indexing; effects are wavelength-dependent (blue harmful).
Safety notes
Direct corneal/ocular irradiation needs validated low-power dosimetry; note blue light is harmful to corneal cells while red is protective — wavelength choice matters. Adjunct to standard ophthalmic wound care.
PBM for atopic dermatitis helps symptoms in older data but a full-body blue-light RCT failed objective endpoints
Limited evidence· Mixed findings
The picture for atopic dermatitis is mixed. An older retrospective series reported 830 nm NIR reduced itch in 79% and skin eruption in 71% of patients (Morita 1993), and mouse studies show PBM can modulate the Th2 immune response and ameliorate AD-like lesions (Chen 2009; Kim 2016, 850 nm). But the most rigorous human test — a double-blind RCT of full-body blue light (415 vs 450 nm) — produced only modest reductions in itch and IL-31 and did not improve any objective measure of AD (Buhl 2023). Honest read: possible symptomatic (itch) benefit and good safety, but no convincing objective disease control yet, and delivery/wavelength clearly matter.
Studied in Patients with atopic dermatitis (plus supportive mouse models).mixed
How strong the finding is
~9 studies (2 human, 7 animal); Buhl 2023 RCT (full-body 415/450 nm, modest itch/IL-31 effect, no objective improvement), Morita 1993 retrospective (830 nm, itch -79%), Chen 2009 / Kim 2016 mouse.
How it may work
PBM modulates cutaneous immune signaling (shifting Th2 cytokines, lowering IgE/IL-31/histamine in models) and supports barrier-cell function via mitochondrial/redox effects, plausibly easing itch and inflammation.
What complicates this
Best controlled trial negative on objective endpoints; positive human data are old and retrospective; animal results may not translate; wavelength/delivery heterogeneity (blue full-body vs NIR localized).
Safety notes
Standard PBM safety; full-body blue light had a favorable safety profile. Evidence for objective disease control is weak — PBM is at most an adjunct for symptom relief, never a replacement for emollients, topical anti-inflammatories, or systemic AD therapy.
904 nm PBM for breast-implant capsular contracture - clinician-rated softness improved, patient-rated outcomes unchanged (mixed RCT)
Limited evidence· Mixed findings
Two human studies test 904 nm PBM for capsular contracture after implant breast reconstruction. A phase II double-blind RCT (Azimi 2018, n=42) found no significant change in patient-reported outcomes or breast symmetry/shape, but significantly better clinician-reported breast softness and contracture grade (p<0.05); an earlier single-arm study (Johnson 2015) reported surgery avoided in 93.9% of grade III/IV cases with about 44% average stiffness improvement. The signal is mixed - objective/clinician measures favor PBM while subjective patient measures do not - so evidence is limited. A reasonable adjunct to explore, not a proven alternative to surgical revision.
Studied in Women with capsular contracture after implant-based breast reconstruction (often post-radiotherapy).clinical studies
How strong the finding is
2 human studies; Azimi 2018 (phase II double-blind RCT, n=42, 904 nm, weekly x6; higher clinician-rated softness/contracture p<0.05, no change patient-reported/symmetry); Johnson 2015 (single-arm, 904 nm, surgery avoided 93.9% grade III/IV, ~43.6% stiffness improvement).
How it may work
NIR via cytochrome c oxidase to ATP modulates fibroblast activity, TGF-beta and collagen remodeling around the implant capsule, potentially softening contracted tissue.
What complicates this
RCT discordance between clinician- and patient-reported outcomes; single-arm study lacks a control; small n; durability uncertain.
Safety notes
Eye protection; plastic-surgery oversight; adjunct to surgical assessment; benefit may be modality- or rater-dependent.
Robust, replicated animal evidence that PBM quiets acute lung inflammation — human translation the open question
Anecdotal only· Points toward a benefit
Across ~15 rat/mouse studies, transcutaneous 650-660 nm PBM over the chest consistently reduces lung edema, neutrophil influx, MPO activity, ICAM-1, and TNF-α/IL-1β/IL-8 while raising IL-10 and antioxidant defenses (Mafra de Lima 2010; de Lima 2013; Costa Carvalho 2016). This is one of the more reproducible preclinical PBM stories — multiple labs, multiple injury models, consistent anti-inflammatory direction. It remains animal-only, so human use is a strongly motivated plausible extension to confirm, and PBM would be adjunctive to standard care.
Studied in Preclinical: rat and mouse models of acute lung inflammation (LPS, intestinal ischemia-reperfusion, allergic); no human trialsexpert opinion
How strong the finding is
15 animal studies (study_count 17, all animal). Four starred rat/mouse studies converge: Mafra de Lima 2010 and de Lima 2013 (650-660 nm) cut edema, MPO, ICAM-1, TNF-α/IL-1β and raised IL-10/PPARγ/HSP70; Costa Carvalho 2016 and Carvalho 2017 reduced eosinophils, chemokines, and restored oxidative balance.
How it may work
PBM restores the pro-/antioxidant balance and downregulates NF-κB-driven cytokines and adhesion molecules (ICAM-1) in lung tissue, reducing neutrophil recruitment and edema, partly via PPARγ and HSP70 upregulation and cytochrome c oxidase-mediated redox signaling.
What complicates this
Despite consistency, the entire body is animal/in-vitro from largely overlapping research groups; no human trials, and effective lung-depth dosimetry in people is unestablished.
Safety notes
No human acute-lung-inflammation PBM data; chest PBM is non-thermal and well tolerated generally. Strictly adjunct to medical management of the underlying cause.
Red/NIR light reliably boosts sperm motility ex vivo — strong lab signal, 810 nm the sweet spot, in-body human use still unproven
Anecdotal only· Points toward a benefit
Across dozens of in-vitro and ex-vivo studies, irradiating sperm with red/NIR light (notably 810 nm) consistently increases motility and restores mitochondrial energy in asthenozoospermic samples, with little or no DNA damage at appropriate doses — and a large pig field trial translated treated semen into better reproductive outcomes. This is one of PBM's most reproducible energetic effects, but it is a lab/IVF-handling intervention applied to collected semen, not light shone on a man's body. Wavelength and dose matter sharply: 810 nm helped while 635 nm reduced sperm energy in the same study.
Studied in Ex-vivo human semen (including asthenozoospermic samples) in andrology/IVF settings; animal semen for breeding — not in-vivo treatment of menexpert opinion
How strong the finding is
64 studies (45 in-vitro, ~6 animal, 4 human, 5 reviews). Starred: Sun 2026 (1,499-sow field trial, red light improved pregnancy/delivery rates) and Preece 2017 (633 nm raised motility without DNA damage). Human ex-vivo: Stigliani 2024 and Balbi 2025 (810 nm 1 W restored ATP/motility in asthenozoospermic sperm).
How it may work
PBM drives cytochrome c oxidase in the sperm midpiece mitochondria, raising the ATP/AMP ratio and modulating nitric oxide, which restores progressive motility; the boost is wavelength- and dose-dependent and transient (peaks near 1 W 810 nm, fading by 60 min).
What complicates this
Almost entirely ex-vivo/in-vitro; benefit is transient and highly parameter-sensitive (810 nm helps, 635 nm hurt energy in Balbi). No evidence that transcutaneous PBM to the testes improves a man's own sperm — that remains unproven.
Safety notes
DNA-damage screening (Preece 2017) found little/no double-strand breakage at red-light doses, but over-dose and wrong wavelength can lower sperm energy. This is laboratory semen processing; clinical fertility decisions stay with a reproductive specialist.
PBM around canine TPLO surgery: mostly null trials with isolated gait/weight-bearing signals — inconclusive
Anecdotal only· Mixed findings
Across several controlled canine studies, PBM added to TPLO (cranial cruciate surgery) recovery has mostly failed to beat sham: Chavez 2023 and Kennedy 2018 found no benefit (Kennedy even hinted at detriment or a beneficial control-light effect), while Rogatko 2017 (preoperative LLLT) showed better 8-week peak vertical force and Renwick 2018 showed improved ACOI gait but nothing else. The net is inconclusive — scattered positive endpoints against a backdrop of null results. PBM cannot be recommended as established TPLO care; further dose-optimized trials are needed.
Studied in Dogs undergoing tibial plateau leveling osteotomy for cranial cruciate ligament rupture (veterinary clinical population)expert opinion
How strong the finding is
3 controlled canine studies in the rating (study_count 5; 4 animal). Null: Chavez 2023 (RCT, n=54: no CRP/%WB/pain differences) and Kennedy 2018 (n=12, 635 nm: no benefit, possible detriment). Positive endpoints: Rogatko 2017 (preop 800-900 nm: better 8-wk peak vertical force, 39.6% vs 28.9%); Renwick 2018 (multi-wavelength: improved ACOI gait only).
How it may work
PBM is proposed to reduce post-surgical inflammation and pain and support bone/soft-tissue healing via cytochrome c oxidase → ATP; the inconsistent results suggest dose, timing (pre- vs post-op), and wavelength are not yet optimized for this deep orthopedic target.
What complicates this
Predominantly null primary outcomes with only isolated secondary endpoints positive; small samples, varied wavelengths/timing (pre- vs post-op), and a confounding 'red-light control' in Kennedy. No consistent, clinically meaningful benefit demonstrated.
Safety notes
Non-invasive, generally well tolerated; standard precautions. Adjunct to surgery and rehabilitation only; veterinary evidence does not transfer to humans without study.
Red/NIR light alters blood rheology ex vivo — lower viscosity, better oxygenation — but this is bench-top human blood, not a clinical outcome
Anecdotal only· Points toward a benefit
In ex-vivo human blood and in-vitro work, low-level laser light has decreased whole-blood viscosity and erythrocyte aggregation while improving deformability (Elblbesy 2019, 635 nm), increased blood oxygen tension (PO2/SaO2 with 633 nm; Wasik 2007), and affected lipid-laden samples (Wang 2018, 405 nm) and stored red-cell stability (Mohammed 2024). These are real, measurable photophysical effects on blood properties — a credible mechanistic basis for claims about microcirculation and oxygenation. But they are test-tube findings; whether irradiating blood ex vivo translates to clinical benefit in a living person is a plausible extension to confirm, not established.
Studied in Ex-vivo human blood and in-vitro samples; not yet validated as an in-vivo clinical outcome.expert opinion
How strong the finding is
~15 studies (7 in vitro, 5 animal, 2 ex-vivo human, 1 other); key ex-vivo findings Elblbesy 2019 (635 nm, lower viscosity/aggregation), Wasik 2007 (633 nm, higher PO2/SaO2), Wang 2018 (405 nm), Mohammed 2024 (RBC storage).
How it may work
Light absorption by hemoglobin and membrane chromophores changes erythrocyte membrane charge/deformability and aggregation, lowering viscosity; effects on red-cell oxygen binding raise measured PO2/SaO2.
What complicates this
Predominantly ex vivo/in vitro; UV vs LLL produced opposite viscosity effects (Elblbesy); no controlled in-vivo human outcome data; heterogeneous wavelengths and endpoints.
Safety notes
Standard PBM safety. Note that some of this literature involves intravascular/blood-irradiation techniques (ILIB) that are clinical procedures, not consumer devices. No basis for treating any blood disorder with light; adjunct/mechanistic interest only, never a replacement for hematologic care.
Low-dose He-Ne laser strengthened colonic anastomoses in rats - preclinical, sharply dose-dependent
Anecdotal only· Points toward a benefit
Three rat studies (Asencio-Arana group, 1988-1992) found 633 nm He-Ne laser at low doses (~1.9 J/cm2) nearly doubled anastomotic bursting strength by postoperative day 4 and improved epithelialization and neovascularization - but the effect vanished at higher doses (6.4 J/cm2), a classic PBM biphasic response. This is consistent preclinical evidence for a wound-strengthening mechanism, not human proof; surgical anastomotic-leak prevention remains governed by technique and standard care. Investigational adjunct only.
Studied in Preclinical (rats); potential future relevance to colorectal anastomotic healing.expert opinion
How strong the finding is
3 animal studies (rat, 633 nm He-Ne); ~100% increase in bursting strength at day 4 with 1.9 J/cm2 (lost at 6.4 J/cm2); increased fibroblasts, vessels, epithelialization; hydroxyproline differences non-significant.
How it may work
Low-dose red light via cytochrome c oxidase to ATP boosts fibroblast proliferation, collagen organization, round-cell recruitment and angiogenesis at the healing anastomosis (biphasic - too much light abolishes benefit).
What complicates this
Animal-only, single research group, old studies; strongly dose-dependent (benefit only at low fluence); collagen-content changes not significant; no human translation.
Safety notes
No human data; intra-operative delivery and dose are unsolved in people; investigational only - does not replace sound surgical technique.
670 nm PBM consistently inhibits diabetic retinopathy lesions in animals — robust mechanism, human DR trials still owed
Anecdotal only· Points toward a benefit
In rodent and cell models, 670 nm photobiomodulation repeatedly inhibits the neural and vascular pathology of diabetic retinopathy — Cheng (2018) showed 8 months of daily 670 nm PBM curbed capillary degeneration and permeability in diabetic mice, and Tang (2013) found red light ameliorated DR lesions in vivo while reducing oxidative stress and cell death in vitro. The mechanism (mitochondrial protection, reduced oxidative injury) is coherent and reproducible, but this indication's grounding is animal/in-vitro only, so human DR benefit is a plausible extension to confirm (the sibling DME indication does have human data).
Studied in Diabetic retinopathy (animal/in-vitro models; human application extrapolated)expert opinion
How strong the finding is
11 studies (8 animal, 3 in-vitro): Cheng 2018 (starred, mouse, 670 nm, reduced capillary degeneration/permeability), Tang 2013 (starred, rat+in-vitro, 670 nm, 6 J/cm2, reduced RGC death, +50% ERG b-wave), Opazo 2024 and Ge 2024 (mouse, 654/670 nm). No human DR trials in this set.
How it may work
670 nm light raises retinal cytochrome c oxidase activity and ATP, reduces diabetes-driven oxidative stress, inflammation and retinal-ganglion-cell death, and improves capillary integrity — slowing early neurovascular DR pathology.
What complicates this
Entirely preclinical; long daily exposure regimens in rodents may not translate to practical human protocols; effect sizes and safety in human retina unestablished.
Safety notes
Retinal red-light exposure at studied animal doses was well tolerated; human ocular dosimetry must be validated. Adjunct to glycemic control and standard DR management, not a replacement.
PBM after canine hemilaminectomy: faster ambulation in one RCT, no benefit in another — mixed
Anecdotal only· Mixed findings
Two controlled canine studies of post-hemilaminectomy recovery disagree: Draper 2012 found dogs given 810 nm LLLT reached ambulation far faster (median 3.5 vs 14 days), while Bennaim 2017 found no difference between PBM, sham-plus-rehab, and sham alone. The conflicting results — likely driven by protocol and dose differences — make this a genuinely mixed picture. PBM is a plausible adjunct in post-operative spinal rehab to confirm with larger trials, not an established one.
Studied in Dogs recovering from hemilaminectomy for intervertebral disk disease (veterinary clinical population)expert opinion
How strong the finding is
2 controlled canine studies (study_count 2). Draper 2012 (controlled, n=36, 810 nm cluster, 25 W/cm² to skin): time to Frankel score 4 was 3.5 vs 14 days (p=0.0016). Bennaim 2017 (n=32, 660 nm): no difference among PBM, rehab+sham, and sham.
How it may work
PBM over the surgical site/spinal cord is proposed to reduce post-operative inflammation and edema and support neural recovery via cytochrome c oxidase → ATP, potentially speeding return to ambulation after disk-herniation surgery.
What complicates this
Directly conflicting outcomes between the two studies, plausibly from different wavelengths (810 vs 660 nm), doses, and rehab co-interventions; both are small. Larger studies are explicitly called for.
Safety notes
Non-invasive, well tolerated in dogs; standard precautions. Adjunct to surgery and physical rehabilitation — not a replacement; veterinary evidence does not transfer to humans without study.
660 nm PBM aided anal sphincter muscle recovery in rabbits - best combined with stem cells/enzymes, preclinical only
Anecdotal only· Points toward a benefit
Two rabbit studies (Sarveazad 2019, 2021) show 660 nm PBM after sphincterotomy promoted myogenesis, angiogenesis and improved sphincter pressures - most effective when co-applied with chondroitinase ABC or adipose-derived stem cells rather than laser alone. This is preclinical only; it supports a regenerative mechanism worth testing in humans, not an established treatment for anal sphincter injury or fecal incontinence. Parameters were poorly reported in one study.
Studied in Preclinical (rabbits); potential relevance to patients with anal sphincter injury / fecal incontinence.expert opinion
How strong the finding is
2 animal studies (rabbit, 660 nm); laser+ChABC raised resting pressure and motor-unit counts above sphincterotomy controls (p<0.0001); laser+hADSCs superior to either alone.
How it may work
Red PBM stimulates satellite/muscle-cell proliferation (myogenesis), VEGF-driven angiogenesis and collagen remodeling via cytochrome c oxidase to ATP, aiding functional muscle repair.
What complicates this
Animal-only, 2 studies from the same group; benefit mainly with combination therapy, not PBM alone; one study poorly reported parameters; no human evidence.
Safety notes
No human data; sphincter injury needs specialist surgical/continence care; investigational adjunct only.
He-Ne red light (633 nm) reversed atrophic-gastritis changes in rat mucosa - preclinical, intragastric delivery
Anecdotal only· Points toward a benefit
Two rat studies (Yang 2005, Shao 2005) report that 633 nm He-Ne laser at about 3.36 J/cm2 thickened atrophic gastric mucosa, reduced mucosal inflammation and restored near-normal cell morphology versus untreated controls. This is preclinical evidence using direct (endoscopic-type) mucosal irradiation; it suggests a mechanism but has no human validation, and delivery to the human stomach is non-trivial. Strictly investigational - standard gastritis management (e.g., H. pylori eradication, surveillance) takes precedence.
Studied in Preclinical (rats); potential future relevance to chronic atrophic gastritis.expert opinion
How strong the finding is
2 animal studies (rat, 633 nm He-Ne, 3.36 J/cm2 optimal); significantly thicker mucosa (p<0.01), fewer inflammatory cells (p<0.05), restored morphology, increased gastric acid secretion.
How it may work
Red light via cytochrome c oxidase to ATP stimulates epithelial proliferation (cyclin D1) and dampens mucosal inflammation, supporting mucosal regeneration.
What complicates this
Animal-only, 2 studies, dose-dependent (only 3.36 J/cm2 optimal); intragastric delivery hard to translate; no human trials.
Safety notes
No human data; atrophic gastritis is a premalignant condition requiring surveillance - do not substitute for endoscopic or H. pylori management; investigational only.
Near-infrared PBM improved fat-graft retention in rats - preclinical; the lone human study addresses a different outcome
Anecdotal only· Points toward a benefit
A rat study (Sert 2021) found polychromatic near-infrared light (600-1200 nm) applied both before and after fat transfer significantly improved graft weight and volume retention (p=0.049, p=0.043), consistent with PBM's pro-angiogenic, anti-inflammatory effects. The dataset's only human entry (Paiva 2024) actually reports survival in head-and-neck cancer patients receiving PBM for oral mucositis - not fat grafting - so on-topic evidence here is animal-only. Treat fat-graft PBM as a plausible preclinical mechanism to confirm in humans, not an established technique.
Studied in Preclinical (rats) for fat-graft retention; the off-topic human study concerns head-and-neck cancer patients.expert opinion
How strong the finding is
2 studies in set but only the animal one is on-topic: Sert 2021 (rat, n=24, 600-1200 nm, before+after application superior, p=0.049/0.043 for weight/volume); Paiva 2024 (human, n=751) is about PBM and survival in head-and-neck cancer, not fat grafts.
How it may work
NIR via cytochrome c oxidase to ATP stimulates angiogenesis/neovascularization, adipocyte viability and anti-inflammatory signaling at the recipient site, supporting graft revascularization and survival.
What complicates this
On-topic evidence is a single animal study; the human study is mislabeled/off-topic for this indication; small n; polychromatic parameters; no human fat-graft trials.
Safety notes
No on-topic human data for fat grafting; investigational adjunct only; in any oncologic context coordinate with oncology.
Wavelength matters: 635 and 810 nm sped dermal-abrasion healing in mice while 730 and 980 nm did nothing
Anecdotal only· Points toward a benefit
A well-controlled mouse study delivered four wavelengths at matched fluence (4 J/cm2) and irradiance (10 mW/cm2) and found 635 nm and 810 nm promoted dermal-abrasion healing — with 810 nm best — while 730 nm and 980 nm showed no benefit (Gupta 2014). That wavelength specificity is exactly the kind of mechanistic detail that distinguishes real PBM from generic light exposure. A veterinary study in cownose rays found no clear difference (Gilewski 2024). Preclinical evidence; human translation is a plausible extension to confirm, with wavelength selection clearly important.
Studied in Preclinical (mouse partial-thickness dermal abrasion; plus a cownose-ray study).expert opinion
How strong the finding is
1 starred mouse study (Gupta 2014; 635 & 810 nm effective, 810 best; 730 & 980 nm ineffective; 4 J/cm2, 10 mW/cm2) and 1 veterinary study (Gilewski 2024, no clear difference).
How it may work
635 and 810 nm sit near cytochrome c oxidase absorption peaks, raising ATP and driving fibroblast/keratinocyte proliferation and wound closure; 730 and 980 nm fall in less photoactive bands, explaining the lack of effect.
What complicates this
Animal-only; veterinary study null; single rodent study for the positive finding; human relevance untested.
Safety notes
Standard PBM safety. Animal evidence only; underscores that effective wavelength/dose selection is not arbitrary. Adjunct/experimental interest for wound healing, never a replacement for proper wound care.
Red/near-infrared light reliably drives angiogenesis in cells and rodents — a strong mechanistic basis, human dosing still to be defined
Anecdotal only· Points toward a benefit
Across numerous cell-culture studies and rodent models of hindlimb ischemia, ischemic flaps, and cutaneous wounds, red and near-infrared PBM consistently stimulates new blood-vessel formation (Zhang 2022, Stepanov 2022, Winter 2018, Lim 2011; Huang 2021, Lohr 2013, Dungel 2014, de Sousa 2013). The angiogenic effect is one of the better-supported PBM mechanisms at the bench. Blue light is inconsistent (positive in one rat study, null in another) and green showed a signal in one study. This is preclinical: the mechanism is well-grounded, and human application — accelerating wound and tissue perfusion — is a plausible extension to confirm with controlled human dosing rather than a proven clinical claim.
Studied in Preclinical (cell cultures and rodents); plausibly extends to humans needing improved tissue perfusion/wound healing.expert opinion
How strong the finding is
~9 animal studies (mouse, rat, rabbit) plus ~7 cell-culture studies, broadly concordant for red/NIR; blue mixed, green single positive.
How it may work
Cytochrome c oxidase absorption raises ATP and briefly increases reactive oxygen species, activating redox-sensitive signaling (e.g. VEGF, HIF-1, NO release) that upregulates endothelial proliferation and capillary sprouting.
What complicates this
No human RCT grounding provided here; wavelength dependence (blue inconsistent); preclinical models do not fix human fluence/timing.
Safety notes
Standard PBM safety (eye protection; caution with photosensitizing drugs). Pro-angiogenic effects are generally desirable for healing but warrant caution where neovascularization is unwanted (e.g. active tumors, proliferative retinopathy). Adjunct support for healing, not a replacement for wound or vascular care.
PBM reliably lowers oxidative-stress markers in tissue — a mechanistic anchor, not yet a psychological-stress therapy
Anecdotal only· Points toward a benefit
Across preclinical work, photobiomodulation consistently shifts redox balance toward antioxidant defense — Tonetto (2023) showed six weeks of 660 nm PBM reduced oxidant activity and raised antioxidant capacity in diabetic rats, and a nine-study review (Irber 2026) found uniform modulation of oxidative stress, with lower superoxide and cytochrome c and higher catalase, SOD and glutathione peroxidase. This is solid mechanistic biology, but it speaks to cellular/oxidative stress, not psychological stress; applying it to perceived stress or HPA-axis outcomes is a plausible extension that human studies have not confirmed here.
Studied in Preclinical (animal/in-vitro) oxidative-stress biology; human psychological-stress benefit unprovenexpert opinion
How strong the finding is
One rat study (Tonetto 2023, 660 nm, 21 J/cm2) plus a nine-study animal review (Irber 2026); both consistent on antioxidant modulation. No human stress-outcome trials in this set.
How it may work
Red/NIR light drives cytochrome c oxidase activity and transiently modulates reactive oxygen species, upregulating endogenous antioxidant enzymes (catalase, superoxide dismutase, glutathione peroxidase) and reducing apoptotic signaling.
What complicates this
The grounding measures biochemical oxidative stress, not psychological stress — a meaningful gap. Animal/in-vitro only; no clinical endpoints, blinding, or human dosing established.
Safety notes
PBM is low-risk at standard doses. Not a treatment for clinical anxiety or stress disorders on this evidence — adjunctive at most, never a substitute for prescribed mental-health care.
PBM dampens neuroinflammation in animal brains — consistent preclinical anti-inflammatory effect, human use a plausible extension
Anecdotal only· Points toward a benefit
Across rodent models — diet-induced obesity, aging, and LPS-induced neuroinflammation — transcranial red/NIR light (630-670 nm) repeatedly reduced glial activation (CD68 microglia, GFAP astrocytes) and shifted brain inflammatory cytokines, with correlated memory improvement. The anti-inflammatory signal is consistent and mechanism-aligned. It is entirely preclinical, though, so reduced human neuroinflammation is a biologically reasonable extension to confirm, not a demonstrated outcome.
Studied in Preclinical only — diet-induced obese, aged, and LPS-challenged rodent brains; no human studies for this endpointexpert opinion
How strong the finding is
7 animal studies. Saieva 2021/2022 (mouse, 670 nm; HFD-induced CD68/GFAP increases reversed by NIR), Cardoso 2021 (aged rat, 660 nm; cortical/hippocampal cytokine modulation), Haghjoo 2022 (rat, 630 nm; reduced memory impairment via LRP-1/TRPA-1, with light-phase timing effects).
How it may work
Transcranial NIR lowers activated-microglia (CD68) and astrocyte (GFAP) markers and modulates inflammatory cytokines/chemokines (e.g., IL-1alpha, IL-5, fractalkine) in hippocampus and cortex via mitochondrial activation, reducing the neuroinflammatory burden linked to cognitive decline.
What complicates this
All preclinical and non-starred; cytokine changes are mixed in direction (some up, some down), and rodent penetration greatly exceeds human. No human confirmation.
Safety notes
No human neuroinflammation data; transcranial NIR is generally tolerated in other human work but no claim is made here. Adjunct/wellness concept to investigate, not a treatment.
Low-level laser relieved arterial spasm in a large-animal model — a small but clean mechanistic signal
Anecdotal only· Points toward a benefit
Building on in-vitro evidence that low-level laser relaxes vascular smooth muscle, an in-vivo study in atherosclerotic Yucatan microswine showed that percutaneous laser light (633 or 1064 nm) reversed histamine-induced arterial vasoconstriction/spasm (Gal 1992). It is a single, older large-animal study, but mechanistically clean and consistent with PBM's nitric-oxide-mediated vasodilation. Human relevance — relieving vasospasm — is a plausible extension to confirm, not an established therapy.
Studied in Preclinical (atherosclerotic microswine with induced arterial spasm).expert opinion
How strong the finding is
1 in-vivo large-animal study (Gal 1992, 633/1064 nm) reversing histamine-induced spasm, supported by the authors' prior in-vitro smooth-muscle work.
How it may work
Photon absorption reduces isometric tension in vascular smooth muscle (likely via nitric-oxide release and altered calcium handling), promoting vasodilation and reversing spasm.
What complicates this
Single, dated study; large-animal model only; no human data; mechanism inferred.
Safety notes
Standard PBM safety. Arterial vasospasm (e.g. coronary) is a medical condition requiring proper care; this is a single animal study with no human data. Adjunct/experimental interest only, never a replacement for prescribed care.
PBM rescued auditory-nerve function in a gerbil model - preclinical only, and a companion study was negative
Anecdotal only· Mixed findings
Evidence for auditory neuropathy is preclinical and mixed. In a gerbil model of ouabain-induced auditory neuropathy, 808 nm PBM lowered ABR thresholds and preserved spiral ganglion cells (Lee 2016), but a later mouse/in-vitro study combining stem cells with PBM did not improve hearing or auditory-nerve response (Chang 2023). The neural-rescue mechanism is intriguing, yet with no human data and an inconsistent animal record, human use is a speculative extension to investigate, not a treatment.
Studied in Preclinical (gerbil, mouse, in vitro); human applicability unprovenexpert opinion
How strong the finding is
2 preclinical entries: Lee 2016 (gerbil, starred, 808 nm, recovered auditory function, preserved spiral ganglion cells), Chang 2023 (mouse + in vitro, 808 nm, stem cell + PBM did not improve hearing).
How it may work
PBM may support auditory neuron survival and axonal regeneration and reduce neural oxidative stress (mitochondrial photon absorption -> ATP), potentially preserving spiral ganglion cells after insult.
What complicates this
Only animal/in-vitro data, with one positive and one negative result; no human studies and no established dosimetry for cochlear/neural targets.
Safety notes
Preclinical only. Not an evidence-based treatment for auditory neuropathy; do not substitute for audiologic care. Standard PBM safety would apply to any future human use.
PBM boosts bone-formation markers in animal models - a bone-density benefit in humans is an untested extension
Anecdotal only· Points toward a benefit
For bone density specifically, the available evidence is preclinical: a systematic review of rat studies (de Oliveira 2022) found near-infrared PBM increased new bone formation, osteocytes, osteoblasts, and vascularization, particularly in irradiated-bone healing, though one of six studies showed no difference and parameters varied widely. The mechanism is real and reproducible in animals, but no controlled human bone-density data are presented here - human benefit is a plausible extension to confirm, not an established outcome.
Studied in Preclinical (rat models), including irradiated-bone healing; human applicability unprovenexpert opinion
How strong the finding is
Animal-only: de Oliveira 2022 systematic review of 6 rat studies (NIR laser, increased bone formation in most; 1 of 6 negative; high parameter variability). The indication also references Patrocinio-Silva (rat).
How it may work
PBM stimulates osteoblast proliferation and differentiation, osteocyte activity, and angiogenesis via mitochondrial photon absorption (cytochrome c oxidase -> ATP) and modulated signaling (e.g., RUNX2), promoting new bone-matrix formation.
What complicates this
No human bone-density trials in this evidence set; animal studies are heterogeneous in dose/protocol, one was negative, and the authors caution that clear conclusions await standardized preclinical work and then clinical trials.
Safety notes
Preclinical only. Not a treatment for osteoporosis or low bone density in humans; do not substitute for established bone-health care. Standard PBM safety would apply to any future human use.
Red/NIR PBM reduced TRAM-flap necrosis in rats via angiogenesis - consistent preclinical, 830 nm favored
Anecdotal only· Points toward a benefit
Four rat studies converge that PBM (660, 670, 830 nm) improves transverse rectus abdominis musculocutaneous (TRAM) flap viability - smaller necrotic area, more mast cells, higher VEGF/CD34 and angiogenesis - including under nicotine stress, with 830 nm performing best (das Neves 2016) and effective doses spanning ~6-144 J/cm2. This is consistent preclinical evidence for a pro-angiogenic mechanism, not human proof; flap viability in patients depends on surgical perfusion management. A plausible human adjunct to test.
Studied in Preclinical (rats, including nicotine-exposed); potential future relevance to musculocutaneous flap reconstruction.expert opinion
How strong the finding is
4 animal studies (rat); das Neves 2016 (830 nm best, higher VEGF/CD34); Leite 2017 (660 nm, 140 J/cm2 > 10 J/cm2, less necrosis in diabetic rats); Pinfildi 2009/2013 (670 nm, 6-144 J/cm2, more angiogenesis/VEGF, less necrosis).
How it may work
Red/NIR via cytochrome c oxidase to ATP upregulates VEGF and CD34, recruits mast cells and drives angiogenesis/neovascularization, improving perfusion and reducing distal flap necrosis.
What complicates this
Animal-only; dose/wavelength heterogeneity; effects vary with comorbidity models (diabetes, nicotine); no human trials.
Safety notes
No human data; investigational surgical adjunct; coordinate with the reconstructive team.
NIR PBM rescued alcohol-related cognitive deficits in mice — clean preclinical signal, human use a plausible extension
Anecdotal only· Points toward a benefit
In a chronic-alcohol mouse model, transcranial 830 nm laser significantly improved cognitive and spatial memory deficits, with histological correlates in the hippocampus. The mechanism — NIR protecting against apoptosis and neuroinflammation while supporting bioenergetics — is well aligned with PBM's known brain effects. This is a single animal study, though: human application is a biologically plausible direction to test, not an established treatment for alcohol-related cognitive impairment.
Studied in Preclinical only — chronic-alcohol mouse model; no human studies for this indicationexpert opinion
How strong the finding is
1 mouse study: Hong 2025 (C57BL/6 chronic-ethanol model, 830 nm transcranial; significant improvement in cognitive and spatial memory tasks with supporting histology).
How it may work
Near-infrared light penetrates to hippocampus and cortex, driving cytochrome c oxidase to restore ATP, while reducing neuroinflammation and apoptosis — countering alcohol-induced hippocampal vulnerability and supporting spatial memory.
What complicates this
Single preclinical study; rodent skull/scalp penetration far exceeds human, so effective human dosing is unknown. No behavioral confirmation in people.
Safety notes
No human data; transcranial NIR is generally well tolerated in other human brain studies, but no safety claim can be made here. Any human use would be an adjunct to addiction and cognitive care, never a replacement.
670 nm LED rescued retinal function in methanol-poisoned rats — a landmark cytochrome-oxidase proof of concept, preclinical
Anecdotal only· Points toward a benefit
In a classic mechanistic demonstration, three brief 670 nm LED treatments (4 J/cm2) significantly recovered rod- and cone-mediated retinal function and protected against formate-induced histopathology in methanol-intoxicated rats (Eells 2003). Because methanol's toxic metabolite, formic acid, poisons cytochrome oxidase — exactly the chromophore PBM stimulates — this is one of the cleanest mechanistic stories in the field. It remains animal proof-of-concept; human use is a plausible extension to confirm.
Studied in Methanol-induced retinal toxicity (rat model; human application extrapolated)expert opinion
How strong the finding is
One starred rat study (Eells 2003, PNAS, 670 nm LED, 4 J/cm2, 3 treatments at 5/25/50 h): significant recovery of rod/cone ERG function and protection from formate histopathology.
How it may work
Formic acid inhibits mitochondrial cytochrome c oxidase, the same enzyme red/NIR light stimulates; 670 nm photons restore cytochrome-oxidase activity, ATP production and retinal cell survival, counteracting the toxic block.
What complicates this
Single animal study; timing-dependent dosing; no human data and an emergency context that complicates clinical translation.
Safety notes
Methanol poisoning is a medical emergency requiring antidotal/critical care (fomepizole/ethanol, dialysis) — PBM is an experimental adjunct concept only, never a substitute for emergency treatment.
Single-study animal signal: PBM reduced immune-complex lung hemorrhage comparably to celecoxib
Anecdotal only· Points toward a benefit
In a controlled rat model of immune-complex lung injury, 650 nm LLLT at 2.6 J/cm² cut the hemorrhagic index and myeloperoxidase activity to a degree not significantly different from celecoxib (Aimbire 2007). It is an intriguing anti-inflammatory/anti-hemorrhagic mechanism signal, but it rests on one animal study. Human application is a plausible extension to confirm, not a therapy — and PBM would be adjunctive only.
Studied in Preclinical: rat model of immune-complex (BSA-induced) lung hemorrhage; no human dataexpert opinion
How strong the finding is
1 animal study (Aimbire 2007, rat): 650 nm at 2.6 J/cm² reduced hemorrhagic index and MPO, comparable to celecoxib and approaching dexamethasone for MPO.
How it may work
PBM dampens the acute inflammatory cascade (neutrophil influx, MPO activity, and downstream vascular injury) via cytochrome c oxidase-mediated modulation of oxidative stress and inflammatory mediators, limiting hemorrhagic tissue damage.
What complicates this
Single small animal study, one wavelength/dose, one injury model; dexamethasone was slightly more effective on hemorrhagic index. No human or even replicated animal evidence.
Safety notes
No human data for this indication; PBM would be adjunctive only. Lung hemorrhage is a medical emergency requiring conventional management.
PBM after canine thoracolumbar disk surgery: better neuro status in deep-pain-positive dogs, no survival-curve difference
Anecdotal only· Mixed findings
In a controlled study of dogs operated for thoracolumbar disk extrusion, those given PBM plus rehab were more likely to improve neurological status (Modified Frankel >3 within 30 days) when deep nociception was preserved on admission (p=0.04), though Kaplan-Meier analysis showed no overall difference in time to recovery (Bruno 2020). So there is a conditional signal tied to baseline severity, within an otherwise mixed/contested literature. PBM is a plausible adjunct in post-op spinal rehab, best viewed as unproven pending larger trials.
Studied in Dogs after surgery for thoracolumbar disk extrusion (veterinary clinical population)expert opinion
How strong the finding is
1 controlled canine study (Bruno 2020, n=24): laser+rehab improved neurological status (Frankel >3 within 30 days) when deep nociception was maintained (p=0.04), but no Kaplan-Meier difference in time to regain function.
How it may work
PBM over the surgical site is proposed to reduce post-operative inflammation and edema and support neural repair via cytochrome c oxidase → ATP; benefit appears contingent on residual neural function (deep pain perception) at baseline.
What complicates this
Single small study with a conditional (subgroup) positive and a null primary time-to-event result; the broader post-op disk-herniation PBM literature is contradictory, and confounding by rehab protocol is likely.
Safety notes
Non-invasive, well tolerated; standard precautions. Adjunct to surgery and rehabilitation — not a replacement; veterinary findings do not transfer to humans without study.
Water-filtered infrared/visible light cut chlamydial load in a guinea-pig conjunctivitis model — preclinical only
Anecdotal only· Points toward a benefit
In a guinea-pig model of chlamydial inclusion conjunctivitis, water-filtered infrared-A plus visible light (wIRA/VIS) reduced both clinical pathology scores and conjunctival chlamydial load versus untreated infected controls (Inic-Kanada 2020), echoing earlier in-vitro/ex-vivo findings that the irradiation lowers chlamydial infectivity. A genuinely interesting adjunct concept for a blinding neglected disease (trachoma), but it is animal-only — human benefit is a plausible extension to confirm.
Studied in Chlamydial (inclusion) conjunctivitis / trachoma (guinea-pig model; human application extrapolated)expert opinion
How strong the finding is
One guinea-pig study (Inic-Kanada 2020, 380-1400 nm wIRA/VIS, 2100 W/m2): reduced clinical pathology (days 7,14) and chlamydial load (days 2,4,7,14) vs infected controls; supported by prior in-vitro/ex-vivo data.
How it may work
wIRA/VIS irradiation appears to impair Chlamydia replication/infectivity and modulate the host inflammatory response, reducing inclusion formation and ocular-surface pathology — a photobiological antimicrobial/anti-inflammatory effect.
What complicates this
Animal model only; high-irradiance protocol; no human efficacy or safety data for ocular use.
Safety notes
Water-filtered IR limits thermal load, but ocular IR dosimetry must be carefully controlled in humans. An adjunct concept to antibiotic SAFE-strategy trachoma control, not a replacement.
Red laser sped wound closure in hemophilic mice — a healing effect, not a correction of the bleeding disorder
Anecdotal only· Points toward a benefit
In a hemophilia B mouse model, three daily treatments of 650 nm laser (12 J/cm2) accelerated closure of punch-biopsy wounds (10 days vs 13 days in sham, approaching the 9-day wild-type rate) (Hoffman & Monroe 2012). The signal is plausible and consistent with PBM's general wound-healing biology, but it is a single animal study addressing impaired wound healing in hemophilia — not the underlying clotting deficiency. Human application is a plausible extension to confirm; PBM does not and cannot replace factor replacement.
Studied in Preclinical (hemophilia B mice with cutaneous wounds).expert opinion
How strong the finding is
1 animal study (Hoffman & Monroe 2012, 650 nm, 12 J/cm2, 3 daily treatments) showing faster wound closure in hemophilic mice.
How it may work
PBM enhances proliferation of cutaneous cells and likely additional healing pathways beyond hemostasis, partly compensating for the abnormal inflammatory/proliferative wound response seen in hemophilia.
What complicates this
Single mouse study; addresses wound healing, not bleeding; no human data.
Safety notes
Standard PBM safety. Hemophilia is managed with clotting-factor therapy; PBM addresses only wound healing in this model and is not a treatment for the coagulopathy. Strictly adjunct/experimental, never a replacement for prescribed hematologic care.
850 nm PBM restored irradiated thyroid cells in preclinical models - mechanistic only, human use a plausible extension
Anecdotal only· Points toward a benefit
In a mouse and in-vitro study (Yoo 2021), 850 nm PBM restored function of thyroid follicular cells damaged by ionizing radiation, increasing proliferation and cAMP. This is preclinical evidence only - no human trials for radiation-induced thyroid dysfunction - so it establishes a plausible mechanism and a hypothesis worth testing in people, not a proven clinical therapy. Any human application would be an experimental adjunct under endocrinology/oncology supervision.
Studied in Preclinical (human thyroid cell line, mice); potential future relevance to patients with radiation-induced hypothyroidism.expert opinion
How strong the finding is
1 preclinical study (Yoo 2021), 850 nm LED, in vitro (2-10 J/cm2) human N-Thy-3.1 cells plus in vivo mice (120 J/cm2); restored proliferation and cAMP after ionizing radiation.
How it may work
NIR photons restore mitochondrial/cytochrome c oxidase activity and cAMP signaling in irradiated thyrocytes, rescuing proliferation (modulating p53/Rb/E2F1 cell-cycle markers) and thyroglobulin expression.
What complicates this
Animal plus in-vitro only, no human data; single study; dose translation to humans unknown; safety near prior radiation fields untested.
Safety notes
Not validated in humans; in cancer survivors avoid irradiating fields near treated or at-risk tumor tissue without oncology sign-off; strictly investigational; adjunct concept only.
PBM eased CRPS-I signs in a mouse model — promising preclinical signal, human use a plausible extension
Anecdotal only· Points toward a benefit
In a mouse model of complex regional pain syndrome type I, 830 nm PBM applied to the affected paw during the acute phase reduced edema, thermal and mechanical hyperalgesia, and improved gait quality. The anti-inflammatory, pro-analgesic mechanism fits PBM's known biology and the timing (acute-phase, local) is informative. But this is a single animal study — human CRPS application is a biologically reasonable direction to test, not established therapy.
Studied in Preclinical only — mouse CRPS-I model; no human CRPS trials in this setexpert opinion
How strong the finding is
1 mouse study: Canever 2021 (830 nm; acute-phase paw irradiation reduced edema, thermal/mechanical hyperalgesia and improved Sciatic Static/Functional Index gait measures).
How it may work
Local NIR light reduces inflammatory edema and modulates peripheral nociceptor sensitization (thermal/mechanical hyperalgesia) via mitochondrial activation and anti-inflammatory signaling, improving limb function in the acute phase.
What complicates this
Single preclinical study; best results required acute-phase, paw-targeted delivery, and translation of timing/dose to human CRPS is untested.
Safety notes
No human data; PBM is generally low-risk topically, but no efficacy/safety claim can be made for human CRPS. Any use would be an adjunct within specialist pain management, not a replacement.
633 nm PBM boosted stem-cell therapy for radiation enteropathy in mice - preclinical, cell-priming mechanism
Anecdotal only· Points toward a benefit
In a mouse model plus in-vitro work (Kim 2019), 633 nm PBM enhanced mesenchymal stem-cell proliferation and self-renewal and, as PBM-preconditioned MSCs, alleviated radiation-induced intestinal mucosal destruction, improved crypt proliferation and barrier function and preserved microvasculature. This is preclinical, mechanism-level evidence - PBM as a cell-priming/angiogenic adjunct - not a human therapy for radiation enteropathy. Strictly investigational.
Studied in Preclinical (mice, human MSCs in vitro); potential future relevance to radiation-induced enteropathy.expert opinion
How strong the finding is
1 preclinical study (Kim 2019), 633 nm; PBM increased MSC proliferation/self-renewal; PBM-preconditioned MSCs reduced mucosal damage, improved crypt proliferation/barrier, preserved microvascular endothelium in irradiated mice.
How it may work
Red PBM stimulates MSC proliferation and a pro-angiogenic secretome (via cytochrome c oxidase to ATP), and conditioned medium reduces irradiation-induced apoptosis and supports endothelial tube formation, protecting intestinal microvasculature.
What complicates this
Animal plus in-vitro only; benefit tied to combined cell therapy, not PBM alone; single study; no human evidence.
Safety notes
No human data; combines PBM with cell therapy; investigational only; standard supportive care for radiation enteropathy remains primary.
Transcranial 670 nm PBM improved memory in a rat hepatic-encephalopathy model - preclinical, CCO-targeted
Anecdotal only· Points toward a benefit
In a rat hepatic-encephalopathy model (Mendez 2021), transcranial 670 nm PBM (9 J/cm2, daily x7) improved memory deficits comparably to intracranial methylene blue, with both targeting cytochrome c oxidase. This is single-study preclinical evidence establishing a plausible mitochondrial mechanism - not human proof for hepatic encephalopathy, which is managed medically (e.g., lactulose, rifaximin). Any human use would be strictly investigational.
Studied in Preclinical (rats); potential future relevance to hepatic encephalopathy.expert opinion
How strong the finding is
1 animal study (Mendez 2021, rat, 670 nm, 9 J/cm2, daily x7); improved Morris-water-maze memory comparable to methylene blue; differential CCO modulation across brain regions.
How it may work
Transcranial NIR penetrates to brain, where cytochrome c oxidase absorption restores mitochondrial respiration/ATP and modulates regional brain metabolism, improving cognition despite hepatic dysfunction.
What complicates this
Animal-only, single study; transcranial dose translation to the human skull uncertain; mechanism inferred; no clinical data.
Safety notes
No human data; HE requires medical management of liver disease; investigational only, not a replacement for standard therapy.
660 nm PBM shrank but did not close anal fistula tracts in rats - preclinical signal only
Anecdotal only· Points toward a benefit
In a rat model (Dos Santos 2021), daily 660 nm PBM reduced the remaining fistula-tract area (248.5 vs 847.2 micrometers^2, p=0.001) and inflammatory infiltrate versus controls, but achieved no complete closure in any animal. This is preclinical, single-study evidence - a plausible mechanism for adjunctive healing, not proof of benefit in human anal fistula, which is surgically managed. Human use would be an experimental adjunct to confirm.
Studied in Preclinical (rats); potential relevance to patients with anal fistula as a surgical adjunct.expert opinion
How strong the finding is
1 animal study (Dos Santos 2021, rat, 660 nm); tract area 248.5 vs 847.2 micrometers^2 (p=0.001), lower inflammatory score (1.3 vs 2.4, p=0.0285); no complete closures.
How it may work
Red light via cytochrome c oxidase to ATP promotes fibroblast activity, angiogenesis and tempered inflammation, supporting granulation within the fistula tract.
What complicates this
Animal-only, single study; no closures achieved; small n; limited parameter reporting; no human translation.
Safety notes
No human evidence; anal fistula requires surgical evaluation (risk of sepsis/incontinence); investigational adjunct only, not a replacement for definitive surgery.
Multi-wavelength PBM regrew hair in canine noninflammatory alopecia — a veterinary proof-of-concept
Anecdotal only· Points toward a benefit
In a veterinary clinical study of seven dogs with noninflammatory alopecia, a multi-wavelength device (470, 685, and 830 nm, 3 J/cm2) applied twice weekly for up to two months increased the area occupied by hair follicles (18% treated vs 11% untreated) and dramatically raised the proportion of haired follicles (93% treated vs 9% control) (Olivieri 2015). It is a single small animal study, but a clean within-subject design with histologic endpoints. Treat as a preclinical/veterinary proof-of-concept; human noninflammatory alopecia application is a plausible extension to confirm.
Studied in Preclinical/veterinary (dogs with canine noninflammatory alopecia).expert opinion
How strong the finding is
1 veterinary clinical study (Olivieri 2015, n=7 dogs; 470+685+830 nm, 3 J/cm2; haired follicles 93% vs 9%).
How it may work
Combined visible/NIR light stimulates follicular stem cells and cytochrome c oxidase/ATP, pushing follicles into the anagen growth phase and increasing the haired-follicle fraction.
What complicates this
Small N; animal/veterinary only; no human data; heterogeneous canine alopecia causes.
Safety notes
Standard PBM safety. Single small veterinary study; no human data. Adjunct/experimental interest only, never a replacement for diagnosis and treatment of the underlying alopecia.
Long-term full-body NIR extended lifespan and reversed cardiac aging markers in mice — a striking signal from a single study
Anecdotal only· Points toward a benefit
In aged AC8-overexpressing mice, eight months of full-body PBM (850 nm, 25 mW/cm2, 120 s each weekday) improved a broad panel of cardiovascular aging measures: reduced left-ventricular mass, end-diastolic volume, and aortic stiffness; increased ejection fraction, gait symmetry, and serum TGF-beta1; and raised survival to 100% versus 43% in untreated mice (Syed 2023). This is exactly the kind of full-body, longevity-oriented signal biohackers care about — but it is one mouse study in a genetically modified strain. It is a genuinely exciting hypothesis to test in humans, not a demonstrated human anti-aging effect.
Studied in Preclinical (aged AC8-overexpressing mice); human cardiovascular aging is a plausible but untested extension.expert opinion
How strong the finding is
1 animal study (Syed 2023): full-body 850 nm, 25 mW/cm2, 120 s/weekday over 8 months; survival 100% vs 43%, with multiple cardiac/vascular improvements.
How it may work
Chronic NIR at the cytochrome c oxidase absorption peak sustains mitochondrial function and ATP output and lowers oxidative stress systemically, plausibly slowing age-related myocardial remodeling and vascular stiffening.
What complicates this
Only one study; a genetically engineered mouse model; no replication; no human data; longevity endpoints are notoriously hard to translate.
Safety notes
Standard PBM safety (eye protection). Single-species, single-study evidence — do not infer a human survival or cardiac benefit. Adjunct/experimental interest only; never a replacement for evidence-based cardiovascular prevention.
Transcranial NIR eased perioperative cognitive decline in aged mice — preclinical signal, human use a plausible extension
Anecdotal only· Points toward a benefit
In aged mice with surgery/anesthesia-induced perioperative neurocognitive disorder, transcranial 810 nm light improved cognition and reversed mitochondrial dysfunction, increasing synapse-related protein expression and neuronal survival. The mitochondrial mechanism fits PBM's core biology and targets a condition (post-operative cognitive decline in older patients) with no approved disease-modifying therapy. This is one animal study, so human application is a biologically reasonable direction to test rather than an established intervention.
Studied in Preclinical only — aged-mouse perioperative neurocognitive disorder model; no human studiesexpert opinion
How strong the finding is
1 mouse study: Zhang 2021 (18-month C57BL/6 mice, exploratory laparotomy under isoflurane, 810 nm transcranial for 2 weeks; improved short- and long-term cognition, restored mitochondrial function, more synaptic proteins and neuronal survival).
How it may work
Transcranial NIR restores neuronal mitochondrial function via cytochrome c oxidase, raising ATP and protecting synapses and neurons against the bioenergetic stress that contributes to perioperative cognitive decline.
What complicates this
Single preclinical study; rodent skull penetration far exceeds human, leaving effective human dosing unknown, and clinical PND endpoints differ from murine behavioral tasks.
Safety notes
No human PND data; transcranial NIR is generally tolerated in other human studies but no claim is made here. Any use would be adjunctive within perioperative/geriatric care, not a replacement.
PBM modestly reduced plaque and improved lipids in animal atherosclerosis models — early, preclinical, and small in magnitude
Anecdotal only· Points toward a benefit
In animal models, visible/red light has reduced aortic plaque burden (~8% smaller plaque area in Yin 2021, 635 nm, ApoE-/- mice) and raised HDL, and polarized light lowered cholesterol/LDL and atheroma in rabbits (Park 2012). The effect on cholesterol in most settings appears relatively small (Paolillo 2021). This is a plausible cardioprotective mechanism with honest but limited preclinical support — promising enough to study in humans, but not yet a human claim, and certainly not a substitute for statins or lifestyle change.
Studied in Preclinical (mouse, rabbit, rat hyperlipidemia/atherosclerosis models).expert opinion
How strong the finding is
3 animal studies (Yin 2021 mouse 635 nm, plaque -8.3%, HDL up; Park 2012 rabbit polarized light; Paolillo 2021 rat, small lipid effect).
How it may work
PBM promotes cholesterol efflux and HDL function, lowers vascular oxidative stress and inflammation via cytochrome c oxidase / ATP and redox signaling, potentially slowing plaque accumulation.
What complicates this
Animal-only; small effect sizes; cholesterol impact described as minor; no human trials; heterogeneous light sources (laser vs polarized broadband).
Safety notes
Standard PBM safety. Atherosclerosis is managed with proven lipid-lowering therapy and lifestyle change; PBM has no human efficacy evidence here and must remain, at most, an investigational adjunct — never a replacement for prescribed cardiovascular care.
PBM curbs lung fibrosis in animal models — strong anti-fibrotic mechanism, human use a plausible extension
Anecdotal only· Points toward a benefit
In bleomycin-induced pulmonary fibrosis models, 660-780 nm PBM reduced inflammatory-cell migration, collagen deposition, and pro-fibrotic TGF-β while upregulating IL-10 from pneumocytes and fibroblasts (de Brito 2019; Brochetti 2017). For a disease as treatment-poor as idiopathic pulmonary fibrosis, that is a mechanistically exciting signal — but it is entirely preclinical. Human anti-fibrotic PBM is a plausible extension to test, not an established therapy, and would only ever be adjunctive to standard IPF care.
Studied in Preclinical: mouse models of pulmonary fibrosis plus type II pneumocyte/fibroblast cultures; no human dataexpert opinion
How strong the finding is
2 animal studies (study_count 2). de Brito 2019 (mouse + in-vitro, 780 nm): reduced collagen, TGF-β, and inflammatory migration; raised IL-10. Brochetti 2017 (mouse, 660 nm, 5 J/cm²): less collagen, fewer inflammatory cells, and improved lung elastance.
How it may work
PBM acts via cytochrome c oxidase to shift the cytokine balance toward anti-inflammatory/anti-fibrotic signaling — lowering TGF-β and pro-inflammatory mediators, raising IL-10, and reducing collagen deposition and airway remodeling.
What complicates this
Animal/in-vitro only, single disease model (bleomycin), small body of work; lung-depth dosimetry through the human chest wall is unvalidated and translatability is unproven.
Safety notes
No human pulmonary-fibrosis PBM safety data; transcutaneous chest PBM is non-thermal and well tolerated in general. Any future use would be strictly adjunct to antifibrotic drugs and pulmonary care.
PBM reduces pleural inflammation dose-dependently in animal models — clean preclinical signal
Anecdotal only· Points toward a benefit
In carrageenan-induced pleurisy, 650-660 nm LLLT dose-dependently reduced leukocyte influx, exudation, and inflammatory mediators (NO, IL-6, MCP-1, TNF-α), with effects partly blocked by a cortisol antagonist — implying a glucocorticoid-linked anti-inflammatory pathway (Lopes-Martins 2005/2006; Boschi 2008). The data are consistent and mechanism-revealing, but animal-only. Human pleurisy use would be a plausible extension to confirm and adjunctive at most.
Studied in Preclinical: mouse and rat carrageenan-pleurisy models; no human dataexpert opinion
How strong the finding is
3 animal studies (study_count 3). Lopes-Martins 2006 (mouse, 650 nm): leukocytes cut ~60%, blocked by mifepristone. Boschi 2008 (rat, 660 nm): dose-dependent drop in leukocytes, exudation, NO, IL-6, MCP-1, TNF-α (2.1 J optimal). Lopes-Martins 2005 (mouse): 7.5 J/cm² > 3 or 15 J/cm².
How it may work
PBM suppresses acute pleural inflammation by reducing leukocyte migration and pro-inflammatory mediators; the partial blockade by mifepristone suggests an endogenous-corticosteroid-dependent component layered on cytochrome c oxidase-mediated redox effects, with a clear dose optimum.
What complicates this
Animal-only, single inflammatory model, overlapping research groups; pronounced dose-dependence (too much or too little blunts the effect) complicates translation, and no human data exist.
Safety notes
No human pleurisy PBM data; adjunct only. Pleurisy needs diagnosis and treatment of its underlying cause.
Higher-power PBM slowed canine degenerative myelopathy progression in a retrospective review
Anecdotal only· Points toward a benefit
In dogs with degenerative myelopathy — a progressive, fatal neurodegenerative disease with no good treatment — a retrospective review found a higher-power NIR protocol (980 nm, 6-12 W) was associated with significantly slower progression and longer survival than a low-power protocol (904 nm, 0.5 W) or historical controls (Miller 2020). This is a single retrospective veterinary study, so it is a hopeful lead rather than proof, and dose (power) appears pivotal. PBM should be an adjunct within rehabilitation, not a stand-alone therapy.
Studied in Canine patients with degenerative myelopathy (veterinary clinical population)expert opinion
How strong the finding is
1 canine clinical study (Miller 2020, retrospective): the higher-power 980 nm (6-12 W) protocol showed significantly slower disease progression and longer survival than 904 nm (0.5 W) or published historical data.
How it may work
NIR PBM is proposed to support stressed motor neurons by boosting mitochondrial ATP via cytochrome c oxidase and reducing oxidative stress and neuroinflammation; the apparent need for multi-watt power reflects the depth required to reach the spinal cord.
What complicates this
Single retrospective review with non-randomized group assignment and historical comparators — prone to selection and rehab-protocol confounding; no controlled or prospective replication.
Safety notes
Multi-watt NIR carries thermal risk and must be dosed by trained operators; eye protection required. Adjunct to physical rehabilitation and supportive care — not curative; this is veterinary evidence and does not transfer to human ALS/myelopathy without dedicated study.
Red/NIR PBM normalizes ovarian and oocyte biology in PCOS models — promising preclinical signal, human use a plausible extension to confirm
Anecdotal only· Points toward a benefit
In estradiol-induced rat PCOS and in cultured PCOS oocytes, photobiomodulation (640-904 nm) has nudged hormone profiles back toward normal, improved oocyte maturation and fertilization, and lowered oxidative stress and apoptosis. This is mechanism-consistent and encouraging, but every data point is animal or in-vitro — there are no human PCOS trials in this evidence set. Treat human application as a plausible, biologically reasonable extension to test, not an established therapy.
Studied in Preclinical only — rat PCOS model and in-vitro human/animal PCOS oocytes; not yet studied in women with PCOSexpert opinion
How strong the finding is
3 grounding studies, all preclinical: Polat 2023 (rat, 904 nm, 2 J/cm2 optimal) and Sahraeian 2023/2024 (in-vitro oocyte, 640 nm) showing improved maturation, fertilization, GSH and miRNA changes. No human trials.
How it may work
Photons at red/NIR wavelengths are absorbed by cytochrome c oxidase, raising ATP and modulating redox tone; in the oocyte work this showed up as higher glutathione, altered miRNA expression, reduced ROS and less apoptosis/autophagy, plus restored hormone balance (LH/FSH/progesterone) in the rat ovary.
What complicates this
Entirely preclinical; the rat author explicitly calls optimal dosing unresolved. In-vitro oocyte irradiation models laboratory/IVF handling, not in-body treatment of PCOS, so extrapolation to clinical PCOS is speculative.
Safety notes
No human PCOS safety data exist for this indication; dose-response was non-linear in the rat work (2 J/cm2 outperformed 6 J/cm2), so 'more is better' does not hold. PBM is an adjunct to confirm, never a replacement for endocrine/fertility care.
Red/NIR LED calms middle-ear inflammation in rats — a mechanism-rich preclinical signal, human ear use a plausible extension
Anecdotal only· Points toward a benefit
In LPS- and MRSA-induced otitis media in rats, dual red/near-infrared LED (655/842 nm) reduced middle-ear mucosal thickening, inflammatory-cell infiltration, and IL-1β/IL-6/TNF-α, and suppressed MRSA biofilm formation. This is a coherent anti-inflammatory, anti-biofilm story — but the evidence is entirely preclinical (rat models plus human/murine cell lines), so framing it as a non-antibiotic option for human ear infection is a plausible extension to confirm, not a proven therapy. PBM here would be an adjunct, never a replacement for indicated antibiotics.
Studied in Preclinical: rats with induced otitis media and human/murine cell lines; not yet tested in human patientsexpert opinion
How strong the finding is
2 preclinical studies from one Korean group (Ko 2023, Ko 2025): the first showed reduced mucosal thickening and pro-inflammatory cytokines after 655/842 nm LED; the second showed suppressed MRSA biofilm and inflammation in a refractory-OM rat model. No human trials.
How it may work
Photons at red/NIR wavelengths are absorbed by cytochrome c oxidase, raising ATP and shifting redox signaling; downstream this dampens NF-κB-driven cytokines (IL-1β, IL-6, TNF-α) and, at higher fluence, disrupts bacterial biofilm architecture.
What complicates this
Single-lab, animal/in-vitro only; no randomized human data, and no dosimetry validated for the human middle ear through an intact tympanic membrane. Translatability is unproven but the mechanism is plausible.
Safety notes
PBM is non-thermal at these doses and generally well tolerated; for ear infection it must remain an adjunct to standard antibiotic/clinical care, not a substitute. No human otologic PBM safety data for this indication yet.
Transcranial NIR protected the brain in carotid-stenosis mouse models — a neuroprotection signal, not a fix for the narrowed artery
Anecdotal only· Points toward a benefit
In mouse models of bilateral common carotid artery stenosis and chronic cerebral hypoperfusion, transcranial PBM improved cognition and regional cerebral blood flow and reduced neuronal loss, though residual necrotic foci persisted (Kim 2025; Lee 2019). The honest read: PBM here is a downstream neuroprotective adjunct for the brain suffering from low perfusion — it does not reverse the carotid narrowing itself. Evidence is animal-only and early; human use would be a plausible extension to confirm, framed as brain support, not vascular reopening.
Studied in Preclinical (mouse chronic cerebral hypoperfusion / carotid stenosis models).expert opinion
How strong the finding is
2 animal studies (Kim 2025 transcranial PBM in carotid-stenosis model, improved cognition/CBF, reduced neuronal loss; Lee 2019 810 nm NIR LED brain-delivery system).
How it may work
Transcranial NIR reaching cortical/hippocampal tissue boosts mitochondrial ATP and modulates hypoxia-responsive pathways (HIF-1) and apoptosis regulators (BCL2), improving neuronal resilience and cerebral blood flow under chronic hypoperfusion.
What complicates this
Animal-only; residual necrotic foci persisted; context-dependent BCL2/HIF-1 effects; authors themselves call for longitudinal mechanistic work; no human data.
Safety notes
Standard PBM safety. Carotid artery stenosis is a stroke risk requiring medical/surgical management; PBM does not treat the stenosis. Any neuroprotective use would be strictly adjunctive and investigational — never a replacement for prescribed care.
650 nm PBM improved ovarian function in naturally aged mice - preclinical, human use a plausible extension
Anecdotal only· Points toward a benefit
In naturally aged mice (He 2024), 650 nm PBM (4 J/cm2, over 2 months) restored sex-hormone levels, increased primordial and growing follicle counts, improved ovarian angiogenesis and reduced apoptosis, oxidative stress and chronic inflammation. This is single-study preclinical evidence - a compelling mechanism for ovarian rejuvenation to test in humans, not a proven therapy. Human application would be experimental and requires reproductive-medicine oversight.
Studied in Preclinical (naturally aged mice); potential future relevance to ovarian aging / diminished reserve.expert opinion
How strong the finding is
1 animal study (He 2024, mouse, 650 nm, 80 mW, 2 or 4 J/cm2 x2 months); 4 J/cm2 recovered sex hormones, increased follicles and angiogenesis, decreased apoptosis/oxidative stress/inflammation, improved mitochondrial function.
How it may work
Red light via cytochrome c oxidase to ATP improves ovarian mitochondrial function, reduces oxidative stress and inflammation, and supports angiogenesis and follicular survival, counteracting age-related decline.
What complicates this
Animal-only, single study; dose translation to the human ovary (depth/access) unknown; long-term safety untested; no human trials.
Safety notes
No human data; reproductive-endocrinology oversight required for any future use; strictly investigational; beware over-promising to patients.
Red-light PBM eased PTSD-like behavior in rodents — promising but preclinical, with one null blast-injury result
Anecdotal only· Mixed findings
In rat models of PTSD, photobiomodulation improved or prevented fear- and stress-related behaviors in two studies, while a third found no benefit in blast-injury-related PTSD (Li 2021, Li 2021, Garcia 2021). The mechanistic rationale is real — transcranial near-infrared light reaches cortical and limbic tissue and can modulate mitochondrial function and neuroinflammation — but every data point here is animal, so human PTSD benefit remains a plausible extension to confirm, not an established effect.
Studied in Adults with PTSD (human application extrapolated from rat models)expert opinion
How strong the finding is
Three rat studies (Li 2021 x2, Garcia 2021): two positive for PTSD-related symptoms, one null for blast-injury PTSD. No human trials in this evidence set.
How it may work
Transcranial near-infrared light is absorbed by cytochrome c oxidase, raising ATP and cerebral blood flow while dampening neuroinflammatory cytokines and oxidative stress in fear-circuit regions (prefrontal cortex, hippocampus, amygdala).
What complicates this
Animal-only and split (2 positive, 1 null). The null result was specifically in blast-injury PTSD, hinting the effect or dose may not generalize across PTSD subtypes. No controlled human data yet.
Safety notes
Transcranial PBM is generally well tolerated; eye protection is required near the head. This is preclinical for PTSD — an adjunct to evidence-based trauma care (psychotherapy, prescribed medication), never a replacement.
PBM restores testicular tissue in animal injury models — consistent preclinical repair, but dose can cut both ways and no human data exist
Anecdotal only· Points toward a benefit
In rodent and ram models of testicular damage (diabetes, heat stress, degeneration), localized NIR PBM (808-890 nm) has repeatedly increased Sertoli and Leydig cell counts, lengthened seminiferous tubules, and improved sperm parameters. The repair signal is consistent and mechanism-plausible, but it is entirely animal — human testicular PBM has not been studied here — and one ram study showed high-dose laser (28 J/cm2) could itself injure semen, underscoring a real dose ceiling. Treat human use as an unproven extension to test carefully.
Studied in Preclinical only — diabetic, hyperthermic and degenerative testis in mice, rats and rams; no human studiesexpert opinion
How strong the finding is
7 studies, all animal/other: Dadras 2018 (mouse, 890 nm, more Sertoli/Leydig cells), Aghajanpour 2024 (mouse hyperthermia, improved sperm + tissue), Alves 2016 (ram, 28 J/cm2 helped tubules but injured semen), Ahn 2013 (rat, 808 nm penetrated better than 670 nm).
How it may work
NIR light energizes mitochondria in testicular somatic and germ cells via cytochrome c oxidase, supporting proliferation/survival of Sertoli and Leydig cells and spermatogenesis; effects are dose-dependent and become harmful above a tissue-specific threshold.
What complicates this
No human evidence; biphasic dose-response with documented harm at high fluence. Cross-species testicular size/penetration differences make human dosing genuinely unknown.
Safety notes
Dose ceiling is real: 28 J/cm2 at 808 nm induced semen injury in rams. The testis is heat- and dose-sensitive; no human safety data. Any human exploration must be cautious and is an adjunct concept only, never a fertility treatment.
PBM protected against acute lung injury in recent animal/in-vitro work — promising mechanism, preclinical only
Anecdotal only· Points toward a benefit
In sepsis-induced acute lung injury models, 650 nm red-light PBM prolonged survival, reduced lung edema and histologic damage, and broadly suppressed pro-inflammatory cytokines and chemokines while reprogramming myeloid responses and preserving mitochondrial function (Zhang 2026); PBM also enhanced mesenchymal-stem-cell therapy for ALI (Chen 2022). The immunometabolic framing is compelling, but the evidence is animal/in-vitro. Human ALI/ARDS use is a plausible extension to confirm, adjunct only.
Studied in Preclinical: mouse/rat models of (sepsis-induced) acute lung injury and human umbilical-cord MSC cultures; no human trialsexpert opinion
How strong the finding is
2 recent studies (study_count 2). Zhang 2026 (mouse + in-vitro, 650 nm): improved survival, less edema, broad cytokine/chemokine suppression, preserved mitochondrial function. Chen 2022 (rat + in-vitro): PBM strengthened hUC-MSC therapy, reducing alveolar damage and inflammation.
How it may work
Red-light PBM preserves mitochondrial function and modulates monocyte/macrophage trafficking and polarization (e.g., via adiponectin signaling), suppressing the dysregulated innate-immune cytokine/chemokine storm of acute lung injury through cytochrome c oxidase-mediated effects.
What complicates this
Animal/in-vitro only, very recent and unreplicated; the MSC-combination design confounds the PBM-specific effect, and human-scale lung dosimetry is unvalidated.
Safety notes
No human ALI/ARDS PBM data; would be strictly adjunctive within intensive-care management. ALI/ARDS is life-threatening and requires conventional critical care.
PBM prevented and arrested abdominal aortic aneurysm in mice — mechanistically compelling, but human use is an unproven, delivery-limited extension
Anecdotal only· Points toward a benefit
In three mouse studies of the angiotensin-II apo-E-deficient model, near-infrared PBM (780 nm, ~2 J/cm2, 9 min) both prevented new abdominal aortic aneurysm and halted progression of pre-induced aneurysm (Gavish et al. 2014, 2012, 2009). This is a genuine, reproducible preclinical signal — but it is animal-only, and no human trials exist. Critically, transdermal light cannot reach the aorta, so any human translation would require internal delivery (the authors propose via the femoral artery, abdomen, or transverse colon), making a full-body red-light bed irrelevant for this indication. Treat as a mechanism worth watching, not a usable protocol.
Studied in Preclinical (apo-E-deficient mice with angiotensin-II-induced aneurysm); no human population yet.expert opinion
How strong the finding is
Three concordant mouse studies (Gavish et al. 2014, 2012, 2009) at 780 nm, ~2 J/cm2, 9 min over ~1 month; delivery-route review (Gavish et al. 2022). No human data.
How it may work
Photons at 780 nm are absorbed by cytochrome c oxidase, raising ATP and lowering oxidative stress in the vessel wall; downstream this is thought to modulate matrix-metalloproteinase activity and inflammatory cytokines that drive aortic wall degradation, stabilizing the aneurysm.
What complicates this
Entirely animal; small models; the central obstacle is that skin irradiation cannot reach the aorta, so the positive findings do not transfer to any non-invasive consumer device.
Safety notes
Standard PBM precautions (eye protection) are moot here because effective dosing would require internal/endoluminal light delivery, which is investigational only. Abdominal aortic aneurysm is a surgical/medical emergency risk — PBM is not a treatment and must never replace vascular surveillance or repair. Adjunct concept only, not a replacement for prescribed care.
660 nm laser reduced cancer-related hyperalgesia and inflammation in tumor-bearing rats — preclinical, human use unconfirmed
Anecdotal only· Points toward a benefit
In Walker-256 tumor-bearing rats, 660 nm laser PBM cut paw edema and mechanical hyperalgesia and shifted the local milieu anti-inflammatory — higher IL-10, lower COX-2 and bradykinin-receptor (Bdkrb1) expression (Petrellis 2020). It is a clean mechanistic result for cancer pain, but it is animal-only, so human analgesic use is a plausible extension to confirm — with the added caveat that irradiating tumor tissue itself demands caution (see tumor-growth evidence).
Studied in Cancer pain (rat model; human application extrapolated)expert opinion
How strong the finding is
One rat study (Petrellis 2020, 660 nm, 3.57 W/cm2, 1 J most effective): reduced edema and hyperalgesia, raised IL-10, lowered COX-2/Bdkrb1. No human cancer-pain trials in this set.
How it may work
PBM lowers pro-inflammatory and pro-nociceptive mediators (COX-2, bradykinin B1 receptor) while raising anti-inflammatory IL-10, and modulates peripheral nociceptor signaling — reducing hyperalgesia and edema.
What complicates this
Single animal study; optimal dose unclear (1 J helped, higher doses also tested); no human data, and applying analgesia directly at tumor sites intersects with unresolved tumor-growth safety questions.
Safety notes
Critical caveat: direct PBM over malignant tissue has conflicting preclinical effects on tumor growth — site selection and oncology sign-off matter. Strictly adjunct to prescribed analgesia and oncologic care, never a replacement.
Red/NIR PBM consistently reduced colitis severity across 7 animal models - strong preclinical signal, human trials needed
Anecdotal only· Points toward a benefit
Seven animal studies converge: red/NIR PBM (660, 830, 940 nm) reduced disease-activity index, mucosal inflammation, crypt damage, myeloperoxidase and pro-inflammatory cytokines (and restored colon length and gut-microbiota diversity) in chemically-induced colitis models. The preclinical consistency is genuinely encouraging for a mechanism in inflammatory bowel disease - but there are no human IBD trials here, so this is a plausible extension to test, not a proven therapy. PBM would be an investigational adjunct to standard IBD care, never a replacement.
Studied in Preclinical (mouse/rat colitis models); potential future relevance to inflammatory bowel disease (ulcerative colitis/Crohn's).expert opinion
How strong the finding is
7 animal studies; Belem 2016 (starred, mouse, 940 nm, 4.05 J/cm2, lower edema/MPO/lesions); Maeng 2026 (mouse, 830 nm, lower DAI p<0.001, restored colon length, microbiota); Bitencourt 2023 (rat, 660 nm, sex-dependent cytokine effects); Hiratsuka 2014 (mouse).
How it may work
PBM drives cytochrome c oxidase to ATP, shifts the cytokine balance (lower TNF-alpha, IL-1beta, IL-6; higher anti-inflammatory mediators), reduces neutrophil infiltration/MPO and oxidative stress, and may favorably modulate the gut microbiome.
What complicates this
Entirely animal models (acute chemically-induced colitis differs from human chronic IBD); heterogeneous wavelengths/doses; some effects sex-dependent; no human trials; delivery to human bowel unsolved.
Safety notes
No human IBD evidence; transabdominal delivery to inflamed bowel is unvalidated in people; investigational adjunct only; continue prescribed IBD therapy.
PBM reduced sciatic nerve-compression pain in rats - a plausible neural mechanism, untested here in humans
Anecdotal only· Points toward a benefit
The available evidence is a single rat study (Bertolini 2011): 830 nm low-level laser reduced pain behavior in a sciatic nerve-compression model. PBM's analgesic and neuro-modulatory mechanism is reasonable for compressive radicular pain, but with only preclinical data presented, human use for sciatica is a plausible extension to test in trials, not a supported clinical recommendation.
Studied in Preclinical (rat sciatic-compression model); human applicability unprovenexpert opinion
How strong the finding is
Animal-only: Bertolini 2011 (rat, 830 nm, 4-8 J/cm2, reduced pain behavior over a 5-day course).
How it may work
PBM may reduce neural inflammation and nociceptor excitability and support nerve repair (mitochondrial ATP, reduced oxidative stress, modulated fast axonal flow) at and around the compressed nerve root.
What complicates this
Single small animal study; the authors note that LLLT for nerve-compression pain remains controversial, and there is no human evidence in this set.
Safety notes
Preclinical only. Not an evidence-based treatment for human sciatica; do not delay evaluation of radicular pain. Standard PBM safety would apply to any future human use.
PBM in epilepsy: anticonvulsant signals in animal models only — human use a plausible extension to confirm
Anecdotal only· Points toward a benefit
The curated evidence describes beneficial effects of PBM in animal models of stroke-induced epilepsy and pentylenetetrazole-induced status epilepticus (Vogel 2020, Tsai 2020). The mechanistic rationale — anti-inflammatory and neuroprotective modulation of hyperexcitable cortex — is reasonable. But this is preclinical only, with no human trials and no extractable trial-level data in our grounding set, so human application is a hypothesis to test, not a treatment.
Studied in Preclinical only — rat models of stroke-induced epilepsy and status epilepticus; no human studiesexpert opinion
How strong the finding is
Curated evidence base of ~3 animal (rat) studies (Vogel 2020, Tsai 2020) reporting benefit in stroke-induced epilepsy and PTZ status epilepticus models; no PMIDs/abstracts or human trials available in this grounding set.
How it may work
PBM is proposed to dampen neuroinflammation, support mitochondrial function and modulate neuronal excitability/network activity in injured or hyperexcitable cortex, raising seizure threshold in animal models.
What complicates this
Entirely preclinical and summarized at a high level (no trial-level abstracts in our set); model-specific findings may not generalize, and rodent brain penetration far exceeds human. Unverified for clinical seizure control.
Safety notes
No human epilepsy data; seizure disorders require established antiepileptic management. Any exploration of PBM would be strictly investigational and adjunctive, never a replacement for prescribed anticonvulsant care.
PBM supports flap viability across ~30 animal studies; lone human RCT (different surgery) shows reduced surgical stress - limited overall
Anecdotal only· Points toward a benefit
The flap-surgery evidence base is large but lopsided: about 30 animal studies (rat/mouse/pig) report PBM improving skin/musculocutaneous flap survival via angiogenesis and reduced necrosis, while the single human RCT provided here (Redkin 2017, n=263) actually tested red LED light (625 nm) on the surgical bed during laparoscopic cholecystectomy and found reduced post-surgical ALT/AST/ESR. So human flap-specific RCT evidence is thin; the mechanism is well-supported preclinically. Promising as a surgical adjunct to confirm in human flap trials, not an established protocol.
Studied in Preclinical flap models (rat/mouse/pig); the human RCT concerns general surgical-stress markers in cholecystectomy.expert opinion
How strong the finding is
1 human grounding RCT (Redkin 2017, 625 nm, n=263, lower ALT/AST/ESR) atop an evidence base of ~30 animal flap-survival studies; consistent preclinical reduction in necrosis and increase in VEGF.
How it may work
Red/NIR via cytochrome c oxidase to ATP increases VEGF-driven angiogenesis and tissue perfusion, recruits mast cells and dampens inflammation, reducing ischemic flap necrosis.
What complicates this
Human evidence is a single RCT on a different surgery (cholecystectomy), not flaps; flap-specific human trials absent here; heterogeneous animal models/wavelengths; publication bias likely in the animal literature.
Safety notes
Limited human flap data; eye protection; investigational surgical adjunct; coordinate with the surgical team.
LED-fluorescence light therapy helped canine otitis externa - veterinary/preclinical, and blue light, not classic PBM
Anecdotal only· Points toward a benefit
The only evidence here is a veterinary RCT (Tambella 2020) in dogs: a topical LED-illuminated chromophore gel (blue 440-460 nm fluorescence) produced positive clinical effects in canine otitis externa, comparable to standard antibiotic/antifungal care. This is preclinical/veterinary and uses fluorescent blue-light biomodulation rather than classic red/NIR PBM, so human ear-canal use is a speculative extension to study, not an established treatment.
Studied in Preclinical/veterinary (dogs with spontaneous otitis externa); human applicability unprovenexpert opinion
How strong the finding is
1 veterinary RCT (Tambella 2020): dogs randomized to LED-illuminated gel (once or twice weekly) vs enrofloxacin plus silver sulfadiazine; all groups showed positive clinical effect.
How it may work
Fluorescent light energy (LED-activated chromophore gel) is proposed to stimulate tissue repair and exert antibacterial effects in the ear canal - a fluorescence/blue-light biomodulation route distinct from red/NIR mitochondrial PBM.
What complicates this
Animal-only and uses a chromophore-gel fluorescence system (440-460 nm), not classic PBM; no human data and no demonstrated superiority over standard care.
Safety notes
Preclinical/veterinary only. Not an evidence-based human treatment for otitis externa; standard ear-canal and phototherapy safety would apply to any future human use. Adjunct concept, not a replacement for standard care.
PBM eased allergic (but not irritant) contact dermatitis in mice — a preclinical anti-inflammatory signal
Anecdotal only· Points toward a benefit
Two mouse studies suggest PBM dampens the allergic arm of contact dermatitis: He-Ne 633 nm (12.2 J/cm2) decelerated allergic contact dermatitis, particularly when applied before challenge, while having essentially no effect on irritant contact dermatitis (Sakihama 1995); a 2024 study found PBM suppressed T-cell activation in an allergic contact dermatitis model via the TGF-beta pathway (Fu 2024). The mechanism is coherent and the immunomodulatory direction is consistent, but this is animal-only — human use is a plausible extension to confirm, not an established treatment.
Studied in Preclinical (mouse allergic and irritant contact dermatitis models).expert opinion
How strong the finding is
2 animal studies (Sakihama 1995, 633 nm, 12.2 J/cm2, allergic CD decelerated, irritant CD unaffected; Fu 2024, PBM suppressed T cells via TGF-beta).
How it may work
PBM moderates naive T-cell activation (in part via TGF-beta signaling) and stabilizes mast cells, reducing the delayed-type hypersensitivity inflammation that drives allergic contact dermatitis; it does little for non-immune irritant dermatitis.
What complicates this
Animal-only; no effect on irritant dermatitis; timing-dependent (pre-treatment) effect; no human data.
Safety notes
Standard PBM safety. No human data; effect appears specific to allergic (immune-mediated) dermatitis. Experimental/adjunct interest only, never a replacement for allergen avoidance or prescribed topical therapy.
He-Ne laser pretreatment curbed scarring after glaucoma filtration surgery in rabbits — preclinical antifibrotic concept
Anecdotal only· Points toward a benefit
Two rabbit studies found that pretreating the filtration site with 633 nm He-Ne laser before trabeculectomy reduced scar formation, downregulating connective-tissue growth factor (CTGF), PCNA and collagen synthesis in fibroblasts (Wang 2010; Hu 2010). It is a coherent antifibrotic rationale for improving bleb survival — the perennial failure mode of glaucoma filtration surgery — but the evidence is animal-only, so human translation is a plausible extension to confirm.
Studied in Glaucoma patients undergoing trabeculectomy (rabbit models; human application extrapolated)expert opinion
How strong the finding is
Two rabbit studies (Wang 2010; Hu 2010, 633 nm He-Ne, 200 mW/cm2, up to 120 J/cm2, 10 min/day x 3 days pre-op): reduced CTGF/PCNA/collagen and less scar formation. No human data.
How it may work
Low-level laser appears to suppress fibroblast proliferation and pro-fibrotic signaling (CTGF, PCNA, collagen synthesis) at the surgical filtration site, reducing scarring that would otherwise close the drainage bleb.
What complicates this
Animal-only; high-fluence pretreatment regimen; no human efficacy/safety data and competition from well-established antifibrotic agents (e.g. mitomycin-C).
Safety notes
Antifibrotic adjuncts at filtration sites carry their own risks (e.g. over-filtration/thin blebs) — established pharmacologic agents are standard; PBM here is preclinical and investigational, not a replacement.
Red/NIR PBM curbed inflammation in a rat reflux-laryngitis model - preclinical signal
Anecdotal only· Points toward a benefit
Two rat studies (Marinho 2013, 2014) found PBM - 780 nm alone or 780+660 nm combined - reduced neutrophil infiltration and myeloperoxidase and improved reparative collagenization in nasogastric-intubation-induced reflux laryngitis. This is consistent preclinical evidence for an anti-inflammatory mechanism, not human proof; laryngopharyngeal reflux in people is managed by reflux control and ENT care. Investigational adjunct only.
Studied in Preclinical (rats); potential future relevance to reflux/laryngopharyngeal laryngitis.expert opinion
How strong the finding is
2 animal studies (rat); Marinho 2013 (starred, 780+660 nm, 17.5+10 J/cm2, modulated early inflammation, fewer neutrophils); Marinho 2014 (780 nm, 105 J/cm2, lower neutrophil influx, improved collagenization).
How it may work
Red/NIR via cytochrome c oxidase to ATP reduces neutrophil influx and MPO activity, modulates the early inflammatory response and improves collagen-based tissue repair in laryngeal mucosa.
What complicates this
Animal-only, same group; intubation model differs from human chronic reflux; heterogeneous doses; no human trials.
Safety notes
No human data; laryngeal delivery in people is non-trivial; manage the underlying reflux; investigational only.
